Elucidating pathological mechanisms of joint degenerative disorders by Salazar-Noratto, Giuliana Eva
ELUCIDATING PATHOLOGICAL MECHANISMS OF JOINT 




























In Partial Fulfillment 
of the Requirements for the Degree 








Georgia Institute of Technology 





COPYRIGHT © 2018 BY GIULIANA E. SALAZAR-NORATTO 
 
ELUCIDATING PATHOLOGICAL MECHANISMS OF JOINT 



























Dr. Robert E. Guldberg, Advisor 
George W. Woodruff School of 
Mechanical Engineering 
Georgia Institute of Technology 
 Dr. Nick J. Willett 





Dr. Greg Gibson 
School of Biological Sciences 
Georgia Institute of Technology 
 Dr. S. Clifton Willimon 
Orthopaedics 




Dr. Johnna S. Temenoff 
Wallace H. Coulter Department of 
Biomedical Engineering 
Georgia Institute of Technology 
  
   









To Giuliana D. Noratto Dongo, Katherine A. Salazar Noratto, Gino A. Salazar Noratto, 
Adonel A. Salazar Mendoza, Doris T. Dongo Montoya and C. Eva Mendoza de 







When I think about how many people have been part of this journey, I am amazed 
at how truly collaborative this thesis work turned out to be. First of all, I need—and 
want—to thank my advisor, Robert (Bob) E. Guldberg. He has often been more positive 
about my data and excited about my projects than myself, and his encouragement and 
positivity were just what my projects needed sometimes. I specially need to thank Bob 
for being supportive of the iPSC project I pitched to him and of me going to Ireland for a 
whole year to learn the technology in Frank Barry’s lab. This single decision made the 
difference in the world for my dissertation. I am happy that Bob chose me as one of his 
graduate students and will be forever thankful for the trust that he placed on me to carry 
out these projects. 
I need to thank the members of my committee as well. I will always appreciate the 
genuine excitement and interest that Greg Gibson had for my projects, and science in 
general. He truly opened up his lab for me, and became an amazing mentor in more ways 
than one. I enjoyed talking to him about science and about life nuances, such as us 
becoming American citizens. I am happy to have worked with him, and I do sincerely 
hope that we keep in touch in the future. I met Nick J. Willett as a post-doc in Bob’s lab 
when I first joined the lab, and soon after, Nick became a professor in Emory University. 
Therefore, I believe that our relationship has leaned more towards peers than with my 
other committee members. This is why it was so special to me, because I learned from 
Nick things that I couldn’t have from other people. I was able to discuss and disagree 
with Nick more openly, which gave me the confidence to do the same with senior 
 v 
professors, and that helped me grow as a scientist. I need to also thank Johnna Temenoff, 
who pushed me to think more critically of my projects and what contribution I was 
actually making to the scientific field. It is because of her that Aim 3 became what it did, 
and I will be eternally grateful for that, because I do think that it helped me become a 
better scientist. Finally, I need to thank Clifton Willimon, who provided me with patient 
samples for my JOCD projects and expertise about JOCD as a disease. I truly appreciate 
the time and effort he gave me considering that he is a very busy surgeon. He made time 
to meet with me, even if it was at 6 am, and to call me on my phone when I had 
questions. He was also constantly worried that I needed more patient samples and 
recruited several staff members at Children’s Healthcare of Atlanta to help me. In that 
sense, I also have to thank Dr. David Busch for being another JOCD doctor who provided 
me with patient samples and Margaux Johnson, who was the person responsible for 
coordinating the patient sample collection and until she came around the project was 
stagnant.  
I need to thank my labmates for being the best labmates I could have asked for. 
Tanushree Thote, Alice Lin, Ashley Allen, and Lauren Priddy were the senior girls (and 
now doctors) in the lab when I joined, and I learned a lot from them. I also learned about 
how to be a female scientist, which is something I had never thought would be different 
from a regular scientist, but I learned that females do still have it difficult in a male-
dominated field and that the experiences that we have are not often what our male 
counterparts would experience. I thank them for fighting the good fight, and I hope to do 
the same. Marian Hettiaratchi and Marissa Rhuele were great back-row desk-mates, and I 
am very thankful to have become great friends with them as well. It meant a lot to me 
 vi 
that Marian teleconferenced from Canada to watch my defense, and that Marissa became 
a close confidant of mine. I will miss Marissa’s and mine walks from and to work. 
David Reece was a fun labmate to have and his upbeat and friendly personality 
always lightened up the day. Brett Klosterhoff was also a great labmate, who would be 
genuinely interested in people’s projects and provide feedback and suggestions. His 
dancing and karaoke skills were also on point! I had a lot of fun hanging out with him 
and his wife Kayla. Then, there were Albert Cheng, Brennan Torstrick and Olivia 
Burnsed. We were all the same year, and we made of the lair a real chaos, especially 
Albert and Brennan—and it was all great fun! I am very happy that I had three other 
people to share my experiences with and that those two guys became like brothers to me. 
Albert, especially, was a great, close friend, who helped me in more ways than I could 
imagine.  
Lastly, I also would like to thank Ryan Akman, Gilad Doron, Angela Lin, and 
Laxmi Krishnan for their friendliness and readiness to help, especially during surgeries, 
and Casey Vantucci for her crazy friendship. And of course, I need to thank Hazel Y. 
Stevens for all the help she has provided me. More than scientifically, it has been 
emotional help. She has truly helped me finished up my dissertation, by ordering 
materials at late hours of the night and reading my papers and chapters. She has been like 
a (lab) mother to me these past couple of months, and I am eternally grateful to have had 
her in my life and my lab life. The Guldberg lab will definitely never be the same without 
her! Moreover, I would like to take this opportunity to thank Eric O’neil, who is Andres 
Garcia’s lab manager, but who helped me nonetheless with lab and protocol-related 
questions in the absence of Hazel.  
 vii 
I had several undergraduate students work with me in these projects that I need to 
thank. Destiny Cobb was my first undergraduate student, and I have to thank her for 
teaching me how to be a better manager and mentor for future students. Nica De Nijs was 
an amazing undergraduate, who helped me a lot with the first project and while I was in 
Ireland. She remained in Atlanta in charge of culturing JOCD skin fibroblasts, and there 
is no one else in the world I would have trusted to do this job. She is a real hard-worker 
and she deserves the best. Mohib Hasain and Catriana (Cat) Nations were my last 
students, and they helped me with the last project in particular. I specially need to thank 
Cat for all the help she provided me this last month. Even when things were wrapping up, 
there was a lot to do and she stayed many nights until 3 am or later with me just to help 
me finish. She also provided me with a constant supply of coffee and some snacks, for 
which I was really grateful. Her dedication to the JOCD project was astounding, and I 
will always appreciate the help and time she gave me. 
The third project of this thesis work was carried out in collaboration with Frank 
Barry’s lab in the National University of Ireland Galway, and I need to thank him and his 
lab. When I pitched the JOCD project to Bob, he was highly skeptical and it was Frank 
Barry’s support and enthusiasm that convince him that this was a project worth pursuing. 
Therefore, I have to thank Frank not only for hosting when I was in Ireland learning 
about iPSCs, but really for believing in this project from the very beginning; participating 
in the National Science Foundation/Science Foundation Ireland grant I wrote and helping 
me give form to this idea. I also would like to thank Mary Murphy who was also a 
mentor while I was in Ireland and was always interested in the work I was doing and 
provided valuable feedback. 
 viii 
I would like to thank Katya McDonagh and Stephanie Boomkamp, post-doctoral 
fellows at the time in the Regenerative Medicine Institute (REMEDI), for helping me 
with the iPSCs. Culturing iPSCs is a difficult task, especially when the medium 
formulations required daily changes (not longer the case for future iPSC scientists), and I 
do not think I could have made it without the iPSC community in REMEDI. Katya and 
Stephanie taught me best practices for iPSC culture and taught me what I could get away 
with dong or not doing. Most importantly, they helped me feed my iPSCs when I needed 
a break from the long 12-hour-plus feeding days, or when I injured my shoulder. Besides 
labwork, Katya and Stephanie were my best friends in Galway, and I have countless fond 
memories of our infamous steak and wine dates. 
Sean Gaynard helped me with the mesenchymal stem cell aspect of the third 
project, and I am immensely grateful that, busy as he was writing his own dissertation, he 
came in the weekends to help me run flow for multiple hours in a day. Cathy Brougham 
helped me with adipogenesis, but most importantly, she helped me as a labmate and a 
friend. I truly do not know what I would have done without the support of Cathy and 
Claire Dooley in the lab. They helped me ship my cells and they would help me in assays 
for which I wasn’t an expert in. Claire, especially, helped me stained the iPSCs for 
pluripotency when I was swamped with other work. These girls were the labmates I 
needed in Ireland, and they were also my best friends. I will never forget about Monday 
dinner nights turned shots/wine night outs, or the Irish lock-ins. Cathy was particularly 
working long hours as well to finish her thesis work, and I am grateful that she was there 
at late hours and on weekends with me, and that we would go out after lab in very classy 
Irish style (me with my backpack). 
 ix 
Living in Ireland taught me many things and allowed me to mature as a scientist 
and person. The lesson that I perhaps value the most is that, despite weather or workload, 
one should always have a good amount of crazy fun! Irish fun was my kind of crazy fun, 
and I am grateful for the experience and the people who contributed to this experience. I 
am also thankful to Silvia Rosati, Swarna Raman and Patrizio Mancuso for being my 
labmates and friends in Ireland. 
Besides REMEDI and the Barry lab, the Gibson lab was my other foster lab. Greg 
Gibson opened up his lab to me and allowed me to make it my home, and I am grateful 
for that. I am also thankful to Dalia Arafat for helping me with the technical aspect of 
Fluidigm, as well as Monica Pena-Rojas who taught me the JMP software and was 
involved in the original JOCD project collaboration with Children’s Healthcare of 
Atlanta. I am thankful to the Drissi lab and Hicham Drissi specifically because, even 
though he was not involved in my project or was a collaborator, he took the time to meet 
with me in multiple occasions to talk about the third project (JOCD) and took genuine 
interest in my career as a scientist. 
The scientific work in this thesis could not have been possible without the IBB 
core labs. I specially want to thank Aqua Asberry (histology), Andrew Shaw (optical 
microscopy), and David Small (mass spectrometry). In the Emory core labs, I would like 
to thank Hong Yi who carried out the TEM work, which was not presented in this thesis. 
I would also like to thank Laure Paige (BioE coordinator) for helping me get through the 
logistics of these last couple of months, even though I was not part of the BioE program.   
 x 
At this point, I would like to thank my friends, which truly became my Atlanta 
family. I was lucky to part of the 2012 Biomedical Engineering (BME) Cohort, which in 
my opinion was the most friendly, fun, and collaborative. Cheryl San Emeterio (née Lau) 
was the first person who talked to me and became my friend in the program, and she 
introduced me to the rest of our squad: Elizabeth (Betsy) Campbell, Candice Hovell, 
Claire Olingy (née Segar), and Efrain Cermeño. I cannot begin to imagine my life in 
Atlanta without these people. They have all been supportive through tough times and 
essential to all the fun activities and memories I experienced in Atlanta and during my 
Ph.D. Betsy will always be the voice of reason to me (and an amazing gin friend), and 
Efrain my dancing and drinking buddy. Melissa Alvarado-Velez and Juliana Soto-Giron 
were also my best friends, and I am thankful for having them through the fun and tough 
times of this Ph.D. journey. Finally, the lair people, who are the graduate students of the 
Guldberg and Garcia labs, have also been an important part of my life here. 
Before thanking my family, I do need to thank two more people who I believe 
have played an essential role in my accomplishments. Firstly, Linda Jo Huff (née 
Martinez) was my sophomore (high school) math teacher. I connected with her more than 
I had with any other teacher, and it was with her help that I won multiple scholarships for 
college, because her letters of recommendation assured the committees that she had faith 
on me beyond any reasonable doubt that I was going to make a difference in the world. I 
can only hope that I do not disappoint Mrs. Huff. Secondly, I would like to thank Dr. 
Kristen Maitland, who is a professor in BME at Texas A&M University, my 
undergraduate institution. Dr. Maitland never taught me a single course, and yet she 
helped me write my NSF Graduate Research Fellowship Program Application and polish 
 xi 
it. I do believe that she helped me win the NSF fellowship, and it was because she 
genuinely wanted to help this undergraduate student, me. She also taught me something 
that was very empowering and I will never forget: that I should not let people tell me that 
I have gotten where I am because I am a female or a minority. My identities do not cancel 
out my accomplishments, which were earned with hard work and sweat. I believe that it 
is people like Dr. Maitland that will change the science world for the better, and I will 
always be thankful that she changed my world. 
Finally, my family. I am grateful for all the love and support my family has 
always provided me. I have a big family, with more than 15 cousins, and they all have 
always believed in me and have been proud of every accomplishment along the way, no 
matter how small. My uncle Gino Noratto flew from Peru for my defense presentation, 
and that meant the world to me. I know that all of my other uncles and aunts would have 
loved to be here as well, and I also know that I would not be who I am today without my 
family. I am thankful that my sister, Katherine (Kati) Salazar-Noratto, grew up with me, 
because I know now that I will always have a friend in her no matter what happens. Her 
support and her constructive criticisms are things I really value in our friendship. My 
brother, Gino Salazar-Noratto, is the best person I know in this world, and he always 
believes the best of me. His love and understanding have carried me through many 
situations and especially this Ph.D. journey. I am also thankful for my dad, Adonel 
Salazar Mendoza, for always trying his best. 
My mom, Giuliana Noratto Dongo, is the strongest woman I know, and after 
finishing this Ph.D. journey, I am simply in awe at how she was able to do her own Ph.D. 
as a single mother with three (very difficult) children. She is my hero, because since I 
 xii 
was little she taught me that “si no puedes es porque no quieres” (if you can’t do 
something, you must not really want it). Her resilience and constant drive to better herself 
are characteristics I admire. It is because of her that I am strong, confident, and a female 
scientist. It is because of her that I believe all dreams are attainable and that we, as 
humans, can do anything in the world as long as we set out minds to it. It is, really, 
because of her that this thesis work has been accomplished. I thank my mother for all of 
her support—especially her emotional support through turbulent times during this 
journey—and for coming to take care of me when I needed her to and helping me analyze 









TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS iv	
LIST OF TABLES xvi	
LIST OF FIGURES xvii	
LIST OF SYMBOLS AND ABBREVIATIONS xxi	
SUMMARY xxiii	
CHAPTER 1.	 SPECIFIC AIMS 1	
1.1	 Introduction 1	
1.2	 Specific Aim I 2	
1.3	 Specific Aim 2 2	
1.4	 Specific Aim 3 3	
1.5	 Significance and Scientific Impact 4	
CHAPTER 2.	 BACKGROUND 7	
2.1	 Osteoarthritis 7	
2.1.1	 Biological and molecular pathomechanisms 9	
2.2	 Juvenile osteochondritis dissecans 12	
2.2.1	 Diagnosis and Classification 13	
2.2.2	 Treatment 16	
2.2.3	 Etiology 18	
2.2.4	 Biological and molecular pathomechanisms 21	
CHAPTER 3.	 REGIONAL GENE EXPRESSION ANALYSIS OF MULTIPLE 




3.3	 Materials and methods 26	
3.3.1	 MMT model 26	
3.3.2	 Microarray gene expression experiment 26	
3.3.3	 Gene expression statistical analyses 30	
3.3.4	 Immunohistochemistry 31	
3.4	 Results 32	
3.4.1	 Articular cartilage gene expression 32	
3.4.2	 Synovial membrane gene expression 46	
3.4.3	 Confirmation of genes at the protein level 53	
3.5	 Discussion 55	
3.5.1	 Localized gene expression 55	
3.5.2	 Articular cartilage of the medial tibial plateau 55	
 xiv 
3.5.3	 Osteophyte tissue 58	
3.5.4	 Distal medial synovial membrane 60	
3.5.5	 Inflammation in the MMT model 60	
CHAPTER 4.	 LOCALIZED OSTEOARTHRITIS DISEASE-MODIFYING 
CHANGES DUE TO INTRA-ARTICULAR INJECTION OF MICRONIZED 
DEHYDRATED HUMAN AMNION/CHORION MEMBRANE 62	
4.1	 Abstract 62	
4.2	 Introduction 63	
4.3	 Materials and methods 65	
4.3.1	 Animals: Surgery and treatment 65	
4.3.2	 Microarray gene expression 66	
4.3.3	 Histological analysis 69	
4.3.4	 Statistical analyses 69	
4.4	 Results 71	
4.4.1	 Articular cartilage 71	
4.4.2	 Synovial membrane 76	
4.4.3	 Osteophyte region 82	
4.4.4	 AmnioFix sequestration 83	
4.4.5	 Recruitment of helper cells by AmnioFix 83	
4.5	 Discussion 84	
CHAPTER 5.	 DEVELOPMENT AND CHARACTERIZATION OF patient-
specific INDUCED PLURIPOTENT STEM CELL-derived IN VITRO MODELS 
OF JUVENILE OSTEOCHONDRITIS DISSECANS 91	
5.1	 Abstract 91	
5.2	 Introduction 92	
5.3	 Materials and methods 94	
5.3.1	 Tissue and cell samples 94	
5.3.2	 iPSC culture, characterization and validation 97	
5.3.3	 iMSC differentiation 98	
5.3.4	 iMSC characterization and validation 99	
5.3.5	 Chondrogenic and endochondral ossification differentiation models 101	
5.3.6	 Quantitative analyses of differentiation 102	
5.3.7	 Gene expression 103	
5.3.8	 Histology 106	
5.3.9	 Transmission electron microscopy (TEM) 108	
5.3.10	 Statistical analyses 108	
5.4	 Results 108	
5.4.1	 iPSC reprogramming, characterization and validation 108	
5.4.2	 iMSC characterization and validation 109	
5.4.3	 Chondrogenesis model 111	
5.4.4	 Endochondral ossification model 115	
5.4.5	 Protein accumulation in the ER during differentiation 117	
5.5	 Discussion 118	
 xv 
CHAPTER 6.	 ENDOPLASMIC RETICULUM STRESS RESPONSE 




6.3	 Materials and methods 126	
6.3.1	 Cell lines 126	
6.3.2	 Chondrogenic and endochondral ossification models (organoids) 127	
6.3.3	 ER stress-induction model 127	
6.3.4	 Gene expression 128	
6.3.5	 Statistical analyses 131	
6.4	 Results 132	
6.4.1	 Differentiation models 132	
6.4.2	 ER-stress models 137	
6.5	 Discussion 141	
CHAPTER 7.	 SUMMARY AND FUTURE DIRECTIONS 145	
7.1	 Overall summary 145	
7.2	 Future directions 146	
APPENDIX A. TOWARDS AN EARLY-STAGE SMALL ANIMAL MODEL OF 
OSTEOCHONDRITIS DISSECANS 148	
A.1 	 Introduction 148	
A.2 	 Success criteria 149	
A.2.1	 Bone 149	
A.2.2	 Articular cartilage 150	
A.3 	 Chemical insult 150	
A.3.1	 Surgical procedure 150	
A.3.2	 Results and discussion 152	
A.3 	 Thermal insult 153	
A.3.1	 Surgical procedure 153	
A.3.2	 Results and discussion 154	
A.4 	 Mechanical-barrier insult 158	
A.4.1	 Surgical procedure 158	




LIST OF TABLES 
Table 1 Osteochondritis Dissecans grading system. 14 
 
Table 2 
Taqman Gene Expression assays utilized for the 




Taqman Gene Expression Assays utilized for the evaluation of 
the effects of AmnioFix in the MMT model. 
68 
Table 4 Detailed characteristics of JOCD iPSC lines. 95 
Table 5 Detailed characteristics of control iPSC lines. 96 
Table 6 iPSC lines (and iMSCs and organoids) studied in each group: 
control vs. JOCD patients.  
97 
Table 7 Summary of criteria to identify MSC, as set by the 




List of Taqman Gene Expression Assays used for each 
experiment in the development of JOCD-specific iPSC-based 
in vitro models of chondrogenesis and endochondral 
ossification. 
106 
Table 9 List of primary antibodies used in immunohistochemistry for 
each experiment in the development of JOCD-specific iPSC-
based in vitro models of chondrogenesis and endochondral 
ossification. 
107 
Table 10 Unfolded protein response (UPR) has three major ER-stress 
sensors: PERK, ATF6 and IRE1, which play particular roles in 
the ER-stress related activated response [162]. 
125 





List of Taqman gene expression assays used to evaluate the 
expression of ER-stress-related genes in the JOCD-iPSC-based 




List of Taqman gene expression assays used to evaluate the 
molecular response of JOCD and control cell lines to ER-




LIST OF FIGURES 
Figure 1 Prevalence of self-reported musculoskeletal disease by age 
group, reported by the National Health Interview Survey 
(NHIS) 
8 
Figure 2 Osteochondritis dissecans 13 
Figure 3 Decision-making algorithm for treating JOCD of the knee 16 
Figure 4 Representation of an operated left leg in which the medial meniscus 
has been transected (MMT model) 
27 
Figure 5 Volcano plots of the control (unoperated) group of the articular 
cartilage of the tibial plateau. 
33 
Figure 6 Volcano plots and multivariate analysis of the lateral side of the 
articular cartilage of the tibial plateau. 
34 
Figure 7 Clustering of the medial side of the articular cartilage of the 
tibial plateau. 
36 
Figure 8 Radar plot of averaged (mean) ΔCt expression of individual 
genes in the unoperated, control medial tibial plateau cartilage 
(control), the MMT medial tibial plateau cartilage (MMT) and 
the sham medial tibial plateau cartilage (sham), at different 
timepoints. 
36 
Figure 9 Significantly differently expressed genes of articular cartilage of the 
medial tibial plateau for all groups. 
38 
Figure 10 Multivariate analysis between articular cartilage from the 
medial tibial plateau and the osteophyte tissue. 
41 
Figure 11 Significantly differently expressed genes of the articular 
cartilage from the medial tibial plateau of MMT animals (MMT 
group) vs. tissue from the osteophyte-developing region of 
MMT animals (osteo group). 
42 
Figure 12 Radar plot of averaged (mean) ΔCt expression of individual genes in 
the sham osteophyte tissue (sham) and the MMT osteophyte tissue 
(MMT), at different timepoints. 
45 
 xviii 
Figure 13 Significantly differently expressed genes of the osteophyte region 
between the sham and MMT groups for both timepoints. 
46 
Figure 14 Multivariate analysis and clustering of the synovial membrane. 47 
Figure 15 Clustering of the medial side of the synovial membrane. 49 
Figure 16 Radar plot of averaged (mean) ΔCt expression of individual 
genes in the unoperated, control medial synovial membrane 
(control), the sham medial synovial membrane (sham) and the 
MMT medial synovial membrane (MMT), at different 
timepoints. 
50 
Figure 17 Significantly expressed genes in the distal medial synovial membrane 
for all groups. 
51 
Figure 18 Fluorescent immunohistochemistry of collagen type 2, Mmp13, and 
osteopontin of the articular cartilage and the synovium at week 3. 
54 
Figure 19 Clustering and multivariate analysis of the articular cartilage of 
the medial tibial plateau in response to AmnioFix treatment. 
72 
Figure 20 Significantly different genes in the medial tibial plateau 
cartilage between AmnioFix and saline groups. 
73 
Figure 21 Significantly differently expressed genes in the medial articular 
cartilage of the tibial plateau, between control and treatment 
groups. 
75 
Figure 22 Clustering and multivariate analysis of the medial side of the 
synovial membrane in response to AmnioFix treatment. 
77 
Figure 23 Significantly expressed genes between AmnioFix and saline 
groups of the medial synovial membrane. 
79 
Figure 24 Significantly different genes in the medial synovial membrane, 
between the control group and the treatment groups. 
81 
Figure 25 Clustering and multivariate analysis of tissue from the 
osteophyte region in response to AmnioFix treatment. 
82 
Figure 26 Hematoxylin & Eosin staining of the synovial membrane shows 
traces of AmnioFix Injectable in the AmnioFix treatment group 
and not in the saline group at 7 days post-surgery. 
83 
Figure 27 CD68+ staining of cells was observed at day 7 post-surgery in 
the AmnioFix group, but not in the saline group. 
84 
 xix 
Figure 28 iPSC characterization and validation. 109 
Figure 29 Characterization and validation of iMSCs. 110 
Figure 30 Gene expression in chondrogenic pellets over time. 112 
Figure 31 GAG deposition by chondrogenic pellets, normalized to DNA 
content; graphed as means ± SEM. 
113 
Figure 32 Immunohistochemistry staining of chondrogenic pellets for 
collage type II/collagen type I and aggrecan. 
114 
Figure 33 Gene expression in pellets undergoing endochondral 
ossification. 
116 
Figure 34 Calcium deposition by osteogenic pellets, normalized by DNA 
content; graphed as means ± SEM. 
116 
Figure 35 Immunohistochemistry staining of osteogenic pellets for 
collagen type II/collagen type I.  
117 
Figure 36 TEM representative images of chondrogenic pellets at day 49. 118 
Figure 37 Normalized relative expression of ER-stress related genes in 
response to 3D endochondral ossification differentiation, 
graphed as means ± SEM. 
134 
Figure 38 Normalized relative expression of ER-stress related genes in 
response to 3D endochondral ossification differentiation, 
graphed as means ± SEM. 
136 
Figure 39 Normalized relative expression (ΔΔCt) of ER-stress related 
genes in response to PTIC drug. 
138 
Figure 40 Normalized relative expression of (ΔΔCt) of ER-stress related 
genes in response to TUN drug.  
140 
Figure 41 OCD grading system. Early-stage OCD includes grades I and 
II. Our goal was to develop an animal model that emulated 
OCD grade I. 
150 
Figure 42 Set-up of stereotaxic frame and cauterizer for OCD surgeries. 151 
Figure 43 MC3T3 pre-osteoblast cells after 24 hours of MIA treatment at 
the various concentrations. 
152 




Figure 45 Diagram of surgical procedure for thermally-induced OCD 
animal model. 
154 
Figure 46 Representative pictures of gross morphology of the different 
groups in the thermally-induced OCD surgical procedure. 
155 
Figure 47 DAPI staining of the different groups in the thermally-induced 
OCD surgical procedure. 
156 
Figure 48 Histological staining (saf-o/fast green) of the different groups in 
the thermally-induced OCD surgical procedure. 
157 
Figure 49 Attachment for the liquid nitrogen sprayer/gun, of the same 
diameter as the drill hole (0.5 mm). 
158 






LIST OF SYMBOLS AND ABBREVIATIONS 
ANOVA Analysis of variance 
BM-MSC Bone marrow-derived mesenchymal stem cell 
BMP Bone morphogenetic protein 
cDNA Complementary deoxyribonucleic acid 
DMOAD Disease-modifying osteoarthritis drug 
DNA Deoxyribonucleic acid 
EB Embryonic body 
ECM Extracellular matrix 
ELISA Enzyme-linked immunosorbent assay 
EPIC-µCT Equilibrium partitioning of an iconic contrast agent via micro-CT 
ER Endoplasmic reticulum 
ERSD Endoplasmic reticulum storage diseases 
FDA The Food and Drug Administration 
GAG Glycosaminoglycans 
H&E Hematoxylin and Eosin 
IHC Immunohistochemistry 
iMSC Induced pluripotent stem cell-derived mesenchymal stem cells 
IL Interleukin 
iPSC Induced pluripotent stem cell 
JOCD Juvenile Osteochondritis Dissecans 
MCL Medial collateral lligament 
MIA Monosodium iodoacetate 
 xxii 
MMP Matrix metalloproteinase 
MMT Medial meniscus transection 
MSC Mesenchymal stem cell 
NBF Neutral buffered formalin 
NO Nitric oxide 
OA Osteoarthritis 
OCD Osteochondritis Dissecans 
PTIC Protein transport inhibitor cocktail 
QRO Quantile range outlier 
RA Rheumatoid arthritis 
rER Rough endoplasmic reticulum 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RT-PCR Real time polymerase chain reaction 
RT Room temperature 
SD Standard deviation 
SEM Standard error of the mean 
sGAG Sulfated glycosaminoglycans 
TEM Transmission electron microscopy 




 Joint degenerative disorders impose a large burden on lifestyle and the healthcare 
system. The goals of this thesis were to elucidate pathological mechanisms in 
osteoarthritis (OA) and juvenile osteochondritis dissecans (JOCD) in order to improve 
understanding of these diseases, and to provide well-characterized platforms for 
therapeutic development and testing. OA is the leading cause of disability in the U.S., and 
it is a disease of the joint that affects multiple tissues. Despite breakthroughs in molecular 
events (e.g. mechanisms in cartilage degradation), its pathological mechanisms are still 
largely unknown. There are currently no FDA-approved disease modifying OA drugs 
(DMOADs), despite promising preclinical data. In order to bridge the gap in knowledge 
between preclinical and clinical studies, we characterized molecular events that occur in 
the rat medial meniscus transection (MMT) model of post-traumatic OA as the disease 
develops and progresses. Our results indicated that pathological events in the articular 
cartilage and synovium of the MMT model are similar to known human OA 
development. Our results also suggested feedback interactions between joint tissues 
during disease progression.  
 Second, we investigated the mechanisms of action of micronized dehydrated 
human amnion/chorion membrane (AmnioFix Injectable, MiMedx, USA) in order to 
elucidate potential disease-modifying mechanisms of this therapeutic. Results showed 
that AmnioFix does not have a direct influence on the gene expression of articular 
cartilage or tissue from the osteophyte-forming region of the joint. Instead, AmnioFix 
acted through the synovial membrane, modulating its microenvironment to a favorable 
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chondro-protective profile. These results further supported the importance of tissue 
interactions in the MMT model and in OA, and also provided a new view point 
concerning disease-modifying approaches for OA. 
JOCD is an increasingly common disorder that affects children and adolescents 
with an open physis. JOCD results in the partial or complete fragmentation of a necrotic 
osteochondral body from the parent bone, which permanently affects the joint and alters 
its mechanics. Therefore, JOCD patients have a higher probability of developing OA at 
an early age. JOCD presents a unique challenge, as treatment strategies are limited to 
surgical interventions at advanced stages. Although there a number of hypotheses about 
the etiology of JOCD, its pathological mechanisms are yet to be investigated. In this 
thesis, we established induced pluripotent stem cell (iPSC)-derived models of JOCD 
chondrogenesis and endochondral ossification in order to study its pathology. Our results 
demonstrated that cells from JOCD patients have a lower chondrogenic capacity than 
normal, control cells. Results also showed that although endochondral ossification is 
successfully accomplished, there may be irregularities in its process. We also established 
ER-stress induction models in order to dissect mechanistically how JOCD-iPSC-derived 
mesenchymal stem cells (iMSCs) responded to ER stress. Our results showed that JOCD 
cells have a different response to ER stress, which could lead to cell death should the ER 
stressor persist. We propose that this pathological feature could lead to the onset of 
clinical JOCD. 
Taken together, this thesis significantly contributed to the knowledge gap of OA 
and JOCD pathomechanisms. This work provided new insights into development of joint 
degeneration in the MMT model and established a well-characterized baseline to evaluate 
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mechanistic effects of potential therapeutic agents in this OA-like model. It also 
investigated mechanisms of action of AmnioFix, which may be leveraged to develop 
more specific DMOADs. Most importantly, this thesis presented pioneering work on 
patient-specific iPSC-based disease modeling. This is the first study to elucidate 
pathomechanisms of JOCD and to establish JOCD-specific in vitro models for future 
therapeutic testing.   
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CHAPTER 1. SPECIFIC AIMS 
1.1 Introduction 
As the population ages and lives longer, joint degenerative disorders impose a 
larger burden in the healthcare system. Osteoarthritis (OA) is the most common form of 
musculoskeletal disability, affecting approximately 30 million people in the US alone [1]. 
It is forecast that one in four people will develop OA in their lifetime [2]. Due to its 
complexity and the many interactions in the joint space, the pathological events that take 
place in OA development remain largely unknown. Therefore, current available 
treatments are limited to pain management and eventual total joint replacement. 
When OA affects the working or pediatric populations, the burden on lifestyle and 
the healthcare system increases. Juvenile OsteoChondritis Dissecans (JOCD) affects 
children and adolescents, and often progresses to early onset OA. The etiology of JOCD 
is not fully understood, but it is believed to be a combination of factors such as 
biomechanical overuse, trauma, and genetic predisposition. Unfortunately, molecular 
pathological mechanisms are virtually unknown. Previous research has been primarily 
focused on retrospective clinical studies, which has also hampered the development of 
effective therapeutics for this disorder and the prevention of its progression to OA. 
Current treatments are limited to invasive surgical interventions to salvage the necrotic 
lesion at advance stages of this disorder. 
The overall objective of this thesis is to elucidate pathophysiological mechanisms 
of OA and JOCD models in order to fill gaps in knowledge as well to provide the field 
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with well-characterized platforms for future therapeutic development and testing. We 
approached this objective through the following specific aims:  
1.2 Specific Aim I 
Investigate localized molecular events of disease progression in an in vivo post-
experimental model of post-traumatic OA 
 The rat medial meniscus transection (MMT) model is a frequently used model of 
post-traumatic OA and is of high clinical relevance. This model replicates many 
characteristics attributed to human OA, such as cartilage degeneration, osteophyte and 
focal lesion formation, and cartilage fibrillation. However, this model has not yet been 
characterized at the molecular level. The microenvironment that treatments encounter 
upon delivery is unknown and thus mechanisms of action for the therapeutic in question 
cannot be properly assessed. The objective of this aim was to characterize the MMT OA 
model at the molecular level (gene expression), for multiple tissues, regions of interest 
within the joint, and timepoints. Our hypothesis was that the MMT model replicates some 
of the observed human OA pathomechanisms, such as degradation and remodeling of the 
extracellular matrix (ECM) of the articular cartilage and chondrocyte dedifferentiation.  
1.3 Specific Aim 2 
Elucidate therapeutic mechanisms of micronized dehydrated amnion/chorion 
membrane as a potential disease-modifying OA drug 
In a previous study, intra-articular delivery of micronized dehydrated human 
amnion/chorion membrane (AmnioFix Injectable, MiMedx, GA, USA) showed a 
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chondro-protective effect in the MMT post-traumatic OA animal model [3]. AmnioFix is 
hypothesized to act through the synovial membrane. However, it is unknown how 
AmnioFix modulates the microenvironment of the synovial membrane or the joint space, 
if at all. As an ECM-based treatment, AmnioFix Injectable contains a cocktail of growth 
factors and cytokines, and so, in order to dissect its potential disease-modifying 
attributes, in-depth molecular analyses need to be performed. The objective of this aim 
was to elucidate the mechanisms of action (via microarray gene expression) of AmnioFix 
Injectable in the MMT model, in multiple tissues of different regions and at multiple 
timepoints. We hypothesized that AmnioFix does indeed act through the synovial 
membrane, down-regulating ECM degradation markers in the synovium, which protects 
the articular cartilage from a faster degradation rate.   
1.4 Specific Aim 3 
Develop patient-specific iPSC-derived in vitro models of JOCD in order to elucidate 
pathological mechanisms 
 iPSCs allow an endless supply of patient-specific cells and to be able to study 
multiple aspects of the same disease by differentiating multiple tissues. Because JOCD 
occurs in the still-developing pediatric population, its onset has been theoretically linked 
with aberrations in the differentiation of the secondary physis. Previous research has 
studied JOCD primary chondrocytes, but not chondrogenic differentiation or 
endochondral ossification, which occur in the affected joints around the time JOCD 
develops. Moreover, other diseases under the OCD umbrella (familial and equine) have 
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been directly associated with ER dysfunction, yet there are no studies to this date that 
have investigated this pathological feature in JOCD patients. 
The objective of this aim was to develop and study patient-specific iPSC-derived in 
vitro models of JOCD of chondrogenesis and endochondral ossification (both considered 
important processes in JOCD) and of ER-induced stress. Our overarching hypothesis was 
that JOCD patients have a suboptimal bone matrix synthesis and assembly due to 
impaired ER-stress-related responses, which may lead to a higher susceptibility to clinical 
JOCD. These models did not only shed light in our understanding of JOCD pathology, 
but also provided the field with well-characterized platforms for testing of therapeutic 
interventions.  
1.5 Significance and Scientific Impact 
The burden of joint diseases is continually increasing as the population lives 
longer and the incidence of co-morbidities (e.g. obesity) increase. The lack of effective 
disease-modifying therapeutics is in part due to a gap in knowledge concerning the 
pathological mechanisms of these diseases and the relevance of pre-clinical models. The 
work described in this thesis is significant because it provides novel information that may 
help bridge this gap for OA and JOCD. It also presents innovative tools and platforms to 
test new therapeutic interventions for these diseases.  
OA is a complex multi-tissue joint disease with various sub-phenotypes. 
Therefore, the models in which potential drugs are tested should be thoroughly 
characterized in order to understand the mechanisms of action of the therapeutic and to 
infer for which OA cases it may be most efficacious. This thesis is the first to utilize 
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microarray gene expression technology to characterize the molecular events of OA 
development in multiple tissues and regions of interest in the MMT post-traumatic 
model. This work will provide the scientific community with a baseline to determine 
whether the MMT model is appropriate for testing the therapeutic in question. 
Furthermore, by studying molecular events in the MMT model, we shed light on tissue 
interactions and the complexity of OA-like development in this model. 
This work has also isolated molecular events that occur in the MMT model as a 
response to ECM-based therapeutic AmnioFix Injectable. AmnioFix is currently 
considered a potential disease-modifying treatment, and by utilizing our microarray gene 
expression tool, we were able to suggest mechanisms that may be leveraged to create a 
more specific therapeutic than AmnioFix. This thesis introduces the scientific community 
to a perspective concerning the treatment of OA. Conventional approaches often seek to 
treat or inhibit pro-inflammatory pathways within the joint; instead, we suggest the 
approach of modulating the microenvironment of the joint towards a phenotype that 
promotes wound healing mechanisms. 
While OA is an active area of research within the musculoskeletal field, research 
about the development and pathology of JOCD is very limited. This work is the first to 
investigate JOCD differentiation mechanisms, in chondrogenesis and endochondral 
ossification, as well as JOCD-specific mechanistic response to ER stress. By developing 
JOCD-specific iPSC-derived in vitro models, not only did this thesis introduced cutting-
edge technology to the field, but it also became the first work to elucidate possible 
pathological molecular events in JOCD. Early therapeutic interventions in JOCD are 
conservative and with a high rate of failure (34% to 50%, [4-7]). The observations 
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presented in this work may help in the development of treatments and thus possible 
prevention of OA in these patients. This work has also significantly contributed by being 
the first to introduce JOCD-specific in vitro models, both of differentiation and of ER-
stress induction.   
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CHAPTER 2. BACKGROUND 
2.1 Osteoarthritis 
OA is the most common cause of musculoskeletal pain and disability worldwide, 
with almost $200 billion per year impact on healthcare costs in the U.S. [1, 8, 9]. 
Although typically viewed as a result of bodily “wear and tear”, OA is now considered a 
multifactorial disorder and to affect multiple tissues within the joint cavity. OA can be 
divided into subtypes, some of which might have a more biochemical, inflammatory or 
genetic signature than others, but all of which eventually converge into the common 
phenotype [10]. OA is a full organ disease, and it is characterized by the progressive 
breakdown of the articular cartilage, the formation of bony outgrowths at the joint margin 
(osteophytes), subchondral bone sclerosis, hypertrophy of the joint capsule and 
inflammation of the synovial membrane (synovitis) [11, 12]. Despite improved 
understanding, the consequences of pathological events in OA are still poorly understood. 
This is in part due to the heterogeneity of the disease and the complexity of interactions 
among the different tissues within the joint space. Many questions remain about missing 
links (unknown processes) and how the known processes come together to mediate the 
pathogenesis of OA. 
Currently, there are no FDA-approved DMOADs in the market. Therapeutic 
interventions are targeted towards symptomatic management via pain control, 
viscosupplementation (via intra-articular injections of hyaluronic acid) and joint 
replacements [3, 9, 12]. Knee replacements alone cost nearly $30 billion annually in the 
U.S., and they are primarily attributed to knee OA [13]. Total joint replacements are only 
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expected to last 15 to 20 years; therefore, doctors do not recommend these surgeries to 
patients younger than 50 years old. This younger population has to endure OA symptoms 
for longer periods of time despite their advanced stage, and when given the replacement 
surgery, they outlive the implants and need revision surgeries. Although OA is typically 
associated with old age, with approximately 37% of the US population over 60 years of 
age affected [12, 14, 15] and 45% adults expected to suffer from it by the age of 85 [16], 
it also afflicts the young (Figure 1). Degenerative joint diseases impose a larger and 
longer-term burden on the healthcare system when they affect working or pediatric 
populations. Younger people may develop OA as a result of injury, overuse or as a 
secondary effect of another joint disorder. 
 
Figure 1. Prevalence of self-reported musculoskeletal disease by age group, reported 
by the National Health Interview Survey (NHIS): Adult sample (July 2nd, 2013). 
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2.1.1 Biological and molecular pathomechanisms 
2.1.1.1 Cartilage 
Key events occurring in cartilage during pathogenesis of OA include an 
imbalance of metabolic and degradative signals, driven by cytokine cascades and the 
production of inflammatory mediators [17]. Moreover, altered biomechanics, such as 
those seen in joint malalignment, obesity or advanced stages of OA, induce and 
potentiate further biochemical changes. Mechanical stress, by both static and intermittent 
compression, increases nitric oxide (NO) production by chondrocytes as well as nitric 
oxide synthase expression [17].  NO contributes to articular cartilage damage: it inhibits 
collagen and proteoglycan synthesis, activates matrix metalloproteinases (MMPs), and 
increases susceptibility to other oxidant injury [17]. Furthermore, two important 
pathogenic events characteristic of OA chondrocytes, premature senescence and 
apoptosis, appear to results from NO and other oxidative injury [17-21]. As a result, it has 
been postulated that OA is a disease of premature aging of the joint; mechanically driven, 
and chemically, particularly reactive oxygen species (ROS)-mediated [17]. 
2.1.1.2 Synovium  
Accumulating evidence indicates that inflammation has a critical role in OA 
pathogenesis, and that this inflammation is distinct from that in rheumatoid arthritis and 
other autoimmune diseases: it is chronic, comparatively low-grade [12]. Because of this 
feature and its low synovial fluid leukocyte counts, OA is classified as a non-
inflammatory arthritis. Yet, synovitis occurs even in early OA and can be sub-clinical, as 
arthroscopic studies suggest that localized proliferative (thickening) and inflammatory 
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changes of the synovium occur in up to 50% of OA patients – many of whom do not 
appear to have active inflammation [11, 17, 22]. Unlike rheumatoid arthritis, synovial 
inflammation of OA is mostly confined to areas adjacent to pathologically damaged 
cartilage and bone [23], which suggests that synovitis is a response to cartilage injury. 
Once cartilage breakdown has begun, the synovial cells phagocytose the 
breakdown products released into the synovial fluid, resulting in the synovial membrane 
becoming hypertrophic and hyperplasic [11]. The activated synovium then releases pro-
inflammatory cytokines and catabolic mediators, which further alter the balance of 
cartilage matrix degradation and repair and lead to excess production of the proteolytic 
enzymes responsible for cartilage breakdown [11]. In this sense, the synovium and the 
cartilage enter a positive feedback loop, in which destructive molecules are produced in a 
vicious autocrine and paracrine fashion [17]. This inflammatory response is amplified by 
activated synovial T cells, B cells and infiltrating macrophages [11].  
To counteract this inflammatory response, the synovium has shown to produce 
anti-inflammatory cytokines, which decrease the release of pro-inflammatory cytokines 
and MMPs and inhibit the apoptosis of synovial cells, thus contributing to synovial 
hypertrophy [11]. Unfortunately, persistence of the stimuli (injured cartialge) greatly 
complicates the resolution of this inflammatory response in the synovium.  
2.1.1.3 Bone 
Given the intimate contact between the cartilage and bone, alterations of either 
tissue will modulate the properties and function of the other joint component [24]. 
Marked alteration in the contour of the adjacent articulating surfaces in OA result in 
 11 
modification in joint congruity that contribute to an adverse biomechanical environment 
for both the bone and the cartilage itself [24]. Then, cellular processes of remodeling and 
modeling occur in the bone as an adaptation to mechanical loads and damage. 
 Bone changes in OA can be divided into distinct patterns based on the anatomic 
location and mechanisms involved in their pathogenesis [25]. These alterations include 
progressive increase in subchondral plate thickness, modification in the architecture of 
subchondral trabecular bone, formation of new bone at the joint margins (osteophytes), 
development of subchondral bone cysts, bone marrow lesions, and advancement of the 
tidemark associated with vascular invasion of the calcified cartilage [24-27].  
Osteophytes are commonly thought to develop from mesenchymal cells in or near 
the periosteum [28, 29], as a repair response to help stabilize degrading joint surfaces 
[25], even though osteophytes also cause obvious negative effects such as pain and loss 
of movement [30]. In this process, periosteal mesenchymal cells begin to proliferate at 
the joint margin and subsequently differentiate into chondrocytes that undergo 
hypertrophy and then endochondral ossification to create an enlarging skeletal outgrowth 
at the joint margin [25]. 
Osteophyte formation is thought to be initiated and accelerated by the local 
production of growth factors, particularly from the inflamed synovium. Apart from 
mediating synovial activation, macrophages in the synovial lining can produce several 
growth factors in high quantities, including chondroosseous-forming factors (e.g. 
transforming growth factor-β, and bone morphogenetic protein-2 and -4) [30]. In several 
models of experimental arthritis, selective depletion of macrophages from the synovial 
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lining prevents osteophyte formation [30-32]. Thus, synovial macrophages are crucial 
intermediaries in the formation of osteophytes. 
2.2 Juvenile osteochondritis dissecans 
JOCD is an increasingly common cause of pain and dysfunction among skeletally 
immature and young adult patients (typically ages 6 to 19), and progresses to early onset 
OA [33-36]. Increased incidence is in part due to earlier and increasingly competitive 
athletic endeavors and improved advanced imaging technology and diagnostic guidelines 
[37-39]. The majority of JOCD lesions (61.7% [40]) are found in the knee, most 
commonly in the medial femoral condyle. A study found that out of all JOCD lesions, 
35.3% progressed to surgery, and out of that percentage, 58.5% were knee JOCD [40]. 
JOCD is hypothesized to initially involve the formation of an avascular lesion in 
the subchondral bone with secondary effects in the overlaying articular cartilage [33, 34, 
41]. During late stages of this musculoskeletal disorder, the lesion becomes unstable and 
separation of an osteochondral fragment (loose body) ensues (Figure 2). Lesions early in 
their course are associated with poorly defined symptoms: variable pain and swelling. As 
the lesion progresses, catching, locking and pain are constant. The etiology of JOCD is 
not fully understood but believed to be a multifactorial combination of biomechanical 
overuse and genetic predisposition. However, previous research has been primarily 
limited to retrospective clinical studies, and no study to date has thoroughly characterized 
the pathological mechanisms associated with the onset and progression of JOCD [34]. An 
improved understanding of the pathobiological mechanisms of JOCD may facilitate the 
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development of more effective treatment options and ultimately prevent the development 
of OA at an early age in these patients. 
 
Figure 2. Osteochondritis Dissecans results in the formation of a loose body in the 
joint space. Osteonecrosis of the subchondral bone and degradation of the 
overlaying articular cartilage are key characteristics. Source: www.eorthopod.com 
(osteochondritis dissecans). 
 
2.2.1 Diagnosis and Classification 
Osteochondritis dissecans (OCD) has been traditionally subdivided into two 
types, juvenile (JOCD) and adult, on the basis of physeal closure [35]. Currently, there 
exist several classification systems for OCD based on radiographs, MRI findings, and 
arthroscopically. The MRI and arthroscopic gradings have been shown to be highly 
correlated [42], yet further research and collaboration is still needed to reach a consensus 
to accurately describe OCD lesions [42, 43]. Imaging methods fail to provide conclusive 
evidence on the subchondral fragment stability unless the osteochondral fragment has 
dissecated [36].  
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Recognizing the need for a more standardized and universally accepted systems, 
the International Cartilage Repair Society (ICRS) published an OCD classification 
system (Table 1), applicable to both JOCD and adult OCD. This classification is based on 
superficial assessment of the articular cartilage surface, and is used widely as a basis to 
determine the course of patient treatment.  
Table 1. ICRS OCD grading score [44]. Grades I and II are considered stable 
lesions, while III and IV are unstable. 
Stage Characteristics 
I Stable lesions with a continuous but softened area covered by intact cartilage 
II Lesions with partial discontinuity that are stable when probed 
III Lesions with a complete discontinuity that are not yet dislocated (“dead in 
situ”) 
IV Empty defects and defects with a dislocated fragment or a loose fragment 
within the bed 
*Subgroups ICRS OCD I-IVB are lesions greater than 10 mm in depth 
 
JOCD cases are typically classified into ICRS OCD grade I/II (stable lesions). 
Despite the stable and normal appearance of articular cartilage, however, there is a 
controversy about conservative treatment of JOCD, where healing is reported in up to 
50% of cases [5, 39]. The cause of treatment failure in these JOCD cases is still unclear, 
and may be attributed to the initial diagnosis and classification system from which 
clinician determine the appropriate treatment option. Kijowski et al showed that 
previously described MRI for describing OCD instability has a higher specificity for 
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adult (100% sensitivity, 100% specific) but not juvenile lesions of the knee (100% 
sensitivity, 11% specific) [45]. 
Moreover, Yonetani et al. demonstrated that JOCD lesions in 8 symptomatic 
patients had pathological instability despite stability at the articular surface [35]. 
Arthroscopically, the surface of the JOCD lesions appeared normal and stable. 
Cylindrical biopsy (articular cartilage and bone) samples were obtained, and the extent of 
damage was histologically evaluated. It was found that all biopsy specimen had 
undergone separation between the cartilage and the subchondral bone, and that fibrous 
and fibro-cartilage tissue filled in the separation site [35]. Therefore, there is a clear need 
for an improved understanding and classification method for JOCD patients exclusively. 
In spite of similarity, studies have demonstrated that there are physical features in adult 
OCD, which are absent in JOCD. These distinct differences may be explained by the 
level of skeletal maturation, and are sufficient to warrant separate diagnosis and 
classification for JOCD. 
In a recent epidemiology study, Weiss et al showed that progression to surgery for 
OCD of the knee, elbow, and ankle strongly correlated with patient age at the time of 
diagnosis [40]. Patients aged 12 to 19 years were 8.2 times more likely to progress to 
surgery for all OCD lesions than patients aged 6 to 11 years [40]. This drastic difference 
even among skeletally immature patients further supports the need for a better system of 
JOCD classification in order to accurately diagnose a stage and its most appropriate 
treatment. While imaging technology has helped push forward JOCD diagnosis, it has 
shown its limits, and the implementation of biological markers may steer towards an 
improved precise medicine. 
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2.2.2 Treatment 
The management of JOCD is controversial. A number of factors need to be taken 
into account when choosing the appropriate course of treatment: skeletal maturity, 
fragment size, fragment location, and fragment stability [36, 46]. A lesion is classified 
into 3 main groupings: articular cartilage intact, articular cartilage separated (unstable), 
and fragment completely loose. The designated classification influences the surgical 
treatment, as shown in Figure 3. 
 
Figure 3. Decision-making algorithm for treating JOCD of the knee [47, 48].  
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Reportedly, non-operative treatment of JOCD is very successful in properly 
selected patients. However, thanks to the implementation of advanced imaging 
techniques with a higher sensitivity for diagnosis and outcome evaluation of JOCD, new 
studies have started to report a much higher rate of failure. Wall et al. showed 34% 
failure after non-operative treatment using MRI, while Cahill et al reported 50% failure 
using more sensitive bone scintigraphy and radiographs [4-6]. Pain and/or mechanical 
symptoms or lack of evidence of healing on radiographs or MRI that persist represent 
failed non-operative treatment and indicate the need for surgery in up to 50% of patients 
with stable JOCD lesions [4]. With non-operative treatment, an estimated 5% cumulative 
incidence at 5 years after diagnosis developed symptomatic OA; 10% at 10 years, 20% at 
25 years, and 30% at 35 years [49]. Depending on the age at which JOCD was diagnosed, 
this could mean developing OA as early as 15 years of age. 
Bone marrow stimulation techniques, in particular arthroscopic drilling, is 
recommended for stable lesions with intact cartilage. The goal of this technique is to 
create channels for vascular ingress stimulating local revascularization [36]. This 
technique has been successful in skeletally immature patients, with healing rates of 75% 
and higher [7, 50]. In patients with unstable or partially detached (ICRS OCD grade III) 
lesions, fixation with pins or screws is the treatment of choice. Despite success rate, 
patient morbidity associated with intra-articular fragment fixation and complications have 
been reported in a number of cases [36]. Once the lesion has reached ICRS OCD grade 
IV, the loose osteochondral fragment is excise and salvage procedures include 
perichondral/periosteal autografts, autogeneous cell transplantation, abrasion 
chondroplasty, osteochondral autografts, and osteochondral allografts depending on the 
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size and appearance of the lesion [46]. Unfortunately, most of these treatment options 
result in the formation of fibrocartilage covering over the exposed defect rather than true 
hyaline cartilage [36, 39, 46]. The long-term results from these procedures have yet to be 
clearly determined [46], but fragment excision procedures have reported 79% 
degenerative findings at a mean 11 year follow-up [51]. Advanced OCD lesions cause 
mechanical disruption of joint motion, loose body formation, mechanical wear, and 
attrition of associated surfaces on the tibial plateau or the meniscus [39]. In short, they 
lead to the onset of OA.  
2.2.3 Etiology 
2.2.3.1 Repetitive trauma 
Repeated microtrauma is the most recognized cause of OCD, because of the rising 
incidence of this disorder among athletes. Aichroth et al. demonstrated 60% of the 
patients with OCD in his study were involved in high-level, competitive sports [52]. A 
multicenter study conducted by the European Pediatric Orthopeadic Society found nearly 
55% of the patients with OCD were either regularly active in sports or performed 
“strenuous athletic activity” [53]. 
The classic location of OCD in the posterolateral portion of the medial femoral 
condyle suggests that indirect trauma is more likely the cause [54]. Repeated 
impingement of the tibial spine on the lateral aspect of the medial femoral condyle during 
internal rotation of the tibia has also been suggested to be a contributing factor [54, 55]. 
However, this theory would only explain lesions in that particular location. 
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2.2.3.2 Ischemia 
Ischemia has been proposed as a potential cause of OCD. Enneking et al. found 
the vascular supply to the subchondral bone to have poor anastomoses to surrounding 
arterioles [54, 56]. It has been suggested that this propensity for ischemia could lead 
subchondral none to form sequestra, making it particularly vulnerable to traumatic insult, 
resultant fracture, and potential separation [54]. However, this hypothesis has met a 
number of opposing arguments. Rogers and Gladstone studied the vascularity of the 
distal part of the femur and found numerous anastomoses to intramedullary cancellous 
bone [57]. Milgram demonstrated revascularization in 50 OCD lesions that were only 
partially attached [58]. Furthermore, a few studies have shown a lack of osseous necrosis 
upon examination of intact OCD lesions [35, 59], which may suggest that necrosis found 
in OCD may be secondary to the actual detachment of the lesion rather than the 
underlying etiology of formation [51]. Moreover, a number of research scientists believe 
the ischemia hypothesis to be less likely in JOCD cases, because these young patients 
probably have a good distal femoral blood supply (for knee OCD cases) [34]. 
2.2.3.3 Genetics  
While an initial study by Petrie in 1977 found no clear genetic etiology for OCD 
[60], several cases since then have been reported in which symmetric lesions in multiple 
joins were present [61, 62] and in sets of monozygotic and dizygotic twins [62-68]. 
Furthermore, a new study by Gornitzky et al. found that the proportion of pediatric 
patients with OCD (JOCD specifically) with positive family history was 14% [69]. 
2.2.3.4 Epiphyseal abnormalities 
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It has been hypothesized in the past that an aberrant development of only a 
portion of the epiphyseal growth plate may lead to OCD formation [51, 70, 71]. The 
concept is as follows: a single or repetitive insult to the endochondral epiphyseal growth 
plate occurs at an unspecified time (this is where the hypothesis of trauma may converge) 
[51]. With skeletal development, the uninjured region of endochondral epiphyseal 
ossification continues to ossify unhindered creating an ever enlarging OCD, whereas the 
injured region either completely stops ossification or temporarily stops [51].  In support 
of this theory, current unpublished data from the ROCK (Research in OsteoChondritis of 
the Knee) study group shows MRI signal (T2 fat saturation) for the epiphysis appears 
disrupted at the margins of the OCD lesion [51]. In addition, Laor et al. found a 
statistically significant frequency of discontinuity of the epiphysis overlaying JOCD 
lesions and postulated that the chondroosseous irregularities observed might be the result 
of disruption of normal process of endochondral ossification from the epiphysis [37].  
Abnormal epiphysis ossification may also be the result of disruption of local 
vasculature. In the epiphyseal ossification center, the newest bone formation occurs at the 
chondroosseous junction of the growing epiphyseal ossification center. Thus, the 
immediate subchondral bone can be considered a “metaphyseal equivalent.” As such, 
disruption in the vascular supply to the secondary physis would result in persistent 
cartilage extending deep and central to the chondroosseous border of the developing 
epiphysis [37]. Increased width of overlying chondroepiphysis would be observed, just 
like what was found in all of Laor’s JOCD subjects [37]. Furthermore, results of studies 
in veterinary literature suggest that vascular injury to the epiphysis is responsible for the 
development of osteochondral lesions that progress to OCD in animals such as rabbits, 
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birds, and foals [37, 72-75]. Transection of blood vessels within epiphyseal cartilage 
canals in foals resulted in necrosis of vessels and chondrocytes, which led to a focal delay 
in endochondral ossification and pathological cartilage fracture [75]. However, it is 
unclear whether the initial insult in children would be located within the overlaying 
chondroepiphysis or the metaphyseal-equivalent portion of the developing secondary 
center of ossification [37]. 
2.2.4 Biological and molecular pathomechanisms  
It has been shown that chondrocytes isolated from detached JOCD fragments 
maintain similar cell viability and proliferative activity to those from normal healthy 
cartilage [41, 76, 77]. CD166, a MSC surface marker, was detected in chondrocytes 
packaged in normal cartilages and JOCD chondrocytes, suggesting similar regenerative 
potential between these groups [41]. However, compared with normal chondrocytes 
isolated from control samples, both JOCD loose body- and cartilage biopsy-derived 
chondrocytes showed intracellular accumulation of matrix proteins that affected their 
morphology [77]. Histological assessment of JOCD biopsies showed abnormal ECM 
composition, which may be explained by the retention of matrix proteins intracellularly. 
This feature has also been observed in familial [78] and equine OCD [79], and in 
endoplasmic reticulum storage diseases (ERSD) [77]. All ERSD, including type II 
collagenopathies, show a critical accumulation of misfolded proteins that result in 
defective protein trafficking causing a phenotype characteristics of disease [77]. These 
disease similarities may suggest a direct role of the endoplasmic reticulum (ER) in the 
pathogenesis of JOCD.  
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Furthermore, JOCD is a disorder of the articular cartilage as well as the 
subchondral bone; however, no study to date has explored the mechanisms in JOCD 
endochondral ossification or the involvement of JOCD osteoblasts in the pathological 
mechanisms of the disorder. Osteoblasts are highly specialized cells that synthesize bone. 
They are key players in bone remodeling, and their misregulation may contribute to 





CHAPTER 3. REGIONAL GENE EXPRESSION ANALYSIS OF 
MULTIPLE TISSUES OF THE MEDIAL MENISCUS 
TRANSECTION MODEL OF POST-TRAUMATIC 
OSTEOARTHRITIS 
3.1 Abstract 
The objective of this study was to characterize local disease progression of the medial 
meniscus transection (MMT) model of post-traumatic OA at the molecular level, in order to 
establish a baseline for therapeutic testing at the preclinical stage and possibly discern molecular 
events that may further elucidate OA pathogenesis. Weight-matched male Lewis rats underwent 
MMT or sham surgery on the left limb with the right leg as contralateral control. At 1 and 3 
weeks post-surgery, tissues were harvested from different areas of the articular cartilage (medial 
and lateral tibial plateaus, and medial osteophyte region) and synovium (medial and lateral), and 
analyzed separately. RNA was extracted and used for microarray gene expression (RT-PCR) 
analysis.  
Results showed that gene expression changes due to surgery were isolated to the medial 
side of the joint. In the articular cartilage, gene changes in chondrocyte phenotype preceded 
changes in tissue composition genes. Differences in inflammatory markers were only observed at 
the osteophyte region at 3 weeks post-surgery. In the synovium, there was surgical noise at week 
1, which dissipated at 3 weeks post-surgery. At this later timepoint, meniscal instability resulted 
in elevated expression of matrix degradation markers and osteogenic markers in the synovium 
and cartilage. These results suggest feedback interactions between joint tissues during disease 
progression. Regional tissue expression differences found in MMT joints indicated similar 
pathophysiology to human OA, and provided novel insights about this degeneration model. The 
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examination of gene expression at a localized level in multiple tissues provided a well-
characterized baseline to evaluate mechanistic effects of potential therapeutic agents on OA 
disease progression in the MMT model. 
3.2 Introduction 
 There is a need for full characterization of pre-clinical models, with a view to 
comparison to human OA pathophysiology and to establish a baseline for therapeutic 
testing in these systems. Preclinical animal models of OA include experimentally 
accelerated but naturally occurring joint degeneration, transgenic mouse models, and 
surgically or chemically induced OA [80]. Unfortunately, none of these models can fully 
replicate the features and symptoms of human OA. Nevertheless, the impact of 
preclinical research will depend largely on the choice of the most appropriate model of 
OA for the specific process under investigation [80]. The disconnect between positive 
results in preclinical studies and failed clinical trials supports the need for better 
understanding of currently available preclinical models at the biological and molecular 
level in order to evaluate more accurately the therapeutic mechanisms of the tested 
treatment. 
 The rat MMT model is a frequently used model of post-traumatic OA, and is of 
high clinical relevance. The transection of the meniscus at its narrowest point alters the 
mechanical stability of the knee joint and induces OA-like progressive damage: cartilage 
degeneration involving chondrocyte and proteoglycan loss, osteophyte and focal lesion 
formation, collagen degradation and cartilage fibrillation [81]. The MMT model is known 
for localized degeneration primarily restricted to the medial tibial plateau. However, 
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despite being the industry standard for therapeutic testing, local disease progression 
events have not been thoroughly characterized in this model and assessment of 
therapeutic outcomes is largely limited to classical histology or microCT (morphological 
analyses) as endpoint readouts [81]. 
 To date, a single study has reported on changes in the articular cartilage 
transcriptome of the rat MMT model. 20 genes differentially expressed between MMT 
and sham groups were identified, and the study concluded that the model paralleled key 
features of OA pathology, namely articular cartilage extracellular matrix (ECM) 
remodeling, angiogenesis, and chondrocyte cell death [82]. In this study, articular 
cartilage from both medial and lateral sides of the tibial plateaus and femoral condyles 
were collected from each animal, and then the cartilage tissue from 5 animals was pooled 
to create a single sample [82]. Cartilage collection from the entire joint and pooling of 
samples is standard for gene expression analyses in OA small animal models [82-84]. Yet 
this practice may mask identification of localized events in such models, and fails to 
account for inter-individual variability. With advances in microarray RT-PCR 
technology, we are now able to analyze tissues of much lower cell concentration.  
 The objective of this study was to characterize the gene expression changes in 
MMT, sham and control groups for each side of the articular cartilage of the tibial 
plateau, for the osteophyte region, and for each side of the synovium. This study is the 
first to elucidate localized disease progression in the rat MMT model and to identify 
genetic regulation in osteophyte and synovial tissues in an OA preclinical model. 
  
 26 
3.3 Materials and methods 
3.3.1 MMT model 
The Georgia Institute of Technology Institutional Animal Care and Use 
Committee approved all experimental animal procedures (IACUC protocol #A14023). 48 
Weight-matched male Lewis rats (300-325 g) were acclimated for 1 week before 
surgeries. A small incision was made through the skin on the medial aspect of the 
femoro-tibial joint of the left limb. The medial collateral ligament (MCL) was exposed by 
blunt dissection and transected to visualize the joint space and medial meniscus. In the 
MMT group (24 animals), the meniscus was transected completely at its narrowest point; 
while in the sham group (24 animals), the meniscus was exposed but left intact. The 
inclusion of the sham group enabled distinction of gene expression changes due to joint 
instability from those simply due to surgery.  The skin was closed with 4.0 silk sutures 
and then stapled using wound clips. MMT and sham surgeries were randomized.  
 Rats were euthanized via CO2 inhalation at 1 and 3 weeks post-surgery (n=12 per 
group per timepoint), and tissues were harvested and analyzed in a blind manner. The 
naïve right limbs were used as contralateral baseline controls. 9 animals were allocated 
for gene expression experiments and 3 for histology per group (power analysis: α=0.05, 
β=0.05).  
3.3.2 Microarray gene expression experiment 
From each leg, 3 samples of cartilage tissue were collected: the medial tibial 
plateau region, the lateral tibial plateau region, and the osteophyte region at the joint 
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margin of the medial side of the tibia (Figure 4). Tissue from the osteophyte region was 
only collected from MMT and sham groups at 1 and 3 weeks post-surgery due to 
insufficient tissue in naïve controls. Moreover, 2 samples of synovial membrane were 
also collected for all groups, from the medial and lateral sides of the joint, distal of the 
meniscus and directly adjacent to the tibial plateau (Figure 4). 
 
Figure 4. Representation of an operated left leg in which the medial meniscus has been 
transected (MMT rat model). At the indicated timepoint, 3 samples from the articular 
cartilage were harvested for each leg: 1) perceived osteophyte region (sham and MMT 
only), on the joint margin of the medial tibial plateau where osteophytes are known to 
develop; 2) medial tibial plateau, and 3) lateral tibial plateau. Additionally, 2 samples of 
synovium were collected from each leg: A) distal medial synovial membrane and B) distal 
lateral synovial membrane.  
 28 
Total RNA from cartilage tissues was extracted using the RNeasy MinElute 
Clean-up Kit with QIAzol Lysis Reagent. Total RNA from synovium was extracted using 
the RNeasy Lipid Tissue Mini Kit with QIAzol Lysis Reagent. RNA quality and 
concentration for all samples were determined using the Nanodrop ND-1000 
Spectrophotometer (ThermoFisher). Normalized RNA was converted to cDNA via the 
RT2 First Strand Kit. All reagents were from Qiagen unless otherwise stated.  
RNA expression was quantified using the Taqman real-time PCR Fluidigm 
Dynamic Array Integrated Fluidic Circuits (BioMark, Fluidigm). Our cDNA samples 
were tested against 40 genes (TaqMan gene expression assays, ThermoFisher, Table 2), 
which were selected from human OA literature. AccuRef rat universal cDNA (Gene 
Scientific) and ultrapure water were used as positive and negative controls, respectively, 
to ensure run fidelity. The Ct values greater than 37 were treated as 37, namely as null 
(lower Ct values correspond to higher expression since they represent the PCR cycle at 






Table 2. Taqman Gene Expression assays utilized for the characterization of the 
MMT model. Assays were all purchased from Thermo Fisher Scientific. When 
available, selected assays were that of the best coverage, recommended by the 
company. 
Category Taqman Gene Expression Assay 
ECM composition markers 
Col1a1 (Rn01463848_m1), Col1a2 (Rn00670295_m1), 
Col2a1 (Rn01637087_m1), Acan (Rn00573424_m1), Fn1 
(Rn00569575_m1), Fmod (Rn00589918_m1), Tnn 
(Rn01491027_m1) 
ECM remodeling markers 
Mmp2 (Rn01538170_m1), Mmp3 (Rn00591740_m1), 
Mmp9 (Rn00579162_m1), Mmp12 (Rn00588640_m1), 
Mmp13 (Rn01448194_m1), Adamts4 (Rn02103282_s1), 
Adamts5 (Rn01458486_m1), Ctsk (Rn00580723_m1), 
Spp1 (Rn00681031_m1), Timp1 (Rn01430873_g1), Inhba 
(Rn01538592_m1) 
Chondrogenesis markers Sox9 (Rn01751070_m1) 
Chondrocyte hypertrophy 
markers 
Frzb (Rn01746979_m1), Grem1 (Rn01509832_m1), 
Col10a1 (Rn01408030_m1), Tgm2 (Rn00571440_m1) 
Osteogenesis markers 
Bglap (Rn00566386_g1), Bmp2 (Rn00567818_m1), Runx2 
(Rn01512298_m1), Sp7 (Rn_02769744_s1), Sparc 
(Rn_01470624_m1) 
Vascularization marker Vegfa (Rn01511602_m1) 
Inflammation markers 
Tnfα (Rn01525859_g1), Tgfβ1 (Rn00572010_m1), IL1b 
(Rn00580432_m1), IL6 (Rn01410330_m1), IL10 
(Rn01483988_g1), IL17a (Rn01757168_m1), Ccl2 
(Rn00580555_m1), Ccl3 (Rn_01464736_g1), Cxcr2 
(Rn02130551_s1), Ptgs2 (Rn01483828_m1) 
Catabolic factors Epas1 (Rn00576515_m1), Sod2 (Rn00690588_g1) 
Cell apoptosis marker Casp8 (Rn00574069_m1) 




3.3.3 Gene expression statistical analyses 
 Ct values were subtracted from 37 in order to invert them: this converts the data 
to a more intuitive scale in which higher values now represent higher levels of RNA 
transcription for each gene. To calculate the relative gene expression (ΔCt), Ct values 
were normalized by the geometric mean of three housekeeping genes: Ppia, Rplp1 and 
Rpl13a (Equation 1). The raw Ct values of these housekeeping genes were not 
statistically different across different tissue types (cartilage and synovium), regions of 
interest (medial, lateral or osteophyte regions), or timepoints (1 and 3 weeks) (data not 
shown). In order to correct experimental differences observed between biological 
replicates and runs, the medians of each replicate experiment were median centered by 
subtracting the median normalized relative expression level across all conditions in a 
given replicate experiment for that same experiment. This step does not affect the fold 
induction, but it provides a correction for the difference in background or control level 
between independent biological repeats [85]. The Quantile Range Outlier (QRO) test was 
performed to remove any outliers. All statistical calculations were performed with JMP 
Genomic software (SAS Institute, Cary, NC, USA). 
∆𝐶𝑡 = 𝐶𝑡!"#$%! − 𝐶𝑡!!"#$%$$&'() !"#" 
Equation 1. Equation for the relative expression of a target gene (ΔCt).  
3.3.3.1 Principal component analysis (PCA) and unsupervised clustering analysis. 
 Scripts from JMP Genomic software were used to perform both analyses. In the 
weighted average proportions of the PCA models, a residual (unexplained) variance 
higher than 60% was considered as too noisy and to have too many potential confounding 
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variables in the sources of variability (surgery, timepoint, batch effect) to draw 
conclusions.  
3.3.3.2 Differential expression 
Volcano plots were used to compare the gene expression profile of groups. A 
volcano plot is a one-way ANOVA between two groups for multiple comparisons. Each 
gene (observation) is represented by a point on the graph. Significance was determined 
using Bonferroni correction (0.05 (p-value) divided by the number of observations). 
For each individual gene expression, two-way ANOVA was performed to 
determine the statistical significance of the differences between the means for each 
treatment (surgical group) and time groups. Tukey’s post hoc comparison was performed 
to compare the means of parametric cases in which one-way ANOVA assumptions were 
fulfilled. Kruskal-Wallis post hoc test was used for non-parametric cases. P-values less 
than 0.05 were considered statistically significant. Analyses were carried out using JMP 
Genomic software and graphed in it or in GraphPad Prism, version 7 (San Diego, CA). 
3.3.4 Immunohistochemistry 
 In order to validate gene expression results, immunofluorescent staining of full-
joint histological sections was carried out for specific markers: Collagen type 2 (sc-
52658), Mmp13 (ab75606), and Osteopontin (sc-21742). Briefly, control, sham and 
MMT full-joints were fixed in 10% neutral buffered formalin, trimmed, and decalcified 
in ImmunoCal decalcifying agent (StatLab). Samples were processed, embedded in 
paraffin, then sectioned at 5µm thickness. Antigen retrieval (sodium citrate buffer), 
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permeabilization (0.1% Triton-X) and blocking were performed on the sections, before 
incubation overnight in primary antibody at 4°C. Secondary antibody (Cell Signaling 
4409 and 4412) was incubated for 1 hour at room temperature, followed by 
counterstaining with DAPI (ThermoFisher S36938). 
3.4 Results 
3.4.1 Articular cartilage gene expression 
3.4.1.1 Tibial plateau region. 
 There were at least a half dozen innate significant gene expression differences 
between the medial and lateral sides of the tibial plateau, in the control (unoperated) 
group at both 1 and 3 weeks after surgery (Figure 5). There were no significant 
differences in gene expression for the lateral side among surgical groups (MMT, sham, 
and control) at any timepoint, indicating that the lateral side is not affected by surgery 
(Figure 6A). Changes in gene expression in the medial side of the tibial plateau were, 




Figure 5. Volcano plots of the (unoperated) control group of the tibial plateau. There are 
no significant temporal differences in gene expression within a side (medial or lateral). 
There are, however, significant differences between sides at each timepoint. The dotted blue 
lines in the x-axis indicate 2 fold difference (1 in log2 scale), and the dotted red line indicates 
significance threshold for Bonferroni correction of p-value of 0.05 in –log10 scale. These 




Figure 6. Volcano plots of the lateral side of the tibial plateau for all surgery groups. The 
lateral side is not affected by surgery. The dotted blue lines in the x-axis indicate a 2 fold 
difference (1 in log2 scale), and the dotted red line indicates the significance threshold for 
Bonferroni correction of p-value of 0.05 in –log10 scale. The one point at 10-4 in the control 
vs sham plot is borderline significant given the multiple conditions within the experiment, 
and is not indicative of a systematic transcriptional response. B. Principal component 
analysis (PCA) of the medial tibial plateau. Differences in the gene expression profiles of the 





Figure 7. A. Dendogram shows clustering of groups based on their gene expression 
profile. Control at week 1 and 3 cluster with sham at week 1 and 3, while MMT 
forms another group altogether. B. Principal component analysis (PCA) plots 
confirm clustering of control and sham groups away from the MMT group.  There 
are no temporal differences within groups. 
 
Figure 8. Radar plot of averaged (mean) ΔCt expression of individual genes in the 
unoperated, control medial tibial plateau cartilage (control), the MMT medial tibial 
plateau cartilage (MMT) and the sham medial tibial plateau cartilage (sham), at 
different timepoints. Statistical comparisons were carried out for each individual 
 37 
gene as described in the methods. # indicates significant (p<0.05) difference between 
MMT and control at week 1; & between MMT and sham at week 1; % between 
MMT and control at week 3; and $ between MMT and sham at week 3. There were 
not statistical differences between timepoints within surgical groups. 
3.4.1.1.1 Medial tibial plateau. 
 A clustering analysis showed that the gene expression profiles of control and 
sham samples were similar enough to be grouped into one cluster, while the MMT 
samples belonged to a different cluster entirely (Figure 7). This was confirmed with a 
PCA (Figure 1), which showed that MMT samples cluster separately from the control and 
sham groups. There were no temporal differences (week 1 vs. 3) within each cluster. 
Overall, expression of 14 genes was significantly different in the MMT group, when 
compared to control and sham groups (Figure 8 and Figure 9). There were no significant 





Figure 9. Significantly differently expressed genes of articular cartilage of the medial tibial 
plateau for all groups, graphed as means ± 95% confidence interval. % indicates 
statistically significant group difference vs. control (p<0.05), %% = p<0.005, %%% = 
p<0.001; and # group difference vs. sham (p<0.05), ## = p<0.005, ### = p<0.001. 
  
 39 
Chondrocyte hypertrophy genes were differentially regulated as early as 1 week 
in the MMT group: Frzb, Grem1, Col10a1. Frzb (Frizzle-related protein) and Grem1 
(Gremlin 1) are Wnt-pathway antagonists, and were downregulated at weeks 1 and 3. The 
Wnt pathway is associated with articular chondrocyte dedifferentiation [86]. Its activation 
in vivo and in vitro leads to reprogramming of articular chondrocytes toward catabolism 
or loss of stable phenotype with subsequent loss of tissue structure and function [87]. 
Col10a1 (type 10 collagen) was also underexpressed in the MMT group, observed at both 
week 1 and 3. 
 Gene expression of key cartilage extracellular matrix (ECM) protein markers, 
Col2a1 (type II collagen) and Acan (aggrecan), was not significantly different among 
groups. However, Fn1 (fibronectin) and Col1a2 (type I collagen) were overexpressed by 
week 3 in the MMT model. 
 Markers for matrix degradation proteins and their inhibitors were also 
differentially expressed in the MMT group. Mmp13 (metalloproteinase) is considered the 
primary collagenase in OA, and it was overexpressed at weeks 1 and 3, while Mmp2 and 
Ctsk (cathepsin k) were elevated at week 3 only. Timp1 and Inhba are inhibitors of these 
matrix degradation s, and they were both overexpressed at weeks 1 and 3. Timp1 is a 
metalloproteinase inhibitor which acts on Mmps (relevant to this study, Mmp2, Mmp3, 
Mmp9, Mmp12, Mmp13). Inhba has shown to inhibit aggrecanase-mediated cleavage of 
aggrecan in human and rat articular cartilage [82]. 
 Spp1 (osteopontin) is a matrix remodeling marker and was overexpressed as early 
as week 1 in the MMT model. Spp1 has been implicated in a number of physiological and 
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pathological events, including maintenance or reconfiguration of tissue integrity during 
inflammatory processes [88]. 
 Known catabolic factors in OA were dysregulated in the MMT model. Epas1 
encodes hypoxia-inducible factor-2alpha (HIF-2α), a known catabolic factor in the 
osteoarthritic process. HIF-2α regulates the expression of several matrix-degrading 
enzymes, and its overexpression is associated with increased chondrocyte apoptosis and 
OA cartilage destruction [89]. In this study, however, we observed a lower expression of 
Epas1 at weeks 1 and 3. Sod2 (superoxide dismutase 2) is also a marker for catabolism in 
the articular cartilage, and it was overexpressed in the MMT group at weeks 1 and 3. 
Sod2 is a mitochondrial enzyme that converts superoxide to hydrogen peroxide, acts in 
oxidative stress response, and may affect aging [82]. 
Lastly, Ptgs2 (prostaglandin-endoperoxide synthase 2 encoding cyclooxygenase 2 
[COX-2]) is an inflammatory response gene whose product converts arachidonate to 
inflammatory prostaglandins [82]. Ptgs2 was significantly overexpressed in the MMT 
group at weeks 1 and 3. 
3.4.1.2 Osteophyte region. 
 There was significantly more RNA extracted from tissue collected from the joint 
margin (osteophyte) region in the MMT than the sham at 3 weeks (Figure 10). This 
difference in RNA concentration was not observed for any other tissue, for either groups 
or timepoints. A PCA showed that regardless of surgical group, tissue from this 
osteophyte region was distinctively different from that which had been collected from the 
articular tibial plateau (Figure 10). We observed significant overexpression of osteogenic 
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markers and underexpression of chondrogenic markers. There were 20 significantly 
differentiated genes in the MMT osteophyte region when comparing it to the MMT 
medial articular cartilage region (Figure 11). 
  
Figure 10. A. Principal component analysis (PCA) of tissue from the medial tibial plateau 
region (control, sham and MMT groups) and osteophyte region (sham and MMT groups) 
for all timepoints. The significant difference in gene expression profiles is mainly due to the 
region from which tissue was collected (53.7%). Tissue from the osteophyte (sham and 
MMT) is fundamentally different from the tissue from the articular cartilage of the medial 
tibial plateau. B. There is more tissue (and therefore RNA extracted) from the MMT group 
at the osteophyte region at week 3. Concentrations from nanodrop are graphed as means ± 





Figure 11. Significantly differently expressed genes of the articular cartilage from 
the medial tibial plateau of MMT animals (MMT group) vs. tissue from the 
   MTT_1wk  ○ MTT_3wk      Osteo_1wk     Osteo_3wk 
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osteophyte-developing region of MMT animals (osteo group), graphed as means ± 
SEM. The solid blue lines is the mean expression for the articular cartilage from the 
medial tibial plateau of control at 1 week post-surgery, unoperated animals; while 
the dashed light blue line is at 3 weeks post-surgery. $ indicates significance between 
the MMT and osteo groups at the indicated timepoint at a p-value<0.05 ; $$ at a p-
value<0.01; and $$$ at a p-value<0.001. 
The osteophyte region generally expressed a higher degree of osteogenic genes 
and ECM markers related to osteogenesis than the MMT medial tibial plateau region. 
Col1a1, Col1a2, Runx2, and Bglap (Osteocalcin) were significantly higher expressed in 
the osteophyte region as early as week 1.  
 Chondrocyte hypertrophic markers were also differentially regulated in the 
osteophyte region when compared to the medial tibial plateau region of the MMT group. 
At week 1 and 3, Col10, Tgm2 (transglutaminase-2) and Grem1 were significantly 
underexpressed. Frzb was significantly underexpressed in the osteophyte region at week 
1, but at week 3 it went up to similar levels of that of the MMT medial tibial plateau, 
though still lower than the control/sham medial tibial plateau.  
 Chondrogenic and ECM-remodeling markers were also altered depending on the 
region of interest within MMT group. Acan and Fn1 were significantly underexpressed in 
the osteophyte region. Sox9, a marker of chondrogenesis, had significantly lower 
expression levels in the osteophyte region at week 1 and 3. Inhba and Mmp3 were 
significantly underexpressed in the osteophyte region at week 1, while Mmp2, Mmp13 
and Ctsk were significantly overexpressed in the osteophyte region at both time points.  
Catabolic factor Sod2 was lower expressed in the osteophyte region at week 1 and 
3 when compared to the medial tibial plateau in the MMT model. Apoptosis marker 
Casp8 was higher expressed at both timepoints. In the osteophyte region, Ptgs2 was 
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significantly lower at week 1 than the MMT medial tibial plateau and comparable to the 
control medial tibial plateau. Interestingly, Vegf was significantly underexpressed in the 
osteophyte region as early as week 1. 
 Given that the tibial plateau cartilage is dissimilar to the osteophyte tissue, we 
proceeded with comparisons exclusively within the osteophyte tissue of sham vs. MMT 
at the different timepoints. We found that 6 genes were differentially expressed between 




Figure 12. Radar plot of averaged (mean) ΔCt expression of individual genes in the sham 
osteophyte tissue (sham) and the MMT osteophyte tissue (MMT), at different timepoints. 
Statistical comparisons were carried out for each individual gene as described in the 
methods. # indicates significant (p<0.05) difference between MMT and sham at week 1; & 
between MMT and sham at week 3; % between week 1 and 3 for the sham group; and $ 
between week 1 and 3 for the MMT group. 
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Figure 13. Significantly differently expressed genes of the osteophyte region between the 
sham and MMT groups for both timepoints, graphed as means ± 95% confidence interval. # 
indicates statistically significant group difference vs. sham (p<0.05), ## = p<0.005; and * 
between timepoints of the same group (p<0.05), ** = p<0.005. 
The inflammatory genes IL1b (interleukin), IL17, Tgbβ (transforming growth 
factor-β) and Tnfα (tumor necrosis factor-α) were significantly underexpressed in the 
MMT group at week 3 compared to the sham. In the sham group, their expression at 
week 1 was comparable to that of the MMT, but at week 3, these genes were significantly 
overexpressed compared to the sham at week 1 and MMT at week 3. Ccl3 (c-c- motif 
chemokine-3), another gene involved in inflammation, showed a similar trend; however, 
no differences were observed at week 3. 
3.4.2 Synovial membrane gene expression 
In the control group, medial and lateral sides of the synovial membrane had one 
significantly differentially expressed gene (Figure 14). Unlike the cartilage samples, 
however, there were significant differences in the lateral side samples among surgical 
procedures (data not shown), though we note that latent unknown variables beyond 
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surgery type, microarray plate number (batch effect), and timepoint contribute to a large 
residual variance (Figure 14). On the other hand, on the medial side, a small number of 
significant changes were observed in gene expression among groups are largely driven by 
the surgery type (Figure 14). Therefore, we focus only on the differences in the medial 
side of the synovium. 
 
Figure 14. A. Volcano plots of the unoperated, control group of the distal synovial 
membrane. There are very few (1 or 2) significant differences in gene expression 
within a side (different timepoints) and between sides at a specific timepoint. The 
dotted blue lines in the x-axis indicate 2 fold difference (1 in log2 scale), and the 
dotted red line indicates significance threshold for Bonferroni correction of p-value 
of 0.05 in –log10 scale. B. Principal component analysis (PCA) of the distal lateral 
synovial membrane. Differences in gene expression profiles for the lateral side of the 
synovium are largely unexplained (80.5%). C. PCA of the distal medial synovial 
membrane. Differences in gene expression profiles for the medial side of the 
synovium can be attributed to surgical procedures. 
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3.4.2.1 Medial synovial membrane. 
 Our cluster analysis showed that there were temporal differences in the sham 
group (Figure 15). Sham samples at week 1 cluster with the MMT samples (both 
timepoints). At week 3, however, sham samples are equally split between the control 
cluster and the MMT cluster. The PCA further confirms this clustering and shows that 
expression of Mmps is a key driver of principal component 1 (Figure 15). Overall, there 
were 16 genes that were differentially expressed among groups (Figure 16 and Figure 
17). There were no statistical differences between the sham and MMT groups at week 1, 





Figure 15. A. Dendogram shows clustering of groups based on their gene expression 
profile. Sham at week 1 clusters with MMT at week 1 and 3, while at 3 weeks post-surgery, 
sham clusters with both MMT and control groups. B. PCA confirms this clustering and 
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shows that this difference is largely driven by ECM remodeling genes and osteogenic 
markers. These results suggest a surgical effect that dominates at week 1 
 
Figure 16. Radar plot of averaged (mean) ΔCt expression of individual genes in the 
unoperated, control medial synovial membrane (control), the sham medial synovial 
membrane (sham) and the MMT medial synovial membrane (MMT), at different 
timepoints. Statistical comparisons were carried out for each individual gene as 
described in the methods. # indicates significant (p<0.05) difference between sham 
and control at week 1; & between MMT and control at week 1; % between sham 
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and control at week 3; $ between MMT and control at week 3; @ between week 1 
and 3 within sham group; and ^ between week 1 and 3 within MMT group. 
 
Figure 17. Significantly expressed genes in the distal medial synovial membrane for all 
groups, graphed as means ± 95% confidence interval. % indicates statistically significant 
group difference vs. control (p<0.05), %% = p<0.005, %%% = p<0.001; and * indicates 
timepoint difference (week 1 vs. 3) within a group (p<0.05), ** = p<0.005, *** = p<0.001. 
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In general, surgery had an effect on genes related to the ECM. ECM proteins 
Acan and Fmod (fibromodulin) were significantly upregulated, in both sham and MMT. 
Acan was overexpressed in the MMT and sham groups at week 1 and 3, compared to the 
control groups. Fmod was overexpressed in both surgery groups at week 3 only. While 
Tnn (tenascin) was significantly underexpressed at week 1 for the MMT and sham 
groups, it reached the level of the control group at week 3 for the sham group but 
remained significantly lower for the MMT group. 
 Comparing to the naïve control group, the synovium had a sustained significantly 
elevated expression of matrix degradation markers in the MMT group. In the sham 
surgery, these genes were also elevated at week 1 but most declined to the control level 
by week 3. Mmp3, Mmp9, Mmp12, and Mmp13 were significantly higher in the MMT 
group at week 1 and remained so by week 3. Mmp2 and Ctsk were significantly higher 
only at week 3 in the MMT group. In the sham group, Mmp2, Mmp9, Mmp12, Mmp13 
and Ctsk were significantly overexpressed at week 1. However, all, with the exception of 
Mmp2 and Ctsk, declined to expression levels comparable to the control group by week 3. 
Adamts4 was significantly higher in the sham group (vs. control) at week 1, but a similar 
trend could be observed; there seemed to be higher expression in the MMT groups at 
both timepoints and a lower level in the sham group at week 3 (vs. week 1). Adamts5 was 
downregulated in the MMT group (vs. control) at week 1 and 3, while again in the sham 
group it was significantly lower at week 1 but recovered to the control group level by 
week 3. Matrix remodeling gene Spp1 was overexpressed in both the sham and MMT at 
week 1 (vs. control), but only remainded overexpressed in the MMT at week 3. 
Metalloproteinase inhibitor Timp1 was significantly higher in the sham group (vs. 
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control) at week 1, but followed the same pattern in that this expression significantly 
decreased by week 3 in the sham group, to a level comparable to the control. In the 
MMT, Timp1 seemed to remain elevated, though this observation was not statistically 
significant.  
 Osteogenic markers were also dysregulated in the synovium. Col1a1 and Col1a2 
were overexpressed in both the sham and MMT groups at week 1 (vs. control), but 
remained elevated in the MMT group at week 3. Although Bmp2 (bone morphogenetic 
protein-2) showed significantly lower expression in the MMT group alone compared to 
the control at both timepoints, a similar trend was observed where the sham expression 
seemed lower at week 1 and closer to control levels by week 3. 
Frzb was downregulated in both the sham and the MMT groups (vs. control) as 
early as week 1, but in this case, it remained low for the sham group as well as the MMT 
at week 3. Epas1 had a similar profile, where both sham and MMT groups had 
significantly low expression even at week 3. Tgm2 (transglutaminase-2) was 
underexpressed at week 1 for both groups (vs. control), yet recovered to the control level 
in the sham group by week 3. Tgm2 is modulated by inflammatory cytokines, and 
regulates chondrocyte hypertrophic differentiation and ECM mineralization [90, 91]. 
3.4.3 Confirmation of genes at the protein level 
Immunostaining (Figure 18) of collagen type 2 protein (col2a1 gene) showed 
morphological differences in the medial articular cartilage at week 3, confirming damage 
to this area due to MMT surgery. Mmp13 protein detection in the MMT group at week 3 
was confined to the articular cartilage and synovium, confirming our gene expression 
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results. We hypothesize that it was not detected at week 1 (data not shown), as expected, 
due to the natural delay between translation and transduction, and the need for protein 
accumulation for immunolocalization. A similar case was observed with Osteopontin 
(Spp1 gene). It was detected in the MMT group at week 3 only, in the articular cartilage 
and synovium. 
 
Figure 18. Fluorescent immunohistochemistry of collagen type 2, Mmp13, and osteopontin 
of the articular cartilage and the synovium at week 3. Collagen 2 staining was used to 
visualize the articular cartilage, in which fibrillation and lesion formation is apparent in the 
MMT group at 3 weeks post-surgery. White triangles point at positive staining of Mmp13 
and Osteopontin. At 3 weeks post-surgery, Mmp13 and osteopontin were detected in the 




3.5.1 Localized gene expression 
 Regional analysis of the tibial plateau shows that the lateral and medial sides have 
a significantly different gene expression profile, which is not surprising given the 
differences in anatomy between these two sides. MMT surgery creates localized damage 
in the medial tibial plateau [81], and analysis of this specific region allow us to pinpoint 
changes in tissue that might otherwise be lost by the pooling of tissue from both sides of 
the tibial plateaus and femoral condyles; a standard practice in gene expression studies 
[82-84].   
 Localized gene expression analysis is particularly important in the synovium. In 
this tissue type, there are differences in gene expression profiles among medial 
(unoperated) control, sham and MMT groups. In fact, we showed that there is a surgical 
effect that dominates at week 1 and which mostly subsides by week 3, though not 
entirely. This is not wholly surprising as the synovial membrane is cut to access and 
visualize the meniscus in both sham and MMT surgeries. Equally important, this study 
demonstrates that, unlike articular cartilage, both sides of the synovial membrane are 
affected by surgery and show significant differences in their gene expression profiles. 
The fact that changes in the lateral side cannot be pinpointed to the surgery type, 
microarray plate number (batch effect), or timepoint reemphasizes the importance of 
analyzing localized tissue (medial side, in this case) instead of pooling sample from the 
entire joint cavity. 
3.5.2 Articular cartilage of the medial tibial plateau 
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 This study is the first to report gene expression findings specifically for the 
medial tibial plateau of the MMT model. Here, we showed that the MMT model 
replicated several pathologies observed in human OA. Our findings also suggest that 
changes in chondrocyte phenotype may precede changes in ECM in this animal model, 
indicating that the response to destabilization may be firstly to readdress tissue 
composition and secondly to remodel.  
 Chondrocyte phenotype changes begin as early as week 1 in the MMT model. 
Previous studies have identified Wnt signaling to be involved in the response to 
mechanical injury to cartilage [87, 92, 93], since Wnt antagonists, Frzb and Grem1 
function as natural brakes on hypertrophic differentiation of articular cartilage [94]. 
While Frzb inhibits Wnt directly, Bmp antagonist Grem1 functions indirectly [94]. 
Therefore, lower expression of Frzb and Grem1 in the MMT group points toward a de-
differentiation of chondrocytes into the hypertrophic state in the medial tibial plateau.  
 Col10 expression was also significantly lower in the MMT model at week 1 and 
3. Although col10 is a hypertrophic marker associated with endochondral ossification 
during growth and fracture healing and might, therefore, be expected to be expressed at 
higher levels, previous studies have also shown that its gene expression level is actually 
reduced in the OA disease state in animal models. In the anterior cruciate ligament (ACL) 
rabbit model of OA, Bluteau et al. (2001) observed reduced Col10 expression in the 
articular cartilage at 2 and 4 weeks post-surgery, whereas there was an increase in the 
meniscus at 9 weeks post-surgery [95]. Other studies have demonstrated the occurrence 
of col10 at the surface of normal human, porcine and rat articular cartilage, and have 
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suggested that the presence of this protein may be associated with the load bearing 
properties in different zones of the articular surface [96].  
 While chondrocyte phenotypic changes were discernible at week 1, changes in the 
articular cartilage ECM composition (elevated Fn1 and Col1a2) were not significant until 
week 3. In OA, chondrocytes synthesize elevated levels of fibronectin, altering the 
cartilage ECM [97]. Although often considered an earlier sign of OA [97, 98], the MMT 
model did not show significant differences in Fn1 expression until week 3. This suggests 
that, in the MMT model, changes in chondrocyte phenotype precede changes in the ECM 
of the articular cartilage. This is further supported by the fact that Acan and Col2a1 were 
not expressed significantly different from the control group by week 3. 
 It is still unclear whether the increased synthesis of fibronectin in OA acts as an 
attempt by the chondrocytes to repair cartilage or whether it has a deleterious effect [97]. 
Its increased activity has been linked with a switch in synthesis of collagen type, an 
increased activity of locally secreted Mmps and induction of proteolytic activities against 
gelatin and fibronectin itself [97, 99]. In this study, we observed significantly higher 
expression of Col1a2, Mmp2, Mmp13, and Ctsk at week 3, the same timepoint as Fn1, 
paralleling the proposed mechanism for human OA [100, 101] and other rodent models 
[102]. 
 The fact that metalloproteinase and aggrecanase inhibitors Timp1 and Inhba 
(respectively) are overexpressed in the MMT group as early as week 1 suggests a 
protective mechanism in OA in the MMT model. This may be further corroborated by the 
downregulation of Epas1 in the MMT group. A previous study has shown that 
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chondrocyte-specific knockout of Epas1 in mice suppressed DMM (destabilization of the 
medial meniscus)-induced chondrocyte apoptosis and inhibited OA cartilage destruction 
[89]. We, therefore, propose that downregulation of Epas1 in this case may be part of a 
protective mechanism in the MMT model.  
 Higher expression of the catabolism marker Sod2 at weeks 1 and 3 indicates a 
homeostatic imbalance within the chondrocytes. Oxidative stress and dysregulated 
chondrocyte mitochondrial function contribute not only to impaired matrix synthetic 
function and viability, but also to molecular inflammatory processes and matrix 
catabolism in OA [103]. Ptgs2, which we have shown to be overexpressed in the MMT, 
is an inflammatory responsive gene and is regulated by nitric oxide [104].  
 Altogether, analysis of the medial tibial plateau articular cartilage shows that 
sham behaves similarly to the unoperated, control group and that MMT surgery replicates 
several human OA pathomechanisms. The pathomechanistic implications outlined in this 
study should be taken into account when using this model to test and/or explore 
therapeutic mechanisms. It is particularly important to understand the microenvironment 
which is encountered by the therapy of interest upon delivery, for which in depth 
molecular analysis and characterization of the MMT model as the disease progresses is 
needed. 
3.5.3 Osteophyte tissue 
 At the joint margins in the interface between the cortical bone marrow and the 
periosteal lining, osteophytes form in human and experimental OA [105, 106]. While 
osteophytes have been reported and quantified at week 3 in the MMT model [81], they 
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are non-detectable via morphological analysis at week 1. In this study, we showed that 
we are able to detect gene expression differences between the sham and MMT groups at 
3 weeks as well. 
 Osteophyte formation features vascularization of the tissue followed by 
endochondral ossification. It is well established that there are morphological differences 
in osteophyte formation between the MMT and sham groups at 3 weeks post-surgery, 
including increased mineralization and tissue formation [81]. However, we were not able 
to detect differences in these markers between the sham and MMT groups. Interestingly, 
we detected significant differences only in genes related to inflammation. Recent studies 
have reported evidence of the effects of inflammatory mediators on cellular 
differentiation [107]. In fact, Tnfα, IL1β, and NF-κB stimulate osteogenesis at low 
concentrations and inhibit it at high concentrations [107-112]. We, therefore, believe that 
the observed downregulation of inflammation genes in the MMT group is actually 
indicative of a pre-ossification phase of this region at week 3.  
 It is worthwhile mentioning that, while gene expression related to chondrogenic, 
chondrocyte hypertrophy and osteogenic markers is not different between the sham and 
MMT groups at any timepoint, there are signs of cell proliferation in the MMT group at 
week 3. The tissue from this region of the joint is fundamentally different than the tibial 
plateau, and so, we postulate that morphological differences between the sham and MMT 
at 3 weeks post-surgery are due to there simply being more tissue in the MMT model at 
this timepoint. To test this hypothesis, thorough profiling of markers related to 
proliferation in this area, perhaps by RNA sequencing, as well as extended timepoints of 
analyses, will be required. 
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3.5.4 Distal medial synovial membrane 
 To the best of our knowledge, this is the first study to report gene expression 
profiles of the synovial membrane in an experimental animal model, and specifically on 
the medial side of the synovial membrane. Surgical effect (sham and MMT) dominates 
the gene expression profile of the medial synovium at week 1, and it is not until week 3 
that this surgical noise dissipates and meniscal instability starts to have a pronounced 
effect on the medial synovium. This MMT characteristic is of the upmost importance 
when considering experimental design of a new therapy, and it reemphasizes the 
importance of a sham group in an experiment. 
 Overall, we observed an increase in markers related to matrix degradation and 
remodeling in the synovium that remained elevated in the MMT at week 3. We also 
showed an overexpression of most osteogenic markers and underexpression of Wnt 
antagonists in the MMT. These findings suggest a feedback loop with the articular 
cartilage. As in human OA, the synovium is affected by the mechanical instability of the 
model and may exacerbate the changes to the articular cartilage. We, therefore, postulate 
that the joint space acts in concert in the MMT model.  
3.5.5 Inflammation in the MMT model 
 Surprisingly, apart from Ptgs2, our genes related to inflammation (pro- or anti-) 
were not differentially regulated, except in the osteophyte region. We believe that this 
may have been due to our harvesting timepoint. Collecting tissues at earlier timepoints 
may have shown a detectable signal difference between unoperated and operated legs 
(control vs. sham and MMT). However, for the purpose of this study, we wanted to 
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minimize noise due to surgery (inflammation that is inevitable post-surgery) and so we 
decided to collect samples starting at week 1. It was, therefore, interesting that we still 
detected evidence of surgery in the synovium at this timepoint. 
 The MMT model is a mechanically induced model and it is generally not 
associated with substantial inflammation, unlike the MIA model [113]. Nevertheless, it is 
worth pointing out that even though we do not observe changes in genes generally 
associated with inflammation at our timepoints, we may be observing the consequences 
of their dysregulation in the sham and MMT surgical groups. In OA, IL1 (pro-
inflammatory) is synthesized by chondrocytes and capable of inducing the expression of 
Mmps and other catabolic genes [114]. A variety of inflammatory mediators and growth 
factors, including IL1, Tnfα and Pdgf (platelet-derived growth factor), stimulate Spp1 
transcription [88]. In fact, Spp1 has both pro- and anti-inflammatory actions [88]. We 
have shown changes in the expression of several Mmps and Spp1 in the articular cartilage 
and synovium in this study due to MMT surgery. Whether these changes are indeed 
downstream of inflammatory processes remains to be answered, and evaluating the model 
at earlier timepoints would be a useful start for future directions. 
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CHAPTER 4. LOCALIZED OSTEOARTHRITIS DISEASE-
MODIFYING CHANGES DUE TO INTRA-ARTICULAR 
INJECTION OF MICRONIZED DEHYDRATED HUMAN 
AMNION/CHORION MEMBRANE 
4.1 Abstract 
Micronized dehydrated human amnion/chorion membrane (AmnioFix Injectable, 
MiMedx, Marietta, GA, USA) has anti-inflammatory, low immunogenic and anti-fibrotic 
properties, and its delivery intra-articular delivery into the joint space has been shown to 
have a chondro-protective effect on the articular cartilage in an in vivo model of post-
traumatic OA. AmnioFix is an ECM-derived therapeutic, and its mechanisms of action on 
OA progression and potential modification remain largely undetermined. As AmnioFix is 
sequestered in the synovial membrane, we hypothesized that injection of AmnioFix 
attenuates catabolic and inflammatory signaling in the synovium, which in turn protects 
the articular cartilage from further degradation. 
The objective of this study was to elucidate the molecular mechanisms of action of 
AmnioFix treatment with OA development and progression. Weight-matched Lewis rats 
underwent MMT surgery to induce OA-like clinical symptoms, and AmnioFix or saline 
was injected intra-articularly 1 day post-surgery. At 5, 7, and 21 days post-surgery, 
articular cartilage, synovial membrane, and osteophyte tissues from multiple regions were 
collected and analyzed by microarray RT-PCR. 
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Results demonstrated that there were no significant differences between groups for 
the articular cartilage or osteophyte tissue, suggesting that the AmnioFix treatment does 
not have a direct influence on these tissues. In the medial synovial membrane, pro- and 
anti-inflammatory markers were more highly expressed in the AmnioFix group than in 
the saline group.  The gene expression profile of the AmnioFix group in the medial 
synovial membrane was markedly different from the saline group and the control group. 
These data suggest that AmnioFix treatment may modulate the microenvironment of the 
synovial membrane to a favorable chondro-protective profile. The upregulation of pro-
inflammation-related cytokines could promote the recruitment of repair cells, and anti-
inflammatory responses may act as a countermeasure to restore the shift in the pro-/anti- 
inflammation balance that occurs during disease progression and wound healing. 
4.2 Introduction 
An emerging focus of regenerative medicine is the development of ECM-based 
therapies that can stimulate tissue formation or repair by recreating the functional and 
structural properties of native ECM (scaffolds), or by acting as a source of growth 
factors. Decellularized ECM-derived treatments are prime candidates for potential 
DMOADs as they maintain many of the bioactive molecules specific to the native tissue, 
which are not present in synthetic materials, and do not produce an adverse immune 
response [115]. While another advantage of ECM-derived DMOADs is their high degree 
of translatability, a major disadvantage is the fact that these therapies are virtually black 
boxes, for which the mechanisms of effects are not well understood. ECMs are complex 
environments that house many interactions. Donor-to-donor variability of human tissue 
may also impact the biological properties of the resultant ECM-derived DMOADs. 
 64 
Micronized dehydrated human amnion/chorion membrane (AmnioFix® Injectable, 
MiMedx, Marietta, GA, USA) has recently been granted the Regenerative Medicine 
Advanced Therapy (RMAT) designation for use in OA of the knee, and is currently 
undergoing Phase 2 clinical trials. While AmnioFix has shown promising pre-clinical and 
initial clinical data, its therapeutic mechanisms are still largely unknown. The 
composition and properties of AmnioFix have been largely characterized [116, 117], but 
its molecular interactions with tissues in the joint space as OA develops and progresses 
are not known. 
 Human amnion/chorion tissue is derived from the placenta and is rich in cytokines 
and growth factors known to promote wound healing [117]. The processing of AmnioFix 
Injectable permits retention of a large array of these factors – many of which may aid in 
cell proliferation, inflammation, metalloproteinase activity and recruitment of progenitor 
cells in a paracrine manner [116, 117]. Past studies have demonstrated efficacy, e.g. intra-
articular injection of AmnioFix Injectable into the knee joint in the MMT model 
demonstrated a protective effect of this treatment on the articular cartilage [3]. At 3 
weeks post-surgery, the articular cartilage showed little signs of degradation in terms of 
its proteoglycan content and morphology [3]. In this study, the AmnioFix microparticles 
were detected in the synovium up to 3 weeks post-surgery [3]. Therefore, a putative 
mechanism of action of AmnioFix would involve the synovial membrane. 
In wound healing, human amniotic membrane allografts are known to decrease 
inflammation, reduce scar tissue formation, and support soft tissue regeneration [118, 
119]. However, in OA, anti-inflammation drugs targeting the TNFα/IL1-driven cascades 
(inflammation) have not shown consistent evidence of chondro-protective mechanisms in 
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vivo and are not considered successful disease-modifiers [120-125]. Likewise, 
pharmacological upregulation of repair-promoting factors, e.g. TGFβ and/or IGF1, is not 
expected to contribute to disease modification in OA because anabolic repair pathways 
are already overexpressed in this disease [125]. 
Other studies have targeted different inflammatory pathways with initial success 
in clinical trials [125], and so reduced inflammation may be still be a contestant for the 
key therapeutic mechanism of AmnioFix treatment. It is worth noting, nevertheless, that 
the MMT model in which AmnioFix was shown to be effective is not regarded as an 
inflammation model. In fact, in our previous chapter, we did not find detectable levels of 
inflammatory markers as disease developed in the MMT model. Therefore, the question 
remains of which may be the key drivers of the chondro-protective effect observed in 
AmnioFix treatment. 
The objective of this aim was to determine mechanisms of action of AmnioFix 
Injectable on localized regions of the articular cartilage, synovial membrane, and 
osteophyte-forming region within the knee joint of the MMT post-traumatic OA model. 
Our hypothesis was that AmnioFix targets and modulates the microenvironment of the 
synovial membrane as a means to alleviate catabolic mechanisms in the joint space and 
protect the articular cartilage.  
4.3 Materials and methods 
4.3.1 Animals: Surgery and treatment 
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The Georgia Institute of Technology Institutional Animal Care and Use 
Committee approved all experimental animal procedures (IACUC protocol #A14023). 
Weight-matched (275-300g) male Lewis rats were acclimated 1 week before receiving 
MMT surgery. Briefly, a small incision was made through the skin on the medial aspect 
of the femoro-tibial joint of the left limb. The medial collateral ligament was exposed by 
blunt dissection and transected to visualize the joint space and meniscus. The meniscus 
was then cut at its narrowest point. The naïve right limbs were used as contralateral 
baseline controls.  
  1-day post-surgery, animals were randomly divided into two groups to receive 
either 50µl of saline (saline group) or AmnioFix (AmnioFix group) intra-articular 
injections. AmnioFix injections were prepared from 5 pooled donors at a dose of 40 
mg/ml, as previously described [3]. Animals were then taken down at 5 days, 7 days and 
21 days post-surgery and tissues harvested for experiments. 36 animals were allocated for 
gene expression (n=9 per group per timepoint), 12 for histology (n=3 per group per 
timepoint), and 20 for protein extraction of the synovium tissue (n=4-5 per group per 
timepoint). 
4.3.2 Microarray gene expression 
Articular cartilage samples were harvested at 7 and 21 days post-surgery. From 
each leg, tissue was collected from 3 regions: the medial tibial plateau, the lateral tibial 
plateau, and the medial joint margin (osteophyte tissue). Osteophyte tissue was only 
collected from surgerized limbs (saline and AmnioFix groups) at 21 days post-surgery 
due to insufficient tissue in the unoperated limbs (control group) and at earlier timepoints. 
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Synovial membrane was harvested at 5, 7 and 21 days post-surgery. From each leg, 2 
synovium samples were collected, from the medial and lateral sides of the joint, distal of 
the meniscus and directly adjacent to the tibial plateau. Each sample was stored 
separately in RNAlater (Ambion Inc.) at 4°C until processed. 
Total RNA from cartilage and osteophyte tissues was extracted using the RNeasy 
MinElute Clean-up Kit with QIAzol Lysis Reagent. Total RNA from synovium was 
extracted using the RNeasy Lipid Tissue Mini Kit with QIAzol Lysis Reagent. RNA 
quality and concentration for all samples were determined using the Nanodrop ND-1000 
Spectrophotometer (ThermoFisher). Normalized RNA was converted to cDNA via the 
RT2 First Strand Kit. All reagents were from Qiagen unless otherwise stated.  
RNA expression was quantified using the Taqman RT-PCR Fluidigm Dynamic 
Array Integrated Fluidic Circuits (BioMark, Fluidigm). Our cDNA samples were tested 
against 58 genes (TaqMan gene expression assays, ThermoFisher, Table 3), which were 
selected from literature detailing human OA pathomechanisms and about AmnioFix 
composition. AccuRef rat universal cDNA (Gene Scientific) and ultrapure water were 
used as positive and negative controls, respectively, to ensure run fidelity. The Ct values 
greater than 37 were treated as 37, namely as null (lower Ct values correspond to higher 





Table 3. Taqman Gene Expression Assays for evaluation of the effects of AmnioFix 
in the MMT model. Assays were all purchased from Thermo Fisher Scientific. 
Where available, “best coverage” assays were used that are recommended by the 
company. 
Category Taqman Gene Expression Assays 
ECM composition markers Col1a1 (Rn01463848_m1), Col1a2 (Rn00670295_m1), 
Col2a1 (Rn01637087_m1), Acan (Rn00573424_m1), Fn1 
(Rn00569575_m1), Fmod (Rn00589918_m1), Tnn 
(Rn01491027_m1) 
ECM remodeling markers Mmp2 (Rn01538170_m1), Mmp3 (Rn00591740_m1), 
Mmp9 (Rn00579162_m1), Mmp12 (Rn00588640_m1), 
Mmp13 (Rn01448194_m1), Adamts4 (Rn02103282_s1), 
Adamts5 (Rn01458486_m1), Ctsk (Rn00580723_m1), 
Spp1 (Rn00681031_m1), Timp1 (Rn01430873_g1), 
Timp2 (Rn00573232_m1), Timp3 (Rn00441826_m1), 
Inhba (Rn01538592_m1) 
Chondrogenesis marker Sox9 (Rn01751070_m1) 
Chondrocyte hypertrophy 
markers 
Frzb (Rn01746979_m1), Grem1 (Rn01509832_m1), 
Col10a1 (Rn01408030_m1), Tgm2 (Rn00571440_m1) 
Osteogenesis markers Bglap (Rn00566386_g1), Runx2 (Rn01512298_m1) 
Vascularization marker Vegfa (Rn01511602_m1) 
Inflammation and tissue 
repair-related markers 
Tnfα (Rn01525859_g1), Tgfβ1 (Rn00572010_m1), IL1a 
(Rn00566700_m1), IL1b (Rn00580432_m1), IL1rn 
(Rn02586400_m1), IL6 (Rn01410330_m1), IL10 
(Rn01483988_g1), IL13 (Rn00587615_m1), IL15 
(Rn00689963_g1), IL17ra (Rn01757168_m1), Infg 
(Rn00594078_m1), Ccl1 (Rn01752376_m1), Ccl2 
(Rn00580555_m1), Ccl3 (Rn_01464736_g1), Ccl7 
(Rn01467286_m1), Cxcl12 (Rn00573260_m1), Ccr7 
(Rn02758813_s1), Csf1 (Rn01522726_m1), Cxcr1 
(Rn00570857_s1), Cxcr2 (Rn02130551_s1), Ptgs2 
(Rn01483828_m1), Fgf2 (Rn00570809_m1) 
Catabolic factors Epas1 (Rn00576515_m1), Sod2 (Rn00690588_g1) 
Cell stress and apoptosis 
markers and inhibitors 
Casp8 (Rn00574069_m1), SIRT1 (Rn_01428096), Prkaa2 
(Rn00576935_m1) 
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Housekeeping genes Ppia (Rn00690933_m1), Rplp1 (Rn03467157_gH), 
Rpl13a (Rn00821946_g1), Gapdh () 
 
4.3.3 Histological analysis 
In order to confirm AmnioFix sequestration to the synovial membrane, full joints 
were fixed in 10% NBF, processed, and embedded in paraffin. 5 µm sections were 
stained with Hematoxylin and Eosin (H&E). Sections were also stained for CD68 (Bio-
Rad MCA341R), a marker of macrophages. Briefly, antigen retrieval, permeabilization, 
and blocking were performed on the sections before overnight incubation in the primary 
antibody at 4°C. Secondary antibody (Cell signaling 4409S) was incubated for 1 hour at 
room temperature, followed by DAPI staining.  
4.3.4 Statistical analyses 
4.3.4.1 Gene expression 
Ct values were subtracted from 37 in order to invert them. To calculate the 
relative gene expression (ΔCt values), Ct values were normalized by the geometric mean 
of four housekeeping genes: Ppia, Rplp1, Rpl13a, and Gapdh (Equation 1). In order to 
correct experimental differences observed between biological replicates and runs, the 
medians of each replicate experiment were median-centered. The QRO test was 
performed to remove any outliers. All statistical calculations were performed with JMP 
Genomic software (SAS Institute, Cary, NC, USA). 
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4.3.4.1.1 Principal component analysis (PCA) and unsupervised clustering analysis. 
Scripts from JMP Genomic software were used to perform both analyses. In the 
weighted average proportions of the PCA models, a residual (unexplained) variance 
higher than 60% was considered as too noisy and to have too many potential confounding 
variables in the sources of variability (surgery, timepoint, batch effect) to draw 
conclusions.  
4.3.4.1.1 Differential expression 
Volcano plots were used to compare the gene expression profile of two groups. 
Significance was determined using Bonferroni correction (0.05 (p-value) divided by the 
number of observations). 
For each individual gene expression, two-way ANOVA was used to compare 
differences among all groups (control, AmnioFix and saline). Tukey’s post hoc 
comparison was performed to compare the means of parametric cases in which one-way 
ANOVA assumptions were fulfilled. Kruskal-Wallis post hoc test was used for non-
parametric cases. P-values less than 0.05 were considered statistically significant. 
Then, to calculate the difference in normalized expressions between the saline and 
AmnioFix groups, ΔΔCt values were calculated by subtracting the mean of the control 
group from the mean of the experimental group (saline or AmnioFix) for each individual 
gene expression (Equation 2). The SEM for ΔΔCt values was calculated using Gauβ error 
propagation equation (Equation 3). Two-way ANOVA was performed to determine the 
statistical significance of the differences between the means for each treatment and time 
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groups. Tukey’s and Kruskal-Wallis were used as post hoc tests when appropriate. P-
values less than 0.05 were considered statistically significant. 
All graphs were plotted as means ± SEM. Analyses were carried out using JMP 
Genomic software and graphed in JMP, Excel, or GraphPad Prism, version 7 (San Diego, 
CA). 
∆∆𝐶𝑡 = ∆𝐶𝑡!"#!$%&!'()* !"#$% − ∆𝐶𝑡!"#!"#$%&# !"#$% 
Equation 2. Equation to calculate normalized relative expression (∆∆𝑪𝒕) for each 
individual gene expression. In this chapter, samples from the unoperated 
contralateral control group were used as the calibrator. 
𝑆𝐷! = 𝑆𝐷!"#!$%&!'()* !"#$%! + 𝑆𝐷!"#$%&"'(& !"#$%!  
Equation 3. Equation for SD of ΔΔCt, derived using Gauβ’s error propagation. 
4.4 Results 
4.4.1 Articular cartilage 
In agreement with the previous chapter, no significant differences in gene 
expression were observed in the lateral side of the articular cartilage from the tibial 
plateau between the (unoperated) control and the MMT surgery (regardless of treatment) 
(data not shown). This is expected, as it has been shown before that the MMT surgery 
creates a focal defect on the medial side of the tibial plateau, exclusively [81]. Therefore, 
we discuss only the medial side of the synovium forthwith.  
4.4.1.1 Medial articular cartilage 
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The PCA showed that clustering was driven by surgery (unoperated vs. MMT) 
and then timepoint (Figure 19). Differences attributed due to treatment only accounted 
for 0.03%, which are considered negligible. There are only 2 significantly expressed 
genes that are different between the saline and AmnioFix groups in the medial articular 
cartilage. Col1a1 and Col1a2 (collagen type I isoforms) were overexpressed in the 
AmnioFix group comparing to the saline and control groups at 21 days post-surgery 
(Figure 20).  
 
Figure 19. A. PCA of the medial articular cartilage tissues shows that difference in 
groups are driven by surgery first, then timepoint, plate (batch number) and lastly 
treatment. B. PCA of the medial articular cartilage of animals that underwent 
MMT surgery (saline and AmnioFix groups) shows that differences have a high 
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degree of noise (residual at 75%) and are driven by timepoint, plate and, last, 
treatment. Treatment does not appear to be an influential factor in molecular 
changes of the articular cartilage as OA progresses. C. Volcano plots of AmnioFix 
group versus saline group at day 7 and day 21 shows that there is no significant 
difference between the two groups due to gene expression. Only collagen type 1 
(col1a1 and Col1a2) were higher expressed in the AmnioFix group. 
 
Figure 20. Col1a1 and Col1a2 were the only genes significantly different between 
the saline and AmnioFix groups in the medial articular cartilage of the tibial plateau 
of MMT animals, graphed as means ± SEM. && indicates significant difference 
between the two groups at the indicated timepoint at a p-value <0.01. 
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11 genes were differentially expressed between the unoperated animals (control 
group) and those which received MMT surgery (regardless of treatment, AmnioFix or 
saline groups), as shown in Figure 21. ECM gene Fn1 (fibronectin) was significantly 
lower in the control group than in the saline and AmnioFix groups at day 21. ECM 
remodeling genes were also dysregulated due to MMT surgery. Timp1 was significantly 
lower in the control than saline and AmnioFix at all timepoints. Mmp13 and Mmp2 were 
significantly lower in the control than the saline or AmnioFix at day 21. Ctsk was 
significantly lower in the control than the AmnioFix alone at day 21. Spp1 was 
significantly lower in the control than saline at day 21 and AmnioFix at days 7 and 21. 
Inhba was significantly lower in the control than saline at days 7 and 21 and than 
AmnioFix at day 21 only. Chondrocyte hypertrophic markers Frzb were significantly 
higher in the control group than the saline and AmnioFix groups for all timepoints, while 
Grem1 was significantly higher than saline at day 7 and than AmnioFix at day 21. Tgm2 
was significantly lower in the control group than the other two at day 21 only.  Col10a1 
was significantly higher in the control group than the AmnioFix group at all timepoints. 




Figure 21. Significantly expressed genes in the medial articular cartilage of the tibial 
plateau, graphed as means ± SEM. * indicates significant difference between the 
group and the control at the indicated timepoints at p-value <0.05; ** at p-
value<0.01; and *** at p-value<0.001. $ indicated significant difference between the 




4.4.2 Synovial membrane 
According to PCA, the lateral side of the synovial membrane was largely affected 
by choice of treatment (data not shown). This is not surprising since AmnioFix is injected 
intra-articularly and therefore expected to not be specific to one side of the joint space. 
However, because we have shown in the previous chapter that the MMT surgery does not 
have clear effect on the lateral synovial membrane, but instead that differences are driven 
by a rather large percentage of unknown or confounded variables; we focused our 
analyses and interpretations on the medial side of the synovial membrane only. 
4.4.2.1 Medial side of the synovial membrane 
 Surgery is the largest driver of separation among the groups, while treatment is 
second (Figure 22). It is worth noting that the AmnioFix treatment gives the medial 
synovial membrane of MMT rats a profile that is distinct from that of the unoperated, 
control (PCA plot, Figure 22. A. Unsupervised clustering of the distal medial synovial 
membrane tissue showed grouping based on surgery, followed by treatment. B. PCA 
confirms surgery as the largest factor of separation between groups, followed by 
treatment. It should be pointed out that all 3 groups have distinct profiles, which cluster 
in the PCA. The AmnioFix group is not the same as the unoperated control, but an 
entirely different profile.). There were 17 genes that showed significantly different 





Figure 22. A. Unsupervised clustering of the distal medial synovial membrane tissue 
showed grouping based on surgery, followed by treatment. B. PCA confirms surgery 
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as the largest factor of separation between groups, followed by treatment. It should 
be pointed out that all 3 groups have distinct profiles, which cluster in the PCA. The 




Figure 23. Significantly expressed genes between AmnioFix and saline groups of the 
medial synovial membrane, graphed as means ± SEM. & indicates significant 
difference between groups for the indicated timepoint at p-value<0.05; && at p-
value<0.01; and $$ at p-value<0.001. 
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In general, genes related to the ECM structural composition were overexpressed 
in the saline group (vs. the AmnioFix group). The saline group had significantly higher 
expression of Acan and Fmod than the AmnioFix group at days 7 and 21. Col1a2 was 
significantly higher in the saline group than the AmnioFix group at day 21. Col2a1 was 
significantly higher in the saline group than in the AmnioFix group at day 7 only. Genes 
related to ECM remodeling had a variable response. Ctsk, Mmp2 and Timp3 were 
expressed significantly higher in the saline group than in the AmnioFix group at day 21. 
Mmp3 and Mmp12 were significantly higher in the AmnioFix group than in the saline 
group, at days 7 and 21 and at day 21 respectively. 
 10 genes related to immunomodulation were regulated when the MMT model was 
treated with AmnioFix. IL-1a, IL1b, Ccl7, Ccl2, and Ifng were higher expressed in the 
AmnioFix group than in the saline group at every timepoint. Tnfa and Cxcr2 were 
significantly higher in the AmnioFix group than the saline group at day 7. IL1rn was 
significantly higher in the AmnioFix group than the saline group at days 7 and 21. IL15 
and Ptgs2 were significantly lower in the AmnioFix group than the saline group at day 
21.  
 8 genes were significantly different between unoperated animals (control group) 
and MMT animals, regardless of treatment; that is, differences were observed between 
control group vs. AmnioFix and vs. saline, but not between AmnioFix and saline (Figure 
24). Several ECM remodeling markers were significantly different in the control group 
than the saline and AmnioFix groups. Adamts4 was significantly lower in the control than 
the saline and AmnioFix at days 5 and 7. Timp1 was significantly lower in the control 
group than in the other two groups for all timepoints. Adamts5 and Fgf2 were 
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significantly higher in the control group than in the saline and AmnioFix groups at all 
timepoints. Spp1 was significantly lower in the control group than the saline at day 7 and 
the AmnioFix at all timepoints. 
 Tnn was significantly lower in the control group than saline and AmnioFix for all 
timepoints. Csf1 was significantly lower in the saline at days 7 and 21 and in the 
AmnioFix at days 5, 7 and 21 than in the control group. Epas1 was significantly lower in 
the saline and the AmnioFix at days 7 and 21 than the control group. 
 
Figure 24. Significantly different genes in the medial synovial membrane, between 
the control group and the treatment groups, graphed as means ± SEM. * indicates 
significant difference between the group and the control at the indicated timepoint 
at p-value<0.05; ** at p-value<0.01; and *** at p-value<0.001. # indicates significant 
difference between day 21 and day 5 for the indicated group at p-value<0.05; and ## 
at p-value<0.001. $ indicates significant difference between day 21 and day 7 for the 
indicated group at p-value<0.05; and $$$ at p-value<0.001. 
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4.4.3 Osteophyte region 
Gene expression results showed no significant differences between the saline and 
AmnioFix groups at day 21. There was no apparent organized clustering of the samples, 
according to the PCA (Figure 25). 
 
Figure 25. A. Unsupervised clustering shows no distinct grouping of samples 
harvested from the osteophyte region. B. Volcano plots show no significant 
difference between osteophyte tissue collected from saline and AmnioFix groups, 
suggesting that AmnioFix treatment did not directly affect molecular mechanisms in 




4.4.4 AmnioFix sequestration 
At 7 days post-surgery, traces of AmnioFix Injectable were discernable only in 
the AmnioFix-treated group in the synovial membrane (Figure 26). AmnioFix was not 
discernable at 21 days post-surgery.  
 
Figure 26. Hematoxylin & Eosin staining of the synovial membrane shows traces of 
AmnioFix Injectable in the AmnioFix treatment group and not in the saline group 
at 7 days post-surgery. 
4.4.5 Recruitment of helper cells by AmnioFix 
At 7 days post-surgery, cells in the AmnioFix treatment stained positive for CD68 
marker of macrophages in the synovial membrane (Figure 27). No positive CD68 
staining was observed in the saline group in the synovial membrane. 
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Figure 27. CD68+ staining of cells was observed at day 7 post-surgery in the 
AmnioFix group, but not in the saline group. 
4.5 Discussion 
Pre-clinical and clinical data have shown a protective effect on the articular 
cartilage after intra-articular injections of AmnioFix, yet the mechanisms of action of this 
potential disease-modifying OA drug cannot be inferred based on morphological 
endpoint readings or the composition of the material. By performing a localized gene 
expression study on multiple tissues of the MMT OA rat model, of different regions and 
at different timepoints, we were able to elucidate certain molecular events taking place 
with OA progression in this model and how AmnioFix may be modulate these 
pathological changes. 
It was interesting to note that, apart from collagen type I, there were no significant 
differences in gene expression of the articular cartilage for the MMT animals between 
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treatments (saline vs. AmnioFix). In the previous chapter, we have shown that there are 
pathological changes at the molecular level which are identifiable using this gene analysis 
platform, and here also, we observed distinct changes in gene expression due to the MMT 
surgery (regardless of treatment). However, AmnioFix does not appear to act directly on 
the articular cartilage, or on the osteophyte-forming region of this post-traumatic OA 
model. The disease progressing mechanisms, including increased levels of ECM 
remodeling markers and activation of chondrocyte hypertrophic switches, are still taking 
place in the articular cartilage. Mmp13, Mmp2, Ctsk, Inhba, Timp1, Timp3, and Spp1 
were all upregulated as a consequence of MMT surgery, and AmnioFix treatment did not 
appear to influence these genes. Underexpression of Grem1 and Frzb and overexpression 
of Tgm2 may lift the block on chondrogenic differentiation and allows chondrocytes to 
become hypertrophic. These results suggest that, in spite of AmnioFix treatment, 
molecular pathomechanisms still continue in the articular cartilage. They also emphasize 
the role the synovial membrane plays in OA development in the MMT rat model. It is 
possible that by treating the synovial membrane, AmnioFix is able to delay 
morphological changes in the articular cartilage, even though changes have been initiated 
at the molecular level. 
The influence of the synovial membrane in OA has been highlighted as a silent, 
yet pivotal contributor to disease progression in recent years [10, 11]. The joint acts as an 
organ, and it has been shown that OA-induced cartilage degradation triggers a Janus-like 
pro-inflammatory and anti-inflammatory response from the synovium [11]. It is believed 
that, due to the initial stimulus (cartilage injury) not being addressed, the immunogenic 
response becomes chronic and the synovium and the articular cartilage enter a positive 
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feedback loop, in which catabolic factors released by the synovium exacerbate the 
damage to the cartilage. The anti-inflammatory response from the synovium cannot offset 
the catabolic mechanisms at this point. 
In the medial side of the synovial membrane, AmnioFix Injectable elevated the 
expression of pro-inflammatory cytokines and chemokines: IL-1a, IL1-b, IL15, Ccl2 and 
Ifng. AmnioFix Injectable itself is known to contain these factors [117], and results 
suggest that contact with the synovium may have stimulated further production by 
synovial cells. We suggest that this pro-inflammatory gene expression driven by 
AmnioFix may initiate remodeling/repair mechanisms akin to wound healing in the 
synovium, which may alleviate the microenvironment of the cells and prevent the 
synovium from entering the feedback loop with injured cartilage. 
In wound healing, pro-inflammatory signals recruit helper cells, which in turn act 
to modulate the microenvironment of the wound by secretion of factors (including anti-
inflammatory signals) and start the repair process. By promoting a pro-inflammatory 
state, AmnioFix may be recruiting repair cells to the synovial lining. Ccl2 and Ccl7 are 
CC-Chemokines that mediate inflammatory (LY6Chi) monocyte recruitment [126]. 
Furthermore, high expression of Ccl2 suggests macrophage (MΦ) differentiation under 
the influence of macrophage colony-stimulating factor (M-CSF) [127, 128], indicating 
the specialization of recruited monocytes. Expression of Ifng and IL1 suggest a 
preference for M1 (proinflammatory, classically activated)-MΦ phenotype, which is 
involved with cytotoxicity and tissue injury [127]. Although studies have hypothesized 
that M-CSF-derived MΦ are pre-oriented to M2 (anti-inflammatory, alternatively 
activated) subtype [128-130], some studies have found that MC-CSF MΦ can polarize 
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toward a M1 phenotype after Ifng stimulation [129, 131]. If indeed MΦ infiltrate the 
synovium during OA development in the MMT model, our results suggest a bias toward 
polarization to the M1 phenotype. It is worth pointing out that MΦ polarization is not an 
analogy for a dial turning one direction or the other but, instead, for a spectrum in which 
cells can demonstrate traits of a phenotype along the x-axis and of another phenotype 
along the y-axis. In fact, Lacey et al. found the degree of anti-inflammatory phenotype of 
M1-MΦ to be the highest when derived from M-CSF origin [129, 132, 133]. 
Low expression of IL-15 and high expression of IL1rn (usually considered a M2-
MΦ marker [129, 134, 135]) would also suggest an upregulation of an anti-inflammatory 
response in the AmnioFix group. Altogether, these results may suggest that intra-articular 
injection of AmnioFix enhances the recruitment of helper cells to the synovial membrane 
in the MMT model and that these cells may be differentiated along the pro-
inflammatory/anti-inflammatory spectrum in such a way that their secretome is 
counteracting cartilage catabolism. 
Moreover, IL-1 (alpha or beta) and IL-1ra can be produced by the same cells 
(early or late macrophages) [136, 137]. Cauli et al. found that in OA patients, there was a 
higher percentage of macrophages positively stained for IL-1ra detected than those for 
IL-1a, compared to RA in which there is no a statistical difference between the two [136]. 
This high IL-1ra/low IL1a ratio may be a driver for the observed chronic, low 
inflammation in the synovium as OA develops.  Therefore the ratio between IL-1a and 
IL-1ra may help determine the disease process within the joint. Studies have indicated 
that in order to block IL-1-mediated effects, a 100-fold excess of IL-1ra is needed [136, 
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138, 139] Although probably not on this scale, AmnioFix Injectable may help neutralize 
the catabolic effects of IL-1 by influencing this ratio.  
Synovial fibroblast-like cells make up the majority of cells in the synovium, yet a 
study has found that selective depletion of MΦ in the synovium during OA results in the 
downregulation of several fibroblast-produced cytokines and MMPs [140]. This would 
indicate that MΦ play a role not only by secreting factors themselves, but also by 
stimulating responses from synovial fibroblasts, possibly activating them. The synovium 
is part of the joint organ, and so its state and composition affects the articular cartilage 
and bone and vice versa. In a collagenase-induced OA mouse model, MΦ from the 
synovial lining played a pivotal role in mediating osteophyte formation and other OA-
related pathology [30]. In the MMT model, we have not been able to detect 
inflammation-related responses due to injury (previous chapter), and so we are not able to 
postulate the baseline role of helper cells as OA-like characteristics develops in this 
model. We did, however, provide baseline molecular events as OA develops in this 
model, such as dysregulation of ECM composition markers and upregulation of ECM 
remodeling markers, especially elevated levels of MMPs. In this study, we have found 
that treatment with AmnioFix Injectable maintained ECM composition markers to levels 
comparable with the unoperated control group and that some ECM remodeling markers 
are downregulated.  More interestingly, we observed a spike in the expression of 
immunomodulatory markers in response to AmnioFix treatment in the MMT model. We 
postulate that by targeting the synovium, AmnioFix is modulating its microenvironment 
in such a way that could lead to a bias in polarization of MΦ and their secretome. This 
would then influence the secretome to perhaps alleviate the catabolic factors produced by 
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the articular cartilage and thus slow down damage. In order to test this hypothesis, 
isolated cells from the medial synovial membrane of MMT rats with/without AmnioFix 
treatment would need to be further studied. 
This study introduces a new perspective in the OA field, as conventional 
approaches have often focused on lowering inflammation by inhibiting inflammatory 
responses with agonists. Yet, to this date, these approaches have not shown a significant 
advantage as DMOADs, or consistent chondro-protective characteristics. We suggest to 
take a different perspective on inflammation, and instead of attempting to prevent it or 
remove it from the equation, that we leverage it to enhance tissue-repair responses such 
as the ones observed in response to AmnioFix treatment. Initial pro-inflammatory 
signaling is important in wound healing, yet if it extends into a chronic state, it would 
become a problem.  
As an ECM-derived drug, AmnioFix is composed of many factors that may have 
several effects that cross-reference each other that we have not tested in this study. 
Moreover, the MMT model is a post-traumatic model, and it is not generally associated 
with the inflammatory OA subphenotype. Therefore, we suggest that the mechanisms of 
action of AmnioFix should continue to be studied, particularly in different models where 
inflammation is prominent.  An in vitro study from this lab found that AmnioFix 
downregulated the pro-inflammatory response in cytokine-activated synovial fibroblasts. 
It could be entirely possible that, given its complex composition, AmnioFix has different 
effects in different models; that is, in different microenvironments. We propose that 
AmnioFix is further tested in OA models with an inflammatory component, such as the 
monoiodoacetate (MIA) model, and in models of rheumatoid arthritis (RA). RA occurs 
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when the immune system mistakenly attacks the synovial membrane, starting the 
pathological events that cause bone erosion and joint deformity. Since we have shown 
that AmnioFix directly targets the synovial membrane and that it is able to modulate its 




CHAPTER 5. DEVELOPMENT AND CHARACTERIZATION OF 
PATIENT-SPECIFIC INDUCED PLURIPOTENT STEM CELL-
DERIVED IN VITRO MODELS OF JUVENILE 
OSTEOCHONDRITIS DISSECANS 
5.1 Abstract 
JOCD is a degenerative joint disorder in which an osteonecrotic lesion in the 
subchondral bone has secondary effects on the overlaying articular cartilage. Over time, a 
necrotic osteochondral fragment develops and detaches from the parent bone, 
permanently affecting the joint and altering its mechanics. These 5 to 19 year-olds 
develop early onset of OA and contribute to a larger burden to the healthcare system. 
JOCD treatments are mostly conservative, and in advanced stages, surgical intervention 
is used to fix the fragment in place or replace it with an allograft. Limited treatments are 
due to the lack of knowledge about the onset and development of JOCD. The objective of 
this study was to develop JOCD patient-specific iPSC-derived models of chondrogenic 
and endochondral ossification organoids in order to elucidate pathological mechanisms of 
this disorder. 
JOCD-specific iPSCs from 3 donors were reprogrammed from skin fibroblasts 
and validated for pluripotency. Then, they were differentiated into MSCs (iMSCs) and 
validated according to the established minimal criteria. JOCD- and control-iMSCs 
underwent 3D chondrogenesis and endochondral ossification, and these organoids were 
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harvested at different timepoints for gene expression, GAG and calcium quantification, 
histology, and TEM.  
Results from the chondrogenic model showed that cells derived from JOCD 
patients had a significantly lower chondrogenic capacity than those from control patients. 
In the endochondral ossification model, JOCD cells produced the same amount of 
calcium and stained equally well for collagen type I, yet their gene expression profile was 
significantly different than that of the control cells. This may suggest that although JOCD 
cells are able to undergo endochondral ossification, there are irregularities in this process, 
when compared to control cells. This study has utilized cutting-edge iPSC technology to 
study JOCD in vitro and it is the first to report on JOCD pathomechanisms during 
chondrogenesis and endochondral ossification.  
5.2 Introduction 
JOCD is an increasingly common degenerative joint disorder that predominantly 
affects adolescent and young adults, and progresses to early onset OA. JOCD is 
hypothesized to involve the formation of an avascular lesion in the subchondral bone 
with secondary effects in the overlaying articular cartilage. As this disease progresses, 
partial or complete fragmentation of the necrotic bone may occur, which jeopardizes the 
bone integrity and significantly alters the joint mechanisms [36]. Previous research has 
been limited to retrospective clinical studies, and the pathophysiological mechanisms 
associated with the onset and progression of JOCD have yet to be fully characterized.  
Previous studies have shown that chondrocytes isolated from detached JOCD 
fragments maintain similar cell viability and proliferative activity to those from normal 
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healthy cartilage [41, 76, 77]. However, both JOCD loose body- and JOCD cartilage 
biopsy-derived primary chondrocytes showed intracellular accumulation of matrix 
proteins that affected their morphology [77]. This feature has also been observed in 
familial OCD (FOCD) [78] and in endoplasmic reticulum storage diseases (ERSD) [77]. 
Unlike JOCD, FOCD is associated with a mutation in the aggrecan gene. A previous 
study by Xu et al. showed that, because of this mutation, large amounts of the aggrecan 
protein accumulated within the ER of FOCD chondrocytes, which led to a marked 
absence of aggrecan in the ECM [78]. FOCD is, therefore, considered to be an ERSD. All 
ERSDs show critical accumulation of misfolded proteins that result in defective protein 
trafficking, which may cause defective ECM assembly [77].  
However, JOCD is not known to be a genetic disease; there isn’t a specific 
mutation associated with it, and a recent study has found that only 14% of patients have 
family history [69]. Furthermore, characteristic features of FOCD are systemic: people 
with FOCD have multiple lesions that affect several joints, have short stature and develop 
OA at an early age. In contrast, JOCD is not systemic. There may be lesions in one than 
one joint, but developmental abnormalities are not associated with JOCD, as they are in 
the case of FOCD. Therefore, it is unclear whether JOCD may also be a disease of the 
ER. Previous studies have focused on isolated primary chondrocytes and the cartilage 
aspect of JOCD, yet this disorder is hypothesized to initiate in the subchondral bone, in 
the secondary ossification center. Because JOCD patients are still developing, the 
endochondral epiphyseal ossification is still undergoing. This differentiation process is 
prominent in JOCD patients, yet it has never been studied. 
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The objective of this study is to establish JOCD patient-specific iPSC-derived in 
vitro models of chondrogenesis and endochondral ossification in order to investigate 
pathological mechanisms in this disorder. Because these are pediatric patients and their 
lesions are usually treated without the excision of the fragment, stem cells were not a 
viable source. Instead, with as little as a 2mm2 skin biopsy, we were able to generate 
patient-specific iPSCs, which provided us with an unlimited supply of disease-specific 
stem cells and the ability to differentiate them into different tissues to study different 
aspects of the same disease. We chose to study endochondral ossification processes as 
they are highly relevant to the site where JOCD lesions develop (epiphyseal ossification), 
and chondrogenesis processes because cartilaginous templates are a key step in 
endochondral ossification. We hypothesized that cells from JOCD patients produce a 
suboptimal matrix during endochondral ossification and that this is a result of protein 
accumulation in the ER.  
5.3 Materials and methods 
5.3.1 Tissue and cell samples 
Sin biopsies (2mm in diameter) from 3 JOCD patients were obtained in 
collaboration with Children’s Healthcare of Atlanta, Orthopeadics department (IRB study 
#13-098). Dermal fibroblasts from these biopsies were sent to Washington University’s 
iPSC core facility (St. Louis, MI) for reprogramming with sendai virus. 3 clones from 
each JOCD iPSC line were chosen in order to have (3) biological copies of each JOCD 
patient. In order to study a disease, it is important to work with multiple clones per 
 95 
patient as previous studies have found that clone-to-clone variability exists, similar to 
donor-to-donor variability observed in human cells [141]. 
Control (non-disease) iPSC lines were purchased from ATCC and kindly gifted 
by the Shen lab (National University of Ireland Galway, Galway, Ireland). Known 
characteristics of the donors are detailed in Table 4 and Table 5. 
Table 4. Detailed characteristics of JOCD iPSC lines. 
Group Line Characteristics  
JOCD JOCD1 Age 16 
  Sex Male 
  Race Caucasian 
  Involved in competitive sports? Yes (basketball, soccer) 
  Affected joint Right knee 
  Surgery Osteochondral allograft 
  Number of iPSC clones used in 
this study 
3 
  iPSC source Skin fibroblasts 
  Reprogramming method Sendai 
 JOCD2 Age 12 
  Sex Male 
  Race African-American 
  Involved in competitive sports? Yes (basketball) 
  Affected joint Right & left knee 
  Surgery Drilling for intact OCD + 
BMAC 
  Number of iPSC clones used in 
this study 
3 
  iPSC source Skin fibroblasts 
  Reprogramming method Sendai 
 JOCD3 Age 19 
  Sex Female 
  Race African-American 
  Involved in competitive sports? No 
  Affected joint Right knee 
  Surgery Autologous graft to lesion 
  Number of iPSC clones used in 
this study 
3 
  iPSC source Skin fibroblasts 
  Reprogramming method Sendai 
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Table 5. Detailed characteristics of control iPSC lines. 
Group Line Characteristics  
Normal Control 1 Age 9 
  Sex Male 
  Race Caucasian 
  Involved in competitive sports? No 
  Affected joint -- 
  Surgery -- 
  Number of iPSC clones used in 
this study 
2 
  iPSC source Skin fibroblasts 
  Reprogramming method Lentiviral 
 Control 2 Age 20 
  Sex Female 
  Race Caucasian 
  Involved in competitive sports? No 
  Affected joint -- 
  Surgery -- 
  Number of iPSC clones used in 
this study 
1 
  iPSC source Skin fibroblasts 
  Reprogramming method Lentiviral 
 Control 3 Age 33 
  Sex Male 
  Race African-American 
  Involved in competitive sports? Unknown 
  Affected joint -- 
  Surgery -- 
  Number of iPSC clones used in 
this study 
1 
  iPSC source Bone marrow CD34+ cells 
  Reprogramming method Sendai 
 Control 4 Age 31 
  Sex Male 
  Race Non-Hispanic Caucasian 
  Involved in competitive sports? Unknown 
  Affected joint -- 
  Surgery -- 
  Number of iPSC clones used in 
this study 
1 
  iPSC source Bone marrow CD34+ cells 
  Reprogramming method Sendai 
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 For the purpose of this study, we grouped the iPSC lines (and their derivatives) 
into two groups, as described in Table 6. Every experiment described within this study 
(e.g. cell line characterization and validation, differentiation models, etc.) were 
performed using every one of the cell lines in Table 6. 
Table 6. Control group was composed of 2 iPSC lines gifted from REMEDI (one of 
which had 2 clones) and 2 iPSC lines purchased from ATCC, described in Table 5. 
JOCD group consisted of 3 JOCD-specific iPSC lines, with 3 clones each (described 
in Table 4). Cell line identifying number is denoted by the number after the group 
(i.e. cntrl#2, or control cell line #2) and clone number, within the cell line) is denoted 






























5.3.2 iPSC culture, characterization and validation 
iPSCs were cultured in 6-well plates, coated with Geltrex (Thermo Fisher 
Scientific A1413302), with E8 Flex media (Gibco, Thermo Fisher Scientific). In order to 
determine whether reprogramming had an adverse effect on the chromosome of a cell 
line, Karyotyping analyses were performed by Cell Guidance Systems (Cambridge, UK), 
for which samples were prepared following the company’s guidelines. To validate the 
pluripotency of iPSCs, RT-PCR and IHC of the pluripotent markers were performed. 
Embryonic body (EB) and teratoma formation were also carried out in order to show the 
lines’ ability to differentiation into the 3 germ layers.  
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To form EBs, iPSC colonies were dissociated with Dispase (Stemcell 
Technologies 07923) for 10 min at 37 °C and cultured in ultra-low attachment well plates 
(Corning CLS3471). Two days after, medium was changed to 50:50 E8 Flex medium 
(iPSC medium) : EB medium. Then, two days after, medium was changed to 100% EB 
medium, which contains knock-out DMEN, 20% FBS, 1% L-glutamine, 1% non-
essential amino acid (NEAA), and 0.014mM β-mercaptoethanol. EB medium was 
changed every other day, and EBs were fixed in 10% NFB (overnight, at 4°C) at the 5 
week timepoint. 
To form teratomas, iPSCs were dissociated with Dispase and injected 
subcutaneously (Georgia Institute of Technology IACUC protocol A16043) in 60% 
Geltrex. Teratomas were allowed to grow for 8 to 12 weeks. 
5.3.3 iMSC differentiation 
iPSCs were differentiated into iMSCs (iPSC-derived mesenchymal stem cells) via 
an EB intermediate step, as previously described [142, 143]. EBs were formed as 
previously described. After 9 days, EBs were plated on gelatin (0.1%)-coated flasks with 
EB medium. After 5 days, the outgrowth cells were typsinized and passaged into gelatin-
coated T-75 flasks with MSC differentiation medium, which contains knock-out DMEN, 
10% FBS, 1% Penicillin streptomycin (PS), 1% L-glutamine, and 1% NEAA. Cells were 
cultured and passaged until a homogeneous (>70%) fibroblastic morphology appeared. 
Then, differentiating cells were passaged to non-coated, standard tissue culture flasks, 
and cultured with MSC maintenance media (αMEM, 10% FBS and 1% PS) with 2 ng/ml 
FGF2. 
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5.3.4 iMSC characterization and validation 
To confirm MSC status, the International Society for Cellular Therapy’s minimal 
criteria was tested [144] (Table 7). iMSCs automatically fulfill the first criterion as part 
of the differentiation protocol. The second criterion, phenotype, was tested by conducting 
fluorescence-activated cell sorting (FACS) of the indicated MSC surface markers. The 
Human MSC Analysis Kit (BD Biosciences, #562245) was used for this purpose.  
Table 7. Summary of criteria to identify MSC, as set by the International Society for 
Cellular Therapy [144].  
1. Adherence to plastic in standard culture conditions 
2. Phenotype Positive (≥95%) Negative (≤2%) 
 CD105 CD45 
 CD73 CD34 
 CD90 CD14 or CD11b 
  CD79α or CD19 
  HLA-DR 
3. In vitro differentiation: osteogenesis, adipogenesis, and chondrogenesis (demonstrated 
by staining of in vitro cell culture) 
5.3.4.1  Multipotency test 
5.3.4.1.1 Osteogenesis 
iMSCs were cultured at a seeding density of 10,000 cells/cm2 and in MSC 
Maintenance Medium. Once cells reached confluency, they were induced and fed with 
osteogenic medium (DMEN low glucose, 10% FBS, 1% PS, 10mM β-glycerol, 100 µM 
L-ascorbic acid, and 100nM dexamethasone) every other day.  
 100 
After 4 weeks, cultures were taken down for Alizarin Red and Von Kossa 
stainings. For Alizarin Red, cells were washed with PBS and fixed with 10% NBF at RT 
for 15 minutes. Cells were then rinsed with dH2O and stained with Alizarin Red (pH 4.1) 
for 5 minutes. For Von Kossa, cells were washed with PBS and fixed with 70% Et-OH 
for 30 minutes at RT. Cells were rinsed with dH2O and incubated with silver nitrate under 
UV. The reaction was stopped with sodium thiosulfate. 
5.3.4.1.1 Adipogenesis 
iMSCs were cultured at a seeding density of 20,000 cells/ cm2 and in MSC 
Maintenance Medium. Once cells reached confluency, they were induced with 
adipogenic induction medium (DMEN high glucose, 10% FBS, 1µM dexamethasone, 
10µg/ml insulin, 200µM indomethacin, 500µM MIX, and 1%PS). Adipogenic induction 
medium was changed every 3-4 days, 3 times; then, medium was switched to adipogenic 
maintenance medium (DMEN high glucose, 10% FBS, 10µg/ml insulin, and 1% PS) for 
3 days before fixing. Cells were fixed with 10% NBF for 10 minutes at RT and stained 
with oil red-o solution.  
5.3.4.1.1 Chondrogenesis 
2 × 10! iMSCs in 10 µl of MSC maintenance media were incubated at 37°C for 2 
hours in low-adherence tubes. Then, 200 µl of MSC maintenance medium was added to 
each tube, followed by overnight incubation. The next day, medium was replaced by 
chondrogenic medium (DMEN high glucose, 100nM dexamethasone, 50µg/ml Ascorbic 
acid, 40 µg/ml L-proline, 1% ITS + supplement, 1mM sodium pyruviate, and 1% PS) 
with 10ng/ml of TGF-β3 and changed every second day for 21 days. Cell pellets were 
 101 
fixed with 10% NBF overnight at 4°C, routinely processed, embedded in paraffin, and 
sectioned at 5 µm thickness. Sections were stained with 0.01% toluidine blue (pH 4.0) 
and counterstained with nuclear fast red.  
5.3.5 Chondrogenic and endochondral ossification differentiation models 
5.3.5.1 3D chondrogenesis 
3D chondrogenesis model of iMSCs was performed using the high cell-density 
micromass culture model as previously described [78]. Briefly, 2 × 10! iMSCs in 10 µl 
of MSC maintenance media were incubated at 37°C for 2 hours in low-adherence round-
bottom 96-well plates (Sigma-Aldrich). Then, 200 µl of MSC maintenance medium was 
added to each well, followed by overnight incubation. Medium was replaced by 
chondrogenic medium with 10ng/ml TGF-β3 (Peprotech) the following day and was 
changed every second day for 49 days. Micromass cultures were harvested at different 
timepoints. 
5.3.5.2 3D Endochondral ossification 
The 3D endochondral ossification differentiation model was carried out as shown 
in Figure X. The micromass cultures for endochondral ossification were started like in the 
chondrogenesis model and cultured with chondrogenic media for the first 21 days. At day 
21, medium was replaced by osteogenic medium and changed every second day for an 
additional 28 days. Micromass cultures were harvested at different timepoints. 
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5.3.6 Quantitative analyses of differentiation 
5.3.6.1 DNA 
Samples were harvested at day 21 and day 49  (n=5 per cell line). Pellets were 
digested overnight in papain (Sigma Aldrich) at 60°C. DNA was measured by Picogreen 
dsDNA assay kit (Thermo Fisher Scientific), according to the manufacturer’s protocol.  
5.3.6.2 Sulfated glycosaminoglycan (GAG) 
Dimethylmethylene blue (DMMB) quantification was performed as previously 
described [78], with the same papain-digested samples that were used for DNA 
quantification. To assess the chondrogenic capability of control- and JOCD-iMSCs, the 
ratio of GAG to DNA per sample was calculated. 
5.3.6.3 Calcium 
Samples designated for calcium (n=5 per cell line, per timepoint) were vortexed 
overnight at 4°C in 1 N acetic acid to solubilize calcium. Calcium deposition was 
determined by the colorimetric Arsenazo III readent assay (Diagnostic Chemicals Ltd., 
Oxford, CT, USA). To assess the osteogenic capability of iMSCs, the ratio of calcium to 
DNA was calculated. Because these two assays were not quantified from the same 
pellets, the mean and SD of each assay was calculated separately. Then, the ratio was 
computed by dividing the mean of the calcium content by the mean of the DNA 
concentration, for each group. To calculate the SD of the ratio (averaged calcium : 
averaged DNA content), Taylor’s expansion formula was used with the assumption of 












𝐴 × 𝐵  
Equation 4. Approximation formula [145, 146] for the variance of the quotient of 
two random variables; where A and B are the mean values and VA and VB are their 
corresponding variances. The covariance (C(A,B)) is zero and drops out of the 
equation when variables are assumed to be independent. 
𝑺𝑫(𝑨 𝑩) = 𝑽(𝑨 𝑩) 
Equation 5. The variance is squared-rooted in order to calculate the sampled 
standard deviation. 
5.3.7 Gene expression 
5.3.7.1 iPSCs and iMSCs 
Total RNA was extracted by RNeasy Mini Kit (Qiagen). Normalized RNA was 
then synthesized to cDNA using SuperScript VIlo cDNA synthesis kit (Invitrogen). RT-
PCR was run following Taqman’s Gene Expression Assays Protocol, using the Taqman 
gene expression assays specified in Table 8. AccuRef human universal cDNA (Gene 
Scientific) and ultrapure water were used as positive and negative controls, respectively, 
to ensure run fidelity. 
Ct values greater than 37 were treated as 37, namely as null. Gene expression 
analysis was carried out using the ΔΔCt method, outlined in Equation 1 and Equation 2. 
Briefly, the Ct value of each gene was normalized by the expression of the housekeeping 
gene GAPDH to get the relative expression (ΔCt). Then, the ΔCt of each target was 
normalized by the ΔCt of the calibrator (in this case, a control BM-MSC line), to get the 
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ΔΔCt for each gene. In order to get the fold change, ΔΔCt values were transformed using 
Equation 6. Results were graphed in log10 format. 
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =  2!∆∆!" 
Equation 6. Equation to calculate fold change from the normalized relative 
expression (ΔΔCt). 
5.3.7.2 Differentiation models 
Total RNA from micromass cultures was extracted using the RNeasy MinElute 
Clean-up Kit with QIAzol Lysis Reagent (Qiagen). Then, normalized RNA was 
synthesized to cDNA using RT2 First Strand Kit (Qiagen).  
RNA expression was quantified using the Taqman real-time PCR Fluidigm 
Dynamic Array Integrated Fluidic Circuits (BioMark, Fluidigm), for the Taqman gene 
expression assays specified in Table 8. AccuRef human universal cDNA (Gene 
Scientific) and ultrapure water were used as positive and negative controls, respectively, 
to ensure run fidelity.   
Ct values greater than 37 were treated as 37 (null). Gene expression analysis was 
carried out using the ΔΔCt method, outlined in Equation 1 and Equation 2. The Ct value 
of each gene was normalized by the geometric mean of the expressions of the 
housekeeping genes to get the relative expression (ΔCt). Then, the ΔCt of each target was 
normalized by the ΔCt of the calibrator to get the ΔΔCt for each gene. For the 
differentiation experiments, the calibrators were the micromass cultures at 2 hours post-
seeding, of the respective cell line. SD was derived using Gauβ’s error propagation 
(Equation 3). 
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Then, in order to calculate the averaged control or JOCD expression for a specific 
gene, the weighted averaged was computed. The pooled SD formula (Equation 7) was 
used to calculate the SD of averaged control or JOCD expression results.  
𝑆𝐷!""#$% =
𝑛! − 1 𝑆𝐷!! + 𝑛! − 1 𝑆𝐷!! +⋯+ 𝑛! − 1 𝑆𝐷!!
𝑛! + 𝑛! +⋯+ 𝑛! − 𝑘
 
Equation 7. Equation for calculating the pooled SD for three or more groups [145, 
147, 148]. 
Results were graphed in the log2 form (ΔΔCt) because this is the linear form of 
the values and allow for representation of values with descriptive statistics (mean, SD, 
SEM). Converting ΔΔCt into fold change would change the distribution to not longer 
symmetric and would not allow these descriptive statistics, which are essential for 
comparison of statistical significance. 
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Table 8. List of Taqman Gene Expression Assays used for each experiment. Where 
available, assays were of “the best coverage”, recommended by the company. Some 
assays may be listed more than once as they belong to multiple categories and/or 
were used for different experiments. 




Pluripotency Sox2 (Hs01053049_s1), Oct4 
(Hs04260367_gH), Nanog (Hs02387400_g1) 




Pluripotency Sox2 (Hs01053049_s1), Oct4 
(Hs04260367_gH), Nanog (Hs02387400_g1) 
Housekeeping gene GAPDH (Hs02786624_g1) 
Differentiation 
models 
Chondrogenesis Acan (Hs00153936_m1), Col2a1 
(Hs00264051_m1), Col1a1 
(Hs00164004_m1), Comp (Hs00164359_m1), 
Runx2 (Hs01047973_m1), Sox9 
(Hs00165814_m1), Fmod (Hs05632658_s1) 
 Endochondral 
ossification 
Col1a1 (Hs00164004_m1), Sp7 
(Hs01866874_s1), Bglap (Hs01587814_g1), 
Col10a1 (Hs00166657_m1), Mmp13 
(Hs00942584_m1), Runx2 
(Hs01047973_m1), Fmod (Hs05632658_s1) 
 Housekeeping genes Gapdh (Hs02786624_g1), Rps18 




iPSC colonies were fixed with 4% PFA at RT for 10 minutes. iPSCs were 
permeabilized with 0.5% saponin, blocked with 1% BSA in 0.05% saponin for 1 hour at 
RT, and incubated in primary antibody (Table 9) at 4°C overnight. The next day, they 
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were incubated in secondary antibody (Cell Signaling 4409 and/or 4412, depending on 
the primary) for 1 hour at RT and in Hoecht for 5 minutes at RT. 
5.3.8.2 EBs and differentiation models  
Samples were fixed in 10% NBF overnight at 4°C. Only endochondral 
ossification pellets were decalcified with ImmunoCal (StatLab) overnight at 4°C. 
Samples were routinely processed, embedded in paraffin, and sectioned at 5 um. Antigen 
retrieval (sodium citrate buffer), permeabilization (0.1% Triton-X) and blocking were 
performed on the sections, before incubation overnight in primary antibody at 4°C. Table 
9 lists the antibodies used for the corresponding experiment. Secondary antibody (Cell 
Signaling 4409 and/or 4412, depending on the primary) was incubated for 1 hour at RT, 
followed by counterstaining with DAPI (ThermoFisher S36938). 
Table 9. List of primary antibodies used in immunohistochemistry for each 
experiment. 
Experiment Category Primary antibody 
iPSC characterization and 
validation 
Pluripotency Cell signaling technology (#9656): 
1:100 Sox2, 1:100 Oct4, 1:100 
Nanog, 1:100 SEEA4 
Embryonic body validation Mesoderm 1:500 α-smooth muscle actin (Sigma 
#A2547) 
 Endoderm 1:50 α-Fetoprotein (Sigma #A8452) 
 Ectoderm 1:500 Nestin (Millipore 
#MAB5326) 
Differentiation models Chondrogenesis 1:200 Collagen type 2 (Santa Cruz 
#52658), 1:200 Aggrecan (ab36861) 
 Osteogenesis 1:200 Collagen type 1 (ab34710) 
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5.3.9 Transmission electron microscopy (TEM) 
Micromass cultures were harvested at day 49 for each differentiation model (n=5 
per cell line), fixed in 25% glutaraldehyde in 0.2M cacodylate buffer, and sent to 
Emory’s Robert P. Apkarian Integrated Electron Microscopy Core (Atlanta, GA) for 
analyses. Day 49 was chosen as the only timepoint to allow a longer period of time for 
possible protein accumulation in the ER.  
5.3.10 Statistical analyses 
Data were graphed as means ± SEM. Group comparisons were made with Two-
way ANOVA analysis. Tukey’s and Kruskal-Wallis were used as post hoc tests where 
appropriately. P-values less than 0.05 were considered statistically significant. 
5.4 Results 
5.4.1 iPSC reprogramming, characterization and validation 
JOCD-iPSC lines (and their clones) did not have any abnormal chromosome 
changes due to reprogramming (data not shown). They stained positive for intracellular 
pluripotent stem cell markers Sox2, Oct4 and Nanog, and one of the cell surface 
pluripotency markers, SEEA4, as shown in Figure 28. RT-PCR confirmed expression of 
the pluripotent stem cell markers. Control-iPSC lines also tested positive for staining and 
gene expression of pluripotent markers.  
JOCD-iPSC lines (and their clones) were able to form EBs, and these EBs stained 
positive for all 3 germ layers: endoderm, ectoderm, and mesoderm. Control-iPSCs lines 
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from the Shem lab also tested positive for the 3 germ layers. EB pluripotency test was not 
performed for Control-iPSC lines from ATCC as they were certified by ATCC itself. 
 
Figure 28. iPSC characterization and validation. Representative images from 
JOCD1-1 (JOCD-iPSC donor #1, clone #1) showed A. positive staining for 
pluripotent stem cells markers, B. gene expression of pluripotent stem cell markers, 
and C. positive staining for the 3 germ layers once differentiated into EBs: αSMC 
(mesoderm), β-tubulin (ectoderm), and AFP (endoderm). 
5.4.2 iMSC characterization and validation 
Control- and JOCD-iMSCs passed the International Society for Cellular 
Therapy’s minimum criteria. As Figure 29 shows, chosen iMSCs passed the approved 
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MSC surface marker panel. They were also shown to be multipotent and that the 
expression of pluripotent stem cell markers were now downregulated (comparing to their 
iPSC state). 
 
Figure 29. Characterization and validation of iMSCs. Representative images for 
iMSC line JOCD1-1 (derived from JOCD-iPSC donor #1, clone #1) shows A. the 
appropriate cell surface markers, B. lower expression of plutipotent stem cell 
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markers, and C. positive staining for adipogenesis (oil red), chondrogenesis (tol-
blue), and osteogenesis (Von Kossa and Alizarin Red). 
5.4.3 Chondrogenesis model 
JOCD- and control-iMSC-derived chondrogenic pellets showed significant 
differences in gene expression as they differentiated, as shown in Figure 30. JOCD-
chondrogenic pellets had significantly lower expression of Acan, Col2a1, Comp, Runx2 
and Sox9—all of which are markers of chondrogenesis. JOCD pellets had significantly 
lower expression of Acan (aggrecan gene) than control pellets at days 14, 21 and 49. 
Col2a1 (collagen type II) expression was significantly lower in JOCD- than control- 
pellets only at day 28. Comp (cartilage oligomeric matrix protein) and Sox9 (SRY-Box 9) 
expression were significantly lower in JOCD than control-pellets for every time point. 
Runx2 (runt-related transcription factor-2) expression was significantly lower in JOCD- 
than control-pellets at days 7 and 21. 
JOCD-chondrogenic pellets had significantly higher expression of Fmod 
(fibromodulin) and Col1a1 (collagen type I), considered a marker of fibrous cartilage 
during differentiation. Fmod expression was significantly higher in JOCD- than control-
pellets at days 7, 21, and 49. Col1a1 expression was significantly higher in JOCD- than 
control-pellets at every single timepoint. 
Because Col2a1 is a typical marker of differentiated chondrocytes in hyaline 
cartilage, as opposed to Col1a1, the ratio of RNA expression levels of Col2a1 to Col1a1 
can be utilized as a differentiation index related to the expression of collagens during 
chondrogenic differentiation to better assess the efficiency of chondrogenic 
differentiation [149]. Figure 30 shows that JOCD-chondrogenic pellets had a 
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significantly lower ratio of Col2a1 to Col1a1 than control-chondrogenic pellets at days 7, 
21, 28, 35, and 49.  
 
Figure 30. A. Significantly expressed genes in the chondrogenic pellets, graphed as mean 
± SEM. B. Col2a1 to Col1a1 ratio is used as an index of chondrogenic differentiation. * 
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indicates statistically significant difference between JOCD-chondrogenic pellets and 
control-chondrogenic pellets at p-value<0.05, ** at p-value<0.01, *** at p-value <0.001 
There were no significant differences between GAG content in the control-
chondrogenic pellets versus the JOCD-chondrogenic pellets (Figure 31). 
 
Figure 31. GAG deposition by chondrogenic pellets, normalized to DNA content; 
graphed as means ± SEM. 
Col2/Col1 IHC staining showed positive staining at both day 21 and day 49 of 
both markers (Figure 32). At day 21, control-iMSC-derived chondrogenic pellets had 
seemingly less Col1 staining than JOCD-iMSC-derived chondrogenic pellets. At day 49, 
both groups showed an overall increase in Col1-postive staining, and JOCD-
chondrogenic pellets had more Col1-positive staining than control-chondrogenic pellets. 
JOCD-chondrogenic pellets were more likely to form a fibrous shell (2/3 of the time vs. 
½ of the time). Col1 and Col2 stained throughout the pellets, with no apparent signs of 
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intracellular protein retention. Aggrecan IHC also did not show apparent differences in 
protein location within the chondrogenic pellets at day 21. 
 
Figure 32. Immunohistochemistry staining of A. Collagen 2 and Collagen 1 and B. 
Aggrecan of chondrogenic pellets. Representative pictures from Control1-1 




5.4.4 Endochondral ossification model 
JOCD-osteogenic pellets had significantly higher expression of Col1a1 than 
control-osteogenic pellets at every single timepoint. However, JOCD pellets had 
significantly lower expression of endochondral ossification markers than control pellets. 
Col10a1 and Mmp13 are markers of chondrocyte hypertrophic, which is a key step in 
endochondral ossification. JOCD-osteogenic pellets had significantly lower col10a1 than 
control-osteogenic pellets at every time point. Mmp13 expression was significantly lower 
in the JOCD-ostegenic pellets at day 49 only. Runx2 plays an essential role during 
commitment and differentiation of mineralized cell types, and its deletion results in 
complete loss of skeletal mineralization [150]. Here, we observed a lower expression of 
Runx2 during endochondral ossification of our pellets for the JOCD group at days 7, 21, 
28, 35, and 49. Runx2 plays a role in the regulation of Sp7 (osterix), and we observed a 
lower expression of Sp7 in the JOCD-osteogenic pellets at days 21 and 35. Finally, Fmod 
was only significantly higher in the JOCD group at day 7.  
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Figure 33. Significantly expressed genes in the osteogenic pellets, graphed as means ± 
SEM. * indicates statistically significant difference between JOCD-chondrogenic pellets and 
control-chondrogenic pellets at p-value<0.05), ** at p-value<0.01, *** at p-value<0.001. 
The osteogenic pellets did not show significant differences in calcium deposition 
for any timepoint, but each group did significantly increase its deposition over time as the 
pellets differentiated (Error! Reference source not found.). 
 
Figure 34. Calcium deposition by osteogenic pellets, normalized by DNA content; 
graphed as means ± SEM. 
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Col2/Col1 IHC showed positive staining for both markers in both groups. At day 
49, both groups had substantially more col1-postive staining and there were no apparent 
differences in the amount of protein stained or location within the osteogenic pellets 
(Figure 35). 
 
Figure 35. Immunohistochemistry staining of Collagen 2 and Collagen 1 of 
osteogenic pellets. Representative pictures from Control1-1 (Control-iPSC donor #1, 
clone #1) and from JOCD2-1 (JOCD-iPSC donor #2, clone #1). 
5.4.5 Protein accumulation in the ER during differentiation 
TEM did not show differences in ER volume between JOCD and control groups, 
as shown in Figure 36. 
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Figure 36. TEM representative images of chondrogenic pellets of Control-1 and 
JOCD1-1 and JOCD2-1 at day 49.  
5.5 Discussion 
Microtrauma, ischemia, genetic predisposition, and abnormal ossification have all 
been hypothesized as plausible causes of JOCD. Research limited to retrospective clinical 
studies and histological findings has translated into limited knowledge about the 
pathological mechanisms underlying JOCD, which has, in turn, hampered innovation in 
treatment strategies. In this study, we sought to elucidate possible pathological 
mechanisms of JOCD during chondrogenesis and endochondral ossification. JOCD 
occurs in patients with open epiphysis; therefore, endochondral ossification is an 
important physiological process occurring at the injury site. Endochondral ossification 
initiates from a cartilaginous template, and so studying chondrogenesis of JOCD patients 
may also elucidate pathological events in this disorder. 
 In this study, we observed that JOCD patient-specific chondrogenic pellets had 
significantly lower expression of chondrogenic markers than the control chondrogenic 
pellets. This result may have two explanations. First, JOCD-specific iMSCs have a lower 
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chondrogenic potential than control-iMSCs. This result is supported by the significant 
differences in col2a1 to col1a1 ratio, for which JOCD-chondrogenic pellets show a lower 
index of chondrogenic differentiation for most timepoints. IHC confirmed this lower 
chondrogenic potential hypothesis. The GAG assay, however, did not show significant 
differences between the control and JOCD chondrogenic pellets, but the DMMB assay 
may not be sensitive enough. Another possibility for the lower expression of 
chondrogenic markers may be that there is a small amount of protein accumulation in the 
ER, and although not enough to visibly engorge the ER (TEM), it is having an effect on 
protein production. When proteins get accumulated in the ER, response mechanisms 
include the downregulation of those proteins until the cell is able to reduce stress in the 
ER. In order to test this second explanation, we would have to test for ER stress-related 
genes in the differentiation models over time. 
 JOCD endochondral ossification model showed decreased expression of 
chondrocyte hypertrophic markers as well endochondral ossification orchestrators Runx2 
and Sp7. Because col1a1 expression, a key protein in bone, was significantly higher in 
JOCD-osteogenic pellets, it is unclear whether the endochondral ossification process is 
impaired. We suggest that cells from JOCD patients may have an irregular endochondral 
ossification, as demonstrated by significantly lower expressions of Runx2 and Sp7, but 
additional markers would have to be assessed to elucidate pathological pathways. 
During skeletogenesis, Runx2 is expressed in both chondrocytes and osteoblasts, 
and its global deletion results in disrupted chondrocyte and osteoblast differentiation 
[150]. Runx2 expression is required to promote chondrocyte hypertrophy, and conditional 
ablation of Runx2 gene in chondrocytes leads to failed endochondral ossification [150]. 
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In both the chondrogenic and endochondral ossification models, we observed 
significantly lower expression of Runx2 in JOCD organoids. This result may suggest 
lower ability to undergo endochondral ossification for JOCD cells. Runx2 also regulates 
Sp7, which regulates MSC-mediated endochondral ossification. 
With respect to the endochondral ossification model, it was surprising to see that 
once medium was changed at day 21 to induce osteogenesis on the chondrogenic pellets, 
the expression of most markers decreased. It is unclear why expression of Col1a1 
decreased from day 21 to day 28. A possible explanation may be that the snapshots in 
time that we chose (timepoints) missed a spiked expression of the markers earlier. 
Another explanation may be that these findings in gene expression are specific to the in 
vitro model we have developed. In vitro models often diverge in differentiation pathways 
due to a number of factors (e.g. cell source variability, difference in FBS and other 
materials, etc) when compared to in vivo. 
Additionally, it is worth pointing out that, despite successfully fulfilling all the 
MSC criteria, iMSCs are not MSCs. iPSCs are thought to be reprogrammed cells that 
replicate embryonic state. Differentiation of MSCs derived from embryonic, fetal and 
adult sources varies. One studied showed that human embryonic and fetal MSCs were 
able to differentiate towards 3 different cardiac lineages, in contract with adult MSCs, 
and the key difference was cellular response to stimuli [151]. Furthermore, the scientific 
community is often revising its definition of MSCs, as much uncertainty still remains 
regarding the defining characteristics of these cells, including their potency and self-
renewal [152].  For example, the majority of the surface markers in the International 
Society for Cellular Therapy’s minimal criteria are exclusion markers for other cell types. 
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Only 3 markers in the panel are specific to MSCs, and CD105 has been shown to be 
expressed in other cell types [153, 154] and to be absent in some MSCs [155] . 
Despite these potential shortcomings of iPSC-based in vitro models, iPSCs 
provide a limitless source of stem cells and are already launching forward the stem cell 
field. In disease modeling, iPSCs allow for patient-specific models, which may 
revolutionize precision and personalized medicine. In this study, JOCD-specific 
chondrogenic and osteogenic organoid models were developed and studied. Results 
suggest that JOCD cells may have a lower chondrogenic potential than control cells. 
Furthermore, while they are able to undergo calcification to a level comparable to the 
control cell lines (as shown by histology and calcium deposition), the gene expression 
profile of JOCD cell lines during endochondral ossification may suggest irregularities in 
this process. Altogether, we postulate that JOCD pathological mechanisms are tied in 
with chondrogenesis and endochondral ossification processes. Mechanistic studies should 
be done in the future to dissect possible aberrant pathways during differentiation. Lastly, 
because we did not see protein accumulation in the ER at day 49 in either differentiation 
model, we can conclude that protein accumulation was not a key driver of JOCD 
pathology. However, ER stress may still be implicated in the development and 




CHAPTER 6. ENDOPLASMIC RETICULUM STRESS 
RESPONSE SIGNALING IN JUVENILE OSTEOCHONDRITIS 
DISSECANS IN VITRO MODELS 
6.1 Abstract 
FOCD and equine OCD have been linked to ER dysfunction, and JOCD has been 
hypothesized to involve the ER as well, by evidence of protein accumulation in primary 
chondrocytes. However, no study to date has investigated the role of the ER in JOCD. 
Unlike FOCD, JOCD is not associated with a gene mutation and is not present at the 
systemic level. Therefore, the following question arises: if protein accumulation is a 
pathological event in JOCD, why is clinical JOCD not seen in all joint, similar to FOCD? 
The objective of this study was to isolate the ER mechanism in JOCD-specific cells by 
studying the response signaling to induce ER-stress. We hypothesized that JOCD is 
indeed an ER stress-related disease but its pathomechanisms are not in response to 
protein accumulation, but instead, that an impaired UPR is responsible and may cause 
cell death, and thus ultimately the initial necrotic lesion in the epiphyseal. 
In the JOCD-specific chondrogenic and endochondral ossification differentiation 
models, we observed a heightened ER-stress response, which may indicate that JOCD 
cells experienced higher levels of ER stress during differentiation. When the ER stress 
was equated (using our ER-stress induction models), results demonstrated a significantly 
lower expression of all ER-stress-response markers in JOCD than in control cell lines, 
with the exception of those associated with protein degradation. Altogether, these 
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findings suggest that JOCD cells do respond differently to ER stress (during 
physiological and pathological processes). We propose that the impaired ER-stress 
response of JOCD cells may lead to cell death in this disorder, which may initiate the 
necrotic lesion in JOCD patients under pathological processes, such as microtrauma or 
interruption of the microvasculature.  
6.2 Introduction 
ER stress has been hypothesized to be a key player in the disease development of 
the OCD umbrella (FOCD, equine OCD, and potentially JOCD). A study by Skagen et al 
found abundant accumulation of matrix proteins within dilated rER in chondrocytes from 
JOCD-loose fragments and cartilage biopsies [77]. However, it remains unclear what 
could have trigged this protein accumulation and whether this is a pathological feature of 
JOCD. In our previous chapter, we did not observed protein accumulation in our JOCD-
specific in vitro models of chondrogenesis or endochondral ossification. In FOCD, 
however, a similar model of FOCD-specific in vitro chondrogenesis showed protein 
accumulation, marked by dilated ERs [78]. Unlike JOCD, FOCD is associated with a 
mutation in the aggrecan gene that prevents its released into the ECM, and this initial 
protein accumulation leads to secondary accumulation of other matrix proteins, resulting 
in a compromised ECM. While FOCD is systemic, JOCD occurs as a single incident. 
Therefore, the following questions remain to be answered: does protein accumulation 
occur in JOCD as well? If it does, what may cause a localized protein accumulation 
versus the systemic event observed in FOCD? Is protein accumulation primary or 
secondary feature of JOCD? 
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Protein accumulation leads to ER stress, but the opposite is also true. Cells can 
accumulate protein in response to ER stress, which can be induced due to change in the 
internal and external microenvironment of the cells and due to both physiological [156] 
and pathological insults [77, 157]. Chondrocytes and osteoblasts undergo physiological 
ER stress-related response signaling in the course of normal maturation [158]. 
Endochondral ossification is regulated by several genes that also regulate stress responses 
to the ER [159]. Moreover, conditions such as ischemia, obesity (nutrition in pathological 
excess), diabetes mellitus, under-nourishment (glucose starvation), infection and 
chemically induced tissue injury might also give rise to ER stress and therefore 
accumulation of proteins in cells [77]. 
The ER stress-related response signaling is called the unfolded protein response 
(UPR). 4 processes may be activated with the UPR: increased expression of ER resident 
protein chaperones and protein foldases; increased rate of ER-associated degradation 
(ERAD) to eliminate irreparably misfolded proteins; decreased protein production; and 
when the prosurvival efforts are exhausted, ER-stress related apoptosis [160]. In 
mammals, the UPR is signaled through three ER transmembrane protein sensors: inositol-
requiring kinase 1 (IRE1), pancreatic ER eIF2 kinase (PERK), and activating 
transcription factor 6 (ATF6) [161]. Table 10 shows the three major ER-stress sensors 





Table 10. Unfolded protein response (UPR) has three major ER-stress sensors: 
PERK, ATF6 and IRE1, which play particular roles in the ER-stress related 
activated response [162]. 
 ER sensor Downstream effector Role 
ER stress 




ATF6 ATF6F Chaperone synthesis 
IRE1 Splicing of XBP1 Unfolded protein degradation 
 
The typical chemicals that induce ER stress include thapsigargin, which disturbs 
the calcium (Ca2+) homeostasis; tinucamycin, which suppresses glycosylation; and 
brefeldin A, which inhibits protein transportation to the Golgi complex [163]. 
Thapsigargin is a specific inhibitor of sarcoplasmic/ER Ca2+-ATPase (SERCA), and thus 
treatment with Thapsigargin results in a decrease in ER calcium levels [164]. When 
calcium levels are lowered in the ER, calcium-dependent chaperones lose their chaperone 
activity, leading to the accumulation of unfolded proteins [164]. Tunicamycin is an 
inhibitor that blocks the initial step of glycoprotein biosynthesis in the ER, thus causes 
accumulation of unfolded glycoproteins in the ER [164]. Brefeldin A inhibits 
transportation of proteins from the ER to the Golgi and induces retrograde protein 
transport from the Golgi apparatus to the ER [164]. Accumulation of unfolded/misfolded 
proteins due to these chemicals induce ER stress. 
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The objective of this study was to evaluate the UPR in JOCD-specific models in 
order to assess their response to ER stress. To this end, we utilized our differentiation in 
vitro models (chondrogenesis and endochondral ossification) in order to assess responses 
to physiological ER stress during differentiation, and established ER-stress induction 
models to study the ER-stress related responses to well-controlled, pathological settings. 
We hypothesized that JOCD is indeed an ER stress-related disease but its 
pathomechanisms are not in response to protein accumulation, but instead, that an 
impaired UPR is responsible and may cause cell death, and thus ultimately the initial 
necrotic lesion in the epiphyseal. Therefore, we expect to observe lower levels of most of 
the UPR-related genes tested in our ER-stress induction models, except for those which 
are also related to ER-stress associated apoptosis. 
6.3 Materials and methods 
6.3.1 Cell lines 
Skin biopsies from 3 JOCD patients were used to derive JOCD-specific iPSC 
lines. In order to establish the disease phenotype per patient, 3 clones (analogous to 
biological copies) were used per cell line as indicated in Table 11. Control (non-disease) 
patients were gifted by REMEDI and purchased from ATCC.  
iMSCs from JOCD and control groups were differentiated from iPSCs via an EB 
intermediate step, as previously described [142, 143]. iMSCs were characterized and 
validated according to the International Society of Cell Therapy’s minimum criteria 
[144]. iMSCs were cultures in MSC maintenance medium with 2 ng/ml FGF2 
(Peprotech), until experiments. 
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Table 11. Control group was composed of 2 iPSC lines gifted from REMEDI (one of 
which had 2 clones) and 2 iPSC lines purchased from ATCC, described in Table 5. 
JOCD group consisted of 3 JOCD-specific iPSC lines, with 3 clones each (described 
in Table 4). Cell line identifying number is denoted by the number after the group 
(i.e. cntrl#2, or control cell line #2) and clone number, within the cell line) is denoted 






























6.3.2 Chondrogenic and endochondral ossification models (organoids) 
3D chondrogenesis of iMSCs was performed using the high cell-density 
micromass culture model as previously described [78]. Briefly, 2 × 10! iMSCs in 10 µl 
of MSC maintenance media were incubated at 37°C for 2 hours in low-adherence round-
bottom 96-well plates (Sigma-Aldrich). Then, 200 µl of MSC maintenance medium was 
added to each well, followed by overnight incubation. Medium was replaced by 
chondrogenic medium with 10ng/ml TGF-β3 (Peprotech) the following day and was 
changed every second day for 49 days. 
For the model of 3D endochondral ossification, micromass cultures were started 
the same as in the 3D chondrogenesis model and cultured for the first 21 days in 
chondrogenic medium. At day 21, medium was replaced by osteogenic medium, and the 
pellets were cultured for an additional 28 days. 
6.3.3 ER stress-induction model 
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iMSCs were seeded at a 5,000/cm2 cell density in 35mm petri dishes and cultured 
with MSC Maintenance Medium. Once cells reached 60-70% confluency, the medium 
was replaced by MSC Maintenance Medium + ER-stress drug (5ng/ml Tunicamycin 
(Sigma Aldrich) or Protein Transport Inhibitor Cocktail (eBioscience)). It was important 
to expose cells to the ER-stressor at subconfluency in order to prevent cell-contact 
inhibition.  Furthermore, we chose 3 different drugs in order to observe cell responses 
across different ER-stress stimuli and confirm potential mechanistic results. 
6.3.4 Gene expression 
6.3.4.1 RNA extraction  
Total RNA from organoid cultures was extracted using the RNeasy MinElute 
Clean-up Kit with QIAzol Lysis Reagent (Qiagen). Total RNA from the ER-stress-
induction cultures was extracted using the RNeasy MinElute Clean-up Kit (Qiagen). 
Normalized RNA was synthesized to cDNA using the RT2 First Strand Kit (Qiagen).  
6.3.4.2 Microarray RT-PCR 
RNA expression was quantified using the Taqman real-time PCR Fluidigm 
Dynamic Array Integrated Fluidic Circuits (BioMark, Fluidigm). Differentiation models 
were tested again the array indicated in Table 12, and ER-stress induction models were 
tested again the array specified in Table 13. AccuRef human universal cDNA (Gene 
Scientific) and ultrapure water were used as positive and negative controls, respectively, 
to ensure run fidelity.   
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Ct values greater than 37 were treated as 37 (null). Gene expression analysis was 
carried out using the ΔΔCt method, outlined in Equation 1 and Equation 2. The Ct value 
of each gene was normalized by the geometric mean of the expressions of the 
housekeeping genes to get the relative expression (ΔCt). Then, the ΔCt of each target was 
normalized by the ΔCt of the calibrator to get the ΔΔCt for each gene. For the 
differentiation experiments, the calibrators were the micromass cultures at 2 hours post-
seeding of the respective cell line. For the ER-stress induction cultures, the calibrators 
were the respective cell line at the 0 hr timepoint, before the induction of stress with 
drugs. SEM was derived using Gauβ’s error propagation (Equation 3). 
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Table 12. List of Taqman gene expression assays used to evaluate the expression of 
ER-stress genes in the chondrogenesis and endochondral ossification in vitro models. 
Where available, the assays with the best coverage (recommended by the company) 
were selected. Some assays may be listed more than once as they fall in more than 
one category. 
Category Taqman Gene Expression Assays  
Sensors which trigger 
UPR 
Eif2ak3 (common name PERK, Hs00984003_m1), Atf6 
(Hs00232586_m1), Ern1 (common name IRE1, 
Hs00980095_m1) 
Translation inhibition Eif2ak3 (common name PERK, Hs00984003_m1) 
Redox response 
apoptosis 





Hspa5 (common names BIP and GRP78, Hs00607129_gH), 
Hsp90b1 (common name GPR94, Hs00427665_g1), Xbp1 
(Hs00231936_m1) 
Protein degradation Edem1 (Hs00976004_m1), Ern1 (Hs00980095_m1) 
Stimulators of 
osteogenesis 
Atf4 (Hs00909569_g1), Atf3 (Hs00231069_m1), Serpinh1 
(Hs01060397_g1), Creb3l1 (Hs00369340_m1), Gadd45b 
(Hs00169587_m1) 





Table 13. List of Taqman gene expression assays used to evaluate the molecular 
response of JOCD and control cell lines to ER-stress induction models. When 
available, the assays with the best coverage (recommended by the company) were 
selected. Some assays may be listed more than once as they fall in more than one 
category.  
Category Taqman Gene Expression Assays  
Sensors which trigger 
UPR 
Eif2ak3 (common name PERK, Hs00984003_m1), Atf6 
(Hs00232586_m1), Ern1 (common name IRE1, 
Hs00980095_m1) 
Translation inhibition Eif2ak3 (common name PERK, Hs00984003_m1) 
Redox response 
apoptosis 
Atf4 (Hs00909569_g1), Ddit3 (common name CHOP, 




Hspa5 (common names BiP and GRP78, Hs00607129_gH), 
Hsp90b1 (common name GPR94, Hs00427665_g1), Xbp1 
(Hs00231936_m1) 
Protein degradation Edem1 (Hs00976004_m1), Dnajb9 (Hs01052402_m1), Dnajc10 
(Hs00405977_m1), Ern1 (Hs00980095_m1) 
Housekeeping genes Gapdh (Hs02786624_g1), Rps18 (Hs01375212_g1), Actb 
(Hs0106665_g1) 
 
6.3.5 Statistical analyses 
Data were graphed as means ± SEM. Group comparisons were made with Two-
way ANOVA analysis. Tukey’s and Kruskal-Wallis were used as post hoc tests where 




6.4.1 Differentiation models 
6.4.1.1 Chondrogenesis 
ER-stress genes related to chondrogenic maturation and osteogenic differentiation 
were upregulated in the JOCD group (Figure 37). Atf3 was significantly higher in JOCD 
than control at days 14, 21, 35 and 49. Atf4 was significantly higher in JOCD than 
control at days 14, 21, 28, 35 and 49. Creb3l1, Gadd45b and Serpinh1 were significantly 
higher in the JOCD group than control at all timepoints. 
Expression of the sensors which trigger UPR were also upregulated in the JOCD 
group (Figure 37). Atf6 was significantly higher in JOCD at days 14, 35 and 49. Eif2ak3 
(common name PERK) was significantly higher in the JOCD group than the control 
group at days 7, 14, 28, 35, and 49. Ern1 (common name IRE1) was significantly higher 
at days 14, 21, 28, 35 and 49. Eif2ak3 is directly involved in inhibition of protein 
inhibition and Ern1 in degradation of unfolded protein. Edem1 is also a marker of ER-
associated degradation, and it was significantly higher in JOCD at days 14, 21, 28, 35 and 
49. 
Total Xbp1 expression is related to an increased in protein chaperone synthesis, 
and this gene was unregulated in the JOCD group at all timepoints. Consistently, 
chaperone Hspa5 (commonly known as BIP or GPR78) was significantly higher in the 
JOCD group than the control group at days 7, 14, 28, 35, and 49. Chaperone Hsp90b1 
(known as GRP94) was significantly higher in JOCD at day 14 only.  
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Genes associated with ER-stress-induced apoptosis had a variable response 
(Figure 37). Atf4 was significantly higher in JOCD at days 14, 21, 28, 35 and 49. Ddit3 
(commonly known as CHOP) was higher in the control group at day 7, but higher in the 
JOCD group at the later timepoints days 35 and 49. 
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Figure 37. Normalized relative expression of ER-stress related genes during 
chondrogenesis of JOCD- and control-specific iPSC-based organoids, graphed as 
means ± SEM. * indicated difference between JOCD and control cell lines for the 
indicated timepoint at p-value <0.05, ** p-value <0.01, and *** p-value <0.001. 
  
 135 
6.4.1.2 Endochondral ossification 
In general, the JOCD group expressed higher levels of all ER-stress related genes 
during endochondral ossification (Figure 38). Genes specifically related to ER stress 
during chondrocyte maturation and osteogenesis (Atf4, Creb3l1 and Gadd45b) were 
significantly higher in JOCD at all timepoints. Atf3 was significantly higher at days 28 
and 49. 
Expression of the three sensors which trigger UPR (Eif2ak3, Atf6 and Ern1) were 
upregulated in the JOCD group. Eif2ak3 and Ern1 were significantly higher in JOCD at 
all timepoints, while Atf6 was only significantly higher at days 14, 35 and 49. Edem1, 
like Ern1, is a marker of ER-associated degradation, and it was significantly higher in the 
JOCD group than control group at days 14, 21, 48, 35 and 49. 
 Xbp1 and Hspa5, markers of increased chaperone activity, were also significantly 
higher in JOCD. Xbp1 was significantly higher at days 35 and 49, and Hspa5 at every 
timepoint. Chaperone Hsp9b1, however, was not significantly different between the 
JOCD and control groups, for any timepoint. Atf4 is also an indicator of redox balance 
apoptosis and so is Ddit3. Ddit3 was significantly higher in JOCD at days 28 and 35.  
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Figure 38. Normalized relative expression of ER-stress related genes in response to 
3D endochondral ossification differentiation, graphed as means ± SEM. * indicated 
difference between JOCD and control cell lines for the indicated timepoint at p-
value <0.05, ** p-value <0.01, and *** p-value <0.001. 
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6.4.2 ER-stress models 
6.4.2.1 Protein Transport Inhibitor Cocktail 
The normalized relative expression of all genes tested is shown in Figure 39. The 
gene markers for the three sensors that are triggered by ER stress and thus initiate UPR 
had variable expression. Eif2ak3 and Atf6 had similar expression in the control group as 
the JOCD group, for all timepoints. Ern1 was significantly higher in JOCD at 2, 6 and 12 
hours than control. Ern1 is also a marker of ER-stress-associated protein degradation, as 
well as Dnjab9, Dnajc10 and Edem1. Dnajb9 and Edem1 were significantly higher in the 
JOCD group than the control group at 6 hours, while Dnajc10 had similar expression in 
both groups. 
Expression of genes related to ER-stress induced redox balance apoptosis were 
upregulated in the control group. Ddit3 was significantly higher in the control group than 
JOCD at 12 hours, and Asns at 12 and 24 hours. Expression of genes related to protein 
chaperones were generally upregulated in the JOCD group. Xbp1 was significantly 
higher in the JOCD group at 6 hours, and chaperone Hspa5 was significantly higher in 
the JOCD group at all timepoints. There were no significant differences between JOCD 
and control for chaperone Hsp90b1. 
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Figure 39. Normalized relative expression (ΔΔCt) of ER-stress related genes in 
response to PTIC drug, graphed as means ± SEM. * indicated difference between 
JOCD and control cell lines for the indicated timepoint at p-value <0.05, ** p-value 
<0.01, and *** p-value <0.001. 
6.4.2.2 Tunicamycin 
Figure 40 shows the normalized relative gene expression in response to 
tunicamycin treatment. UPR activation transmembrane sensor Eif2ak3 was significantly 
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higher in the control at 6 and 24 hours, while Ern1 and Atf6 had similar expressionin 
both groups for all timepoints. 
The expression of other markers of protein degradation were upregulated in the 
control group: Dnjab9 was significantly higher in the control group than the JOCD group 
at 2 and 24 hours, while Dnajc10 was significantly higher in the control group at 2, 6 and 
24 hours. Dnjac10 was significantly lower in the control group than the JOCD group at 
12 hours. Finally, Edem1 was also significantly lower in the control group than JOCD 
group at 12 hours. Increased chaperone activity and synthesis were also observed in the 
JOCD group. Hspb901 was significantly higher in the control group at 2 hours and lower 
in the control group than the JOCD group at 12 hours. Hspa5 was also significantly lower 
in the control group than the JOCD group at 12 hours. Xbp1 showed a similar trend, but 
differences between groups were not significant. 
Markers related to ER-stress-induced apoptosis were also upregulated in the 
control group. Asns was significantly higher in the control group than JOCD at 2, 6 and 
24 hours, while Ddit3 was significantly higher at 24 hours. Atf4 was significantly higher 




Figure 40. Normalized relative expression (ΔΔCt) of ER-stress related genes in 
response to tunicamycin drug, graphed as means ± SEM. * indicated difference 
between JOCD and control cell lines for the indicated timepoint at p-value <0.05, ** 




ER stress is an important physiological response to normal processes, such as 
osteogenic differentiation, and pathological conditions. Although FOCD and equine OCD 
have been linked with ER-stress related pathogenesis, to this date, no study had explored 
the molecular mechanisms of JOCD related to ER stress. The objective of this work was 
to investigate ER-stress mechanisms during chondrogenic and endochondral ossification 
of JOCD cell lines and in a controlled environment in response to ER-stress inducers. 
 Our chondrogenic and endochondral ossification differentiation models showed 
increased expression of UPR-related genes in the JOCD group. This result may suggest 
that JOCD cell lines may be experiencing a higher ER stress during differentiation than 
control cell lines. Higher expression of Eif2ak3, Atf6, and Ern1 particularly suggest the 
activation of the three transmembrane sensors, which act in response to protein 
accumulation and ER stress. Chaperone Hsp90b1 was the only marker that did not have a 
significantly different expression in JOCD versus control cell lines. Previous studies have 
pointed at distinct functions between the chaperones Hsp90b1 and Hspa5 [165]. 
Compared to Hsp5, the client proteins of Hsp90b1 are more selective with critical roles in 
immunity, growth signaling and cell adhesion [166], which may discard these types of 
proteins from being the culprit of heightened ER stress in JOCD cell lines during 
differentiation.  
Higher expression of ER-related genes that are also involved in chondrocyte 
maturation and osteogenesis may indicate a premature differentiation of our model to 
chondrocyte hypertrophy in the JOCD group. This suggestion agrees with the previous 
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chapter, in which we observed a higher gene expression of col1a1 and deposition of 
collagen type I protein in JOCD chondro-organoids. Expression of Gadd45b is essential 
for chondrocytes during terminal differentiation. In fact, its expression has been shown to 
increase from the proliferative phase to the hypertrophic phase, and to stimulate Mmp13 
(a marker of terminal differentiation of hypertrophic chondrocytes) [167]. Atf4 stimulates 
osteoblast-specific genes and Atf3, whose upregulation has been also reported during 
chondrocyte differentiation and shown to activate a Runx2-dependent promoter [159]. 
Creb3l1 is a transcription factor expressed in osteoblasts, which activates Atf6 of the 
UPR pathway [168]. Atf6 is related to the increased synthesis of protein chaperones, and 
we observed this feature in our differentiation models, including Serpinh1. Serpinh1 is a 
collagen-specific molecular chaperone that, unlike other chaperones, specifically 
recognizes the folded conformation of its client [169], and it is, therefore, directly 
involved in collagen biosynthesis.  
Differentiation of cells is a highly variable process, and even under the same 
differentiation-promoting conditions, there is known donor-to-donor variability and also 
clone-to-clone variability within the same iPSC donor [170-173]. In other words, cell 
lines respond differently to the same stimuli during differentiation. Therefore, in order to 
investigate the cells’ response to ER stress in a controlled environment, ER stress was 
induced with PTIC and tunicamycin. 
PTIC is a cocktail of Brefeldin A and Monensin, and thus prevents protein 
transport to the extracellular space, retaining proteins in the ER and inducing ER stress. 
In PTIC-treated cells, results indicated an increased ER-stress response in JOCD-specific 
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cells comparing to control cells. This heightened response was particularly observed at 
earlier timepoints and confirmed by tunicamycin treatment.  
In PTIC and tunicamycin treatments, the only genes for which JOCD cells lines 
had a significantly lower expression than control cells were related to ER-stress-induced 
apoptosis: Asns and Ddit3 (CHOP). The increased expression of the other genes related 
to the UPR mechanisms in JOCD cells may lead to higher survival and thus lower 
activation of these apoptotic markers.  
  Altogether, these observations point to two overarching conclusions. The first, 
the results from the differentiation models and ER-stress induction models may suggest 
that JOCD cell lines are more susceptible to stress (i.e. physiological and pathological 
stresses). This may indicate that upon encounter with physiological and pathological 
stresses, JOCD cells may respond differently and this characteristic may be linked to its 
pathology.  Dysregulated UPR activity may lead to failure to cope with ER stress over 
prolonged periods of time, which may eventually lead to cell death and may be 
responsible for the initial necrotic lesion observed in clinical JOCD.  
Ischemia is a pathological stresses and a hypothesized etiology for JOCD. It may 
be that upon trauma, which can cause interruption of the microvasculature, JOCD cells 
are not able to cope with the temporary ischemia as well as non-JOCD cells and thus they 
undergo ER-stress-induced cell death, causing initial necrotic lesion observed in JOCD 
patients. This hypothesis may be tested by studying our chondro- or osteo-organoids 
under ischemic conditions (low glucose or a glucose-blocker, and low oxygen). 
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Secondly, we may conclude that chondrogenic and endochondral ossification 
differentiations trigger a higher ER stress in JOCD cell lines, which may suggest that 
there is a difference in differentiation processes between the two groups. This suggestion 
also partially agrees with the previous chapter, in which we saw that although the end 
result of endochondral ossification was similar between the two groups (calcium content 
and collagen type I staining), gene expression during differentiation was significantly 
different.  This second point is not in conflict with our first, but an entirely different 
observation. A study by Vellanki et al. showed that knock-down of Creb3l1 in human 
glioma cell lines resulted in an attenuated UPR to ER stress, but induction of the col1a1 
was unaffected [174]. JOCD cells may have a different UPR activation compared to 
control cell lines, but this does not necessarily affect their osteogenic ability.  
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CHAPTER 7. SUMMARY AND FUTURE DIRECTIONS 
7.1 Overall summary 
In order to improve therapeutic interventions of joint disorders, the knowledge 
gap concerning their pathological mechanisms need to be bridged. The overall objective 
of this thesis was to elucidate pathomechanisms of OA and JOCD in order to provide 
insights about their development and how they may be addressed therapeutically. Both 
OA and JOCD are complex joint diseases that lack appropriate disease-modifying 
treatments. 
In the case of OA, the lack of well-characterized models may be partially 
responsible for failed clinical trials with promising pre-clinical data. In accordance with 
our overall objective, we developed a microarray gene expression tool and established a 
baseline of molecular events for multiple tissues, in different regions, and at different 
timepoints, for the MMT model of post-traumatic OA (Specific Aim I, Chapter 3). By 
characterizing OA development in this model, we were also able to provide insights 
about possible tissue interactions in OA. Utilizing this microarray gene expression tool, 
we then investigated the mechanisms of action of micronized dehydrated human 
amnion/chorion membrane (AmnioFix Injectable, MiMedx, USA) with the goal to 
understand its chondro-protective effect to leverage it in the future development of more 
specific therapeutic (Specific Aim II, Chapter 4). Results showed that AmnioFix does not 
have a direct influence on the gene expression of articular cartilage or tissue from the 
osteophyte-forming region of the joint. Instead, AmnioFix acted through the synovial 
membrane, modulating its microenvironment. These results further supported the 
 146 
importance of tissue interactions in the MMT model and in OA, and also provided a new 
viewpoint concerning disease-modifying approaches for OA. 
Lastly, we sought to elucidate pathological mechanisms of JOCD by establishing 
novel disease-specific iPSC-derived in vitro models (Specific Aim III, Chapter 5 and 6). 
This groundbreaking technology allowed us to study different aspects of JOCD. JOCD-
specific chondrogenic organoids demonstrated a lower chondrogenic ability than control 
(non-diseased)-specific organoids. Even though JOCD-specific endochondral ossification 
model was able to calcify and produce an ECM similar to that of the controls, we suspect 
from the gene expression results that there are irregularities in this differentiation process 
for JOCD. Through ER-stress induction models, we were able to further dissect 
pathological mechanisms of JOCD and demonstrated that JOCD cells possess a 
significantly different UPR signaling (compared to control). We ultimately hypothesized 
that when physiological or pathological events that induce ER stress in the epiphyseal 
occur, JOCD patient cells may not respond properly, which may lead to the eventual 
death of these cells, which turns into the initial necrotic lesion observed in JOCD 
patients. Microtauma and ischemic injury may be possible initiators of the demonstrated 
JOCD pathological events.  
Overall, this thesis presents original research regarding joint degenerative models 
for OA and JOCD, and it provides the scientific field with well-characterized platforms 
for future therapeutic development and testing.  
7.2 Future directions 
 
 147 
  There a number of exciting directions that the work presented in this thesis may 
take. Firstly, AmnioFix Injectable should be further explored in an inflammatory in vivo 
model in order to validate the results observed in this work, or perhaps elucidate the 
variable effect of AmnioFix in environments with different degrees of inflammation. 
Effects of AmnioFix in RA would be particularly interesting, since the primary 
pathomechanisms in RA affect both the synovial membrane and the immune system. 
With respect to OA, the suggested mechanistic effects of AmnioFix in the MMT model 
may point to a benefit from increased pro-inflammatory signaling. Pro-inflammation is, 
after all, important in wound healing at early timepoints. Future work should attempt to 
regulate the inflammatory response in the synovial membrane of the MMT model in 
order to see if similar results are obtained. It will also be worth assessing the response of 
the MMT model due to prolonged modulation, possibly by multiple treatments of 
AmnioFix Injectable with temporal proximity.  
 The differentiation processes of JOCD-specific cell lines should also be further 
assessed. We observed potential dysregulation in endochondral ossification processes in 
JOCD, yet similar end-point results between JOCD and control. We propose large-scale 
array analyses, such as RNA-seq, in order to further dissect differences in cell 
differentiation in JOCD patients. From our ER-stress induction models, we hypothesized 
that a different UPR activation in JOCD cells may ultimately lead to ER-stress-associated 
cell death in the epiphyseal due to changes to the extracellular environment, such as 
ischemia. This hypothesis should be tested by studying our JOCD-specific in vitro 
models under ischemic-like conditions (low to no glucose, low oxygen). 
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APPENDIX A. TOWARDS AN EARLY-STAGE SMALL ANIMAL 
MODEL OF OSTEOCHONDRITIS DISSECANS 
 
A.1  Introduction 
Currently, there are no disease models which recapitulate the development and 
progression of JOCD. A mechanically-induced lapine model is currently available; 
however, this model only replicates the severe late stage in which the osteochondral 
fragment is completely separated from the native bone (stage IV) [175]. In skeletally 
immature female New Zealand White rabbits, a 4-mm diameter plug is taken from the 
weight-bearing osteochondral surface on the medial femoral condyle, as shown in Figure 
5A [175]. Then, a piece of acellular collagen-glycosaminoglycan matrix is placed into the 
cavity and the plug is replaced (Figure 5B) [175]. The matrix prevents healing and 
reattachment of the osteochondral plug, thus creating an osteochondral defect and 
replicating the last stage of JOCD.  
 The Mauck group has developed a similar technique in a swine model. An 
osteochondral defect was created using a curved osteotome, removed, and later replaced 
following interposition of a slowly degrading nanofibrous poly(ε-caprolactone) (PCL) 
barrier membrane [176]. Unlike in the lapine model, sutures were used to secure the 
progeny fragment to the defect site. This swine OCD model attempts to replicate ICRS 
OCD grade III, in which there is a partially detached lesion; essentially, a dissecan in situ. 
However, thanks to advanced imaging modalities and improved guidelines, JOCD is now 
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typically detected in patients at ICRS OCD grade I or II (stable lesion). Therefore, 
although these preclinical animal models may be relevant for late stages of JOCD, their 
utility in the field is limited. Furthermore, it is the failure to treat JOCD at early stages 
what results in the progression of this disorder into partial or complete separation of the 
fragment, which jeopardizes the integrity of the joint and significantly alters the normal 
joint mechanics [35, 36, 177]. At this point, patients will develop OA at an early age. 
Therefore, a new pre-clinical model of early-stage JOCD is needed. Introducing a small 
animal model of JOCD with the ability to emulate early stages of this disorder will allow 
exploration of novel treatment options, as well as tailoring of current clinical approaches. 
The objective of this work was to explore multiple techniques in an effort to develop a 
small animal model of early-stage JOCD, marked by a necrotic lesion around the 
subchondral area and with intact articular cartilage. 
A.2  Success criteria 
The success criteria for this animal was determined in consultation with the 
surgeons specialized in JOCD from Children’s Healthcare of Atlanta, Orthopaedics and 
was as follows: 
A.2.1 Bone 
There should be a localized (emphasis on the localization aspect) osteonecrosis 
near the subchondral bone area. There should be the least amount of fibrosis possible; 
none is ideal. Because the model is meant to be used for early-stage OCD testing, 
continuous bone tissue is essential (e.g. no partial detachment or holes). 
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A.2.2 Articular cartilage 
The articular cartilage overlaying the bone insult should be have intact surface 
and bottom (interface with subchondral bone). This means no fibrillation or remodeling; 
however, thickening of the articular cartilage is acceptable and even desired. When 
measure by uCT methods, there should be only low signal changes in the articular 
cartilage.  
 
Figure 41. OCD grading system. Early-stage OCD includes grades I and II. Our 
goal was to develop an animal model that emulated OCD grade I. 
A.3  Chemical insult 
A.3.1 Surgical procedure 
 The Georgia Institute of Technology IACUC approved all animal procedures 
(#A15023). In male Lewis rats (270-300 mg), the MCL was transected to access the 
lateral aspect of the left medial femoral condyle. Using a customized setting of the 
stereotaxic frame, a drill hole was made, 0.5 mm in diameter and 1 mm in depth, in the 
region just above the subchondral bone layer. After cauterizing, bonewax was placed 
over the drill hole. In OCD animals, 5 µl of 2ml/50ul of monosodium iodo-acetate (MIA) 
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was injected through the bone wax to chemically induce the initial necrotic lesion. In 
sham animals, saline was injected. All animals were sacrificed at 3 weeks post-surgery. 
The stereotaxic frame allowed for consistent location and depth of the drill hole 
(Figure 42). The MIA was injected through the bonewax because previous preliminary 
studies have shown a problem with liquid retention at the drill hole site. Even though we 
cauterized after drilling, blood backflow reinitiates after a few seconds.  
 
Figure 42. Set-up of stereotaxic frame and cauterizer for OCD surgeries. 
 
 MIA was chosen to induce bone cell death because preliminary work (Figure 43) 
showed confirmed MIA-dependent cell death of pre-osteoblasts. The concentration used 
for initial experiments was 5uM of MIA; however, we did not observed cell death at the 




Figure 43. MC3T3 pre-osteoblast cells after 24 hours of MIA treatment at the 
various concentrations. MTT assay was used to read cell survival after treatment. 
*** indicates p-value <0.001. 
A.3.2 Results and discussion 
We observed a reproducible technique in terms of drill hole location and depth 
thanks to the use of the stereotaxic frame. However, MIA injections did not show 
significant differences from saline injections (sham animals), indicating that the MIA 
injections were not having an effect (Figure 44). This is mostly due to the limited space 
allowed for injections (0.5 mm drill hole). We hypothesize that MIA in simply not 
retained at the drill hole site.  
Moreover, histological analysis of the bone showed signs of remodeling (Figure 
44). It appeared that fibrous tissue had formed around the drill hole site. For the purpose 
of this model, we want zero to very minimal fibrous tissue in the bone and we need the 
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bone tissue to be continuous (i.e. not have a hole). Therefore, this chemically-induced 
model failed to pass the success criteria for the desired OCD pre-clinical model. 
 
Figure 44. uCT scans showed consistent drill hole site. Saf-o (red)/Fast green 
(blue/green) staining showed remodeling of the bone at the drill hole site, marked by 
fibrous tissue. Additonatly, there were no signs of articular cartilage degradation, as 
shown by intact staining of Saf-o (red). 
 
A.3  Thermal insult 
A.3.1 Surgical procedure 
 The Georgia Institute of Technology IACUC approved all animal 
procedures (#A15023). Cryogenic insults, coupled with vascular ligation, have been 
increasingly adopted to induce osteonecrosis [178-180].  In cryosurgery, the freezing 
process causes direct cellular and vascular injury [180]. For the purpose of this work, we 
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sought to create localized necrosis near the subchondral bone with the help of a cryogenic 
insult in combination with vascular ligation. The left leg of weight-matched Lewis rats 
(300-325 mg) were surgerized; the right leg was used as contralateral control. We tested 
3 groups (n=2): (A) cryogenic insult only, (B) ligation only, and (C) cryogenic insult 
coupled with ligation. For the cryogenic insult, a drill hole was made near the 
subchondral bone, cauterized, and a direct stream of liquid nitrogen was delivered 
continuously for 10 seconds into the hole followed by warm saline (10 s). The thermal 
insult was repeated 5 times, then the hole was sealed with bonewax. The medial superior 
genicular artery was chosen for ligation because it branches close to the femoral 
condyles, supplying them and the knee-joint. Figure 45 shows a diagram of the surgical 
procedure to induce OCD. Animals were sacrificed 3 weeks post-surgery. 
 
 
Figure 45. Diagram of surgical procedure for thermally-induced OCD animal 
model. 
A.3.2 Results and discussion 
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Figure 43. shows representative pictures of the gross morphology of each group. Group C 
was the most severely damaged, having the entire medial femoral condyle completely or 
partially fragmented (Figure 46). The region around the lesion site showed cell death in 
all groups, as indicated by patches in the trabecular bone devoid of osteocyte nuclei 
(Figure 47). However, only groups B and C had signs of potential osteoclasts (further 
staining would need to be done to confirm this claim) at the edges of the dead bone as 
well as woven bone on the surface of the dead traberculae. These characteristics match 
previously reported morphologic modifications associated with osteonecrosis [181]. Also, 
it is noteworthy to mention that there appeared to be a higher level of remodeling in the 
Group C. 
 
Figure 46. Representative pictures of the gross morphology of each group: (a) 
ligation only, (b) cryogenic insult only, and (c) cryogenic insult in combination with 
ligation. Blue boxes show magnification of the medial femoral condyle. Red arrows 
point at the drill hole site. Yellow arrow points at the partial fragmentation of the 
medial femoral condyle observed in the cryogenic insult plus ligation group, while 
orange arrow points at the damage throughout the shaft of the femur. 
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Figure 47. DAPI staining (cyan) of group A) ligation, group B) cryogenic insult and 
group C) cryogenic insult plus ligation in the region of the drill hole/lesion site. Red 
arrows point at empty while white arrows point at filled osteocytic lacunae. Yellow 
arrows point at signs of woven bone. Magenta arrows point at possible osteoclasts at 
the edges of the traberculae. 
The articular cartilage was also affected, as shown in Figure 48. Histological 
analysis showed significantly less proteoglycans in the articular cartilage, in groups B 
and C. In group C, however, there was evident modification of the structure and integrity 
of the cartilage.  
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Figure 48. Saf-O/fast green staining of the medial femoral condyle of the 
contralateral control, group A) ligation, group B) cryogenic insult, and group C) 
cryogenic insult in combination with ligation. Magenta circle selects the drill 
hole/lesion site location. The red box shows 20x magnification of the top section of 
the cartilage; blue, of the middle section; and yellow, of the bottom section. 
In this preliminary study, we observed an effect in the region of the initial lesion 
site as well as an effect on the articular cartilage in groups B and C. However, group C 
showed severe damage to the shaft of the femur, which might suggest that the insult 
created in this group is too drastic for what our goal was. We, therefore, concluded that 
cryogenic insult alone may be sufficient to accomplish our objective. We followed this 
study with three other ones, in which we sought to optimize the different parameters of 
the thermal insult (duration and frequency). 
At the end, we concluded that it was the liquid nitrogen that was affecting the 
articular cartilage, thus this effect was not secondary to the osteonecrotic lesion. More 
specifically, spraying of the liquid nitrogen was having a direct effect on the cartilage 
regardless of duration and frequency of the treatment. We tried to control for this variable 
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with a different nozzle for the liquid nitrogen sprayer, which was the same diameter size 
as the drill hole (Figure 46). We hoped that this precaution would limited the 
uncontrolled spraying, and we did see an improve articular cartilage composition in 
studies to follow. 
 
Figure 49. Attachment for the liquid nitrogen sprayer/gun, of the same diameter as 
the drill hole (0.5 mm). 
Moreover, on the bone side, we concluded that this technique could not be 
localized because of the nature of the thermal insult. By decreasing the duration and 
frequency, we would fall below the minimum threshold and not longer see osteonecrosis 
in this model. In other words, this model had two settings: osteonecrotic death throughout 
the condyle and no detectable cell death. Because of our inability to localize the lesion in 
this model and the damage observed to the cartilage, this surgical procedure was 
abandoned. 
A.4  Mechanical-barrier insult 
A.4.1 Surgical procedure 
 The Georgia Institute of Technology IACUC approved all animal 
procedures (#A17023). The mechanical-barrier approach consisted of inserting a hollow 
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tube in the bone of the femoral condyle with the expectation that the bone in contact with 
this surface would undergo osteonecrosis. It was hypothesized that, after a period of time, 
when the hollow tube was pulled out, there will be an osteonecrotic lesion akin to OCD. 
The lateral aspect of the femoral condyles of male Lewis rats (~400mg) was 
assessed through blunt dissection. Then, a 2mm biopsy punch was used to core out 
spacing in the lateral femoral condyle for the microtube. The lateral femoral condyle was 
chosen as the lesion site because it was anatomically more resistant to this process. We 
found that medial femoral condyles would collapse more easily under the force of the 
biopsy punch. Furthermore, a biopsy punch was chosen as our tool to make spacing for 
inserting the microtube because companies do not manufacture holesaws (or trephine) of 
the size we needed. In accordance with our success criteria, we did not want to 
compromise the entire condyle, thus 2 mm diameter was the largest size we could core in 
the femoral condyle.  
The microtube was polyamide-made, 1.98 mm in diameter and 1.5 mm in depth 
(courtesy of MicroLumen, FL). Before surgeries, it was washed in detergent and 
subsequent water washes in the sonicator, and then autoclaved sterilized.   The 
microtubes were fit-pressed into the spacing made by the biopsy punch, in the lateral 
condyle. One week after surgery, a second surgery took place to remove the microtubes. 
Animals were taken down 2 weeks after the second surgery. 
In sham animals, the biopsy punch was used to make the spacing for the 




A.4.2 Results and discussion 
 In this pilot study, we observed morphological differences in the bone at the site 
of the insult, for both OCD and sham groups (Figure 50). Remodeling is typical a sign of 
active repair, and thus does not suggest necrosis at the lesion site. Histology would have 
to be performed in order to truly assess whether there is osteonecrosis at the site (DAPI 
staining).  
 
Figure 50. uCT scans showed signs of bone remodeling at the lesion sites (blue 
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